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Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency 
of the α-galactosidase-A (α-gal-A) enzyme. The lack of enzymatic activity results in 
the accumulation of glycosphingolipids (GSLs) in the lysosomes of various tissues 
and organs. Globotriaosylceramide (Gb3) and Globotriaosylsphingosine (Lyso-Gb3) 
and their isoforms/analogues have been identified and quantified as potential 
biomarkers. 
This study aimed to develop an HPLC-MS based method for the quantitation of 
plasma and urinary Lyso-Gb3 and its analogues in Fabry patients to evaluate its utility 
in diagnosis and monitoring FD. 
The results showed that plasma Lyso-Gb3 as a reliable diagnostic biomarker for FD, 
as plasma Lyso-Gb3 levels could easily discern classical Fabry patients from controls. 
Moreover, plasma Lyso-Gb3 could also distinguish male cardiac variant Fabry 
patients from control males. Nevertheless, cardiac variant Fabry females showed an 
overlap of Lyso-Gb3 levels with controls, hence a positive value in this group would 
be considered diagnostic but a negative value could not exclude FD. 
In a small cohort of our patients on ERT there was a trend towards falling Lyso-Gb3 
levels with time suggesting that Lyso-Gb3 has a potential value in monitoring these 
patients. 
Urinary Lyso-Gb3 levels were substantially different between classical and cardiac 
variant Fabry patients, and the lack of detectable urinary Lyso-Gb3 and analogues in 
controls allowed us to differentiate between these patients and healthy controls. The 
total levels of urinary Lyso-Gb3 and its analogues proved particularly useful in 
differentiating between classical and atypical Fabry patients of both genders. 
ii 
 
In the course of the study, a novel rapid MALDI-TOF-MS based Method for 
measuring urinary Gb3 in Fabry patients has been established. Collectively, the final 
findings demonstrate that urinary Lyso-Gb3 is superior to urinary Gb3 as a diagnostic 
biomarker for FD, where the later has been shown to be found in healthy subjects. 
 
Our study subsequently led to development of regional laboratory service for testing 
Lyso-Gb3 in Queen Elizabeth Hospital, Birmingham, UK. This service is now open to 
Fabry patients across England. 
In conclusion both plasma and urinary Lyso-Gb3 levels are useful diagnostic and 
monitoring biomarker in classical and cardiac variant males patients, but have 
questionable utility in cardiac variant females due to overlap with healthy controls. 
Although we studied the role of Lyso-Gb3 in diagnosing FD further studies are 
needed to establish its role in disease severity assessment and a larger study required 
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1.1 INBORN ERRORS OF METABOLISM 
Inborn errors of metabolism (IEM) also known as inherited metabolic disorders 
(IMD) constitute a large group of heterogeneous inherited disorders. Individually, 
IEM are very rare, however collectively numerous. Each disease results from a defect 
in a single gene encoding a regulatory enzyme, co-factor, or catalytic enzyme. These 
catalytic enzymes are responsible for the degradation of various metabolic substrates 
such as carbohydrates, proteins, fats and other metabolites (Figure 1.1). Consequently, 
the defective metabolic pathway results, primarily, in the accumulation of a metabolic 
substrate. Subsequently, this accumulation may be directly toxic to the cell or lead to 
a blockade in the catabolic pathway or production of abnormal metabolic 
intermediates through alternative metabolic pathways [1-5]. Additionally, IEM can 
result from defects in metabolite transportation into cells or energy production and 
utilization.  All of these metabolic abnormalities are considered to be the main reasons 
for the various clinical effects of the EIM [5]. 
IEM vary from being progressive, degenerative diseases to acute life threating 
diseases and can be divided into different types according to the type of the 
accumulated metabolite substrate such as disorders of carbohydrate metabolism, 
disorders of protein metabolism, trace metal disorders and lipid metabolism disorders 
or according to the location (the part of the living cell) its metabolism such as 
lysosomal storage diseases (LSD) and mitochondrial disorders [6]. 
Sanderson and co-workers [7] reported the incidence of some selected IEM in the 
West Midlands-UK in the period between 1999 and 2003. The prevalence of 
phenylketonuria was 0.8 per 10,000, other amino acid disorders excluding 
phenylketonuria 1.9 per 10,000, peroxisomal diseases 0.7 per 10,000, glycogen 
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storage disorders 0.7 per 10,000, mitochondrial disorders 2.0 per 10,000, urea cycle 
disorders 0.5 per 10,000, organic acidemias 1.3 per 10,000, carbohydrates defects 0.6 
per 10,000, lipids and steroids disorders 0.6 per 10,000 and LSD 1.9 per 10,000. The 
reported figures were similar to the published incidence of IEM in the other 
geographic locations in the world [7].  
The diagnosis of IEM is challenging due to the rarity of individual IEM cases, and 
their low prevalence, variable clinical signs and manifestations, which overlap with a 
large number of common diseases [5, 8]. It has been reported that the early diagnosis 
of IEM is fundamental to prevent progression of the metabolic error and, ultimately, 
to treat the disorder. Currently, newborn screening is applied in most developed 






Figure 1.1 Inborn errors of metabolism process: a schematic enlightenment shows the 
process of inborn errors of metabolisms (IEM) in the living cells: The chemical substrate 
(metabolite) is transported into the living cell. So, IEM could be resulted from the deficiency 
of the transporter. In the normal condition, substrate is catalysed to a product metabolite, so 
any deficiency in the enzyme or the co-factor could lead to IEM. Substrate accumulation 
resulting from the enzyme deficiency causes IEM. In some cases the accumulated substrate 





1.2 LYSOSOMAL STORAGE DISEASES 
Lysosomes are sub-cellular membrane-bound vesicles containing hydrolytic enzymes. 
These enzymes are produced in the endoplasmic reticulum and are responsible for 
degradation of carbohydrates, lipids proteins and nucleic acids. Lysosomal storage 
diseases (LSD) are a large group of rare hereditary disorders that result primarily from 
an accumulation of un-catabolised macromolecules, largely due to the absence or 
deficiency of lysosomal enzymes which are responsible for the degradation of 
metabolites in lysosomes. More than 50 LSD have been described worldwide and 
according to the substrate that accumulates, LSD can be classified into different types 
including sphingolipidoses, oligosaccharidoses, mucolipidoses, lipoprotein storage 
disorders, mucopolysaccharidoses, neuronal ceroid lipofuscinoses, lysosomal 
transport defects, and others [9-13]. 
 
1.2.1 Sphingolipidoses 
Sphingolipidoses are a subclass of LSD caused by defects in sphingolipid metabolism. 
Normally, the synthesis and catabolism of sphingolipids are balanced yielding 
relatively constant amounts of these molecules in membranes. However, if the activity 
of a sphingolipid hydrolase is lost or deficient, an accumulation of the substrate 
molecules can occur. Subsequently, the elevated levels of the accumulated lipids leads 
to their accumulation in different organs, tissues and body fluids, causing symptoms 
that characterise the particular sphingolipidosis. Sphingolipidoses include disorders 
such as Fabry disease (FD), Gaucher disease, Niemann-Pick disease, Sandhoff 
disease, Gangliodoses Krabbe Disease (Globoid cell leukodystrophy), Metachromatic 
leukodystrophy Farber disease and Tay-Sachs disease. All sphingolipidoses can be 
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fatal at different stages in life. All are autosomal recessive diseases except FD, which 
is X-linked [13-15]. 
Acid ceramidase (N-acylsphingosine deacylase, EC 3.5.1.23; AC) is an abundant 
enzyme responsible for sphingolipids hydrolysis in cellular lysosomes. AC breaks 
down the ceramide backbone into the sphingolipid base (sphingosine) and fatty acid 
chain. AC plays a role in sphingolipid metabolism, mainly in controlling the levels of 
ceramide and sphingosine in cells. Numerous advances have been made in studying 
the cellular function and diseases associations of AC. Farber disease, extremely rare 
autosomal recessive LSD, is associated with AC deficiency. The first “knock-out” 
mouse model of AC deficiency has been developed, which phenocopies Farber 
disease in most aspects. The gene encoding AC has been cloned and numerous 
mutations have been identified, most, if not all of which are associated with Farber 
disease. Gene cloning has allowed the production of large quantities of the 
recombinant enzyme and certain properties of the enzyme have been characterised in 
vitro. Several anti-AC antibodies are also available and have been used in studies to 
investigate the cell biology of this important protein. However, despite these 
advances, much more information is required fully to understand the role of AC in 
sphingolipid-mediated signal transduction and human disease [16]. 
Guce and Garman [17] have posited that FD can be used as a model to study the 
whole family of LSD. Firstly, it is well known that the mutations observed in FD offer 
a wide spectrum of structural, clinical and genetic information. Secondly, broad 
database of mutations have been identified in FD patients. In addition, the three-
dimensional structure of the glycoprotein has been solved, which has facilitated a 
better understanding of the molecular basis of the disease. Thirdly, due to the 
similarities between FD and other LSD, a better understanding of molecular defects in 
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FD can facilitate a better understanding of the whole family of LSD. Lastly, FD is 
characteristically a protein misfolding disease allowing it to be used as a model for 
other misfolding disorders such as Parkinson’s disease. Figure 1.2 shows the 
metabolic pathways in sphingolipidoses disorders. 
 
Figure 1.2 Metabolic pathways of sphingolipidoses: a schematic illustration shows 
the metabolic pathways in sphingolipidoses. Diseases appear with a yellow 





Glycosphingolipids (GSLs) are a complex heterogeneous class of lipids. GSLs 
constitute a large component of the cellular membrane [18, 19]. This class of lipid is 
characterised biochemically as having two main parts: a hydrophobic ceramide 
backbone and hydrophilic carbohydrate head group portion. The ceramide backbone 
is composed from sphingoide base and fatty acid. GSLs are characterised by their 
diversity which relates to the various structures either in the main ceramide backbone 
or sugar head group [18-20]. Degroote et al [18] reported that more than 300 
carbohydrate chains and 60 sphingoid bases have been identified. These various types 
of sphingoid bases and carbohydrates chains can combine to form a large diversity of 
GSLs structures. 
The structure of sphingoid bases varies according to their length, saturation, 
branching and hydroxylation (Figure 1.3). 3-ketosphinganine is considered to be the 
precursor of other sphingoid bases. The main sphingoid base in humans is 
sphingosine (also known as trans-4-sphingosine, D-erthro-1dihydroxy or 2-
aminooctadec-4-ene), which contains 18 carbon atoms with a single and/or double 
bond. It has been reported that sphingosine represents approximately 80% of the 
sphingoid bases in the kidney of mammals such as cow [18-21]. Other examples of 
the main sphingoid bases in human include sphinganine which is a sphingosine 
lacking C4-C5 double bonds. 
The fatty acid is linked to the amino group of the sphingoid base via an amide bond. 
The variety of these fatty acids contributes to the heterogeneity of GSLs. The fatty 
acids vary in the length, saturation, and hydroxylation based on the host cell type. 
They are typically more than 16 carbon atoms and fully saturated. In certain 
conditions, they are unsaturated at carbon 15 or hydroxylated at carbon 2 (Figure 1.3). 
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The carbohydrate head group in GSLs are categorised into two types according to the 
oligosaccharide linked to the ceramide backbone. These two types are Glucose 
(Gluβ1-) and galactose (Galβ1-). However, although rare, other types of sugars can 
link to the ceramide backbone, as has been observed in human colon cancer cells such 
as Fucose [Fucα1-] [18]. The synthesis of GSLs comprises several steps, starting by 
the condensation of serine and palmitoyl-CoA to 3-ketosphinganine. 
In human living cells, sphingolipids are categorised into two main types’ 
sphingomyelin and GSLs. GSLs synthesis is essentially initiated from the 
hydrophobic ceramide backbone. Subsequently, a glucosylation process of ceramide 
is achieved generating glucosylceramide. The latter is considered the source of about 
400 various species of GSLs. 
Based on the features of the sugar head groups, GSLs can be categorised as follows 
[22]: 
a- According to the structure of sugar head groups, GSLs can be categorised into: 
gal-series glycolipids, muco-series glycolipids, ganglio-series glycolipids, 
lacto-series glycolipids and globo-series glycospingolipids. 
b- According to the number of sugar head groups, GSLs can be categorised into: 
poly-glycosylceramide, penta-glycosylceramide, tetra-glycosylceramide, tri-
glycosylceramide, di-glycosylceramide and mono-glycosylceramide. 
c- According to the substation of sugar head groups, GSLs can be categorised 
into: phosphoinositido-glycolipids, gangliosides-glycolipids, sulfatides-
glycolipids and neutral glycolipids. 
 
Despite the fact that GSLs are chemically well characterised, the biological functions 
of GSLs and their synthesis through ceramide glycosylation process were not fully 
9 
 
characterised. Nevertheless, GSLs-deficient cell lines and the isolation of a cDNA 
clone for glucosylceramide synthase, has revealed clearer insights into the biological 
functions of these complex GSLs molecules [23].  
GSLs play vital roles in the living cell. Many functions are provided by GSLs in the 
cytosolic surface of the cellular membranes. GSLs play significant roles in the sorting 
of proteins, allowing selective intracellular membrane transport. GSLs are involved in 
the recognition and signalling on the cell surface. 
It has been reported that some GSLs are present in tumour cells at levels that exceed 
those in normal cells, findings suggestive of a role of GSLs as tumour-associated 
antigens [24, 25]. Moreover, it has been postulated that GSLs play a role as cell 
surface antigens in the differentiation of different cells during embryonic development 
[22, 24]. In addition, other biological roles for GSLs have been suggested, such as 
acting as receptors for bacterial protein toxins, adhesion roles in the cell surface and 
immunomodulatory and roles in signal transduction [26]. 
 
Figure 1.3 Chemical structures of ceramide and sphingoid bases: (a) Ceramide 
consist a sphingosine moiety (18 Carbon + a single double bond) linked by an amide 
bond to a fatty acid (16 Carbon). The chemical structures of sphingoid bases: (b) 
Sphingosine. (c) Sphinganine. (d) Phytosphingosine (Figure adapted from [20]). 
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1.3 FABRY DISEASE 
 
1.3.1 Overview 
Fabry disease (FD, OMIM#301500) is inherited multi-systemic X-linked LSD. The 
defect in the key enzyme results from a mutation in α-galactosidase-A (GLA) gene 
which results in the expression of a defective enzyme [17, 25, 27-30]. This inborn 
error of GSLs metabolism results from the absence or deficiency of alpha-
galactosidase-A (α-gal-A, also known as ceramide trihexosidase, EC 3.2.1.22) which 
is responsible for the hydrolytic cleavage between the galactose residues in 
galactosylgalactosylglucosylceramide also known as globotriaosylceramide (Gb3), 
galactosylgalactosylglucosylsphingosine also known as globotriaosyalsphingosine 
(Lyso-Gb3) (Figure 1.4) and their related isoforms and analogues. Moreover, it has 
been reported that other GSLs such as galabiaosylceramide (Ga2) and blood group B 
glycolipids can be affected by this enzymatic defect. The none-metabolised GSLs 
accumulate in the lysosomes of various cells, biological fluids, and various body 
organs and tissues such as skin, eye, unmyelinated nerves, small blood vessels, 
vascular endothelium, heart and kidney. GSLs accumulation results in a range of 
symptoms that affect the kidneys, heart, brain, eye, and skin [17, 25, 27-30]. The 
disease process is based on accumulation of the un-catalysed GSLs in lysosomes. 
Every cell except red blood cells has lysosomes. The lysosome in the affected organs 
become enlarged with storage and eventually may burst or leak and trigger secondary 




















Figure 1.4 Metabolic pathway of Gb3: a schematic illustration for the degradation 
pathway of globotriaosylceramide (Gb3), where the hydrolytic enzyme alpha 
galactosidase A (α-gal-A) is responsible for the hydrolytic cleavage between the 
galactose residues forming lactosylceramide. In the same manner the deacylated form 




1.3.2 History of Fabry Disease 
Fabry disease (FD, also known as Anderson-Fabry disease) was first described in 
1898 by two dermatologists working independently in England (William Anderson) 
and Germany (Johannes Fabry), The disease was termed ‘angiokeratoma corporis 
diffusum’ due to its dermatological manifestation [31-33]. In 1947, Ruiter and 
collaborators described the disease as a vascular disease [34]. Later, in 1953, the 
disease was classified as a lipid storage disorder [35]. In 1955, lysosomes and their 
role in living cells were described by the scientist Christian de Duve (Belgium) [36]. 
The concept of LSD was established by Henri-Gery Hers in 1965 after his discovery 
of the aetiology of Pompe disease where he found that the responsible deficient 
enzyme could work better at an acidic pH suggesting that this enzyme being localized 
in lysosomes [37, 38]. In 1963, Sweeley and Klionsky demonstrated that the 
glycolipids ceramide trihexoside (now known as Gb3) accumulate in different organs 

















recognised in 1965 [40]. In 1967, Brady and colleagues linked aetiology of the 
disease with deficiency of Ceramide-trihexosidase enzyme [41]. Later, Kint identified 
this lysosomal enzyme to be known as α-galactosidase-A (α-gal-A) [42]. Hamers and 
co-workers [32] determined that α-gal-A gene is located at Xq22. In 1972, the first 
trial of treatment was achieved by Desnick using kidney transplantation [43]. The 
treatment of FD is further developed in the recent decades through enzyme 
replacement therapy (ERT) [37, 44, 45]. In 2008, Lyso-Gb3 has been introduced for 
the first time by Johannes Aerts and colleagues [46]. 
 
1.3.3 Prevalence of Fabry Disease 
FD is the commonest LSD. However, the reported incidence varies considerably. For 
example, it has been reported that the incidence of FD is very rare, approximately 
1:40,000 to 1:117,000 of male-live births in certain parts of the world [47-50] while 
recent newborn screening data suggest a much higher figure, with frequencies of the 
order of up to 1:3,100 [48]. Spada and co-workers [48] reported that newborn 
screening programs revealed a high incidence of late-onset variants phenotype in 
Fabry patients making the importance and the ideal time of applying the screening for 
Fabry patients to be questionable. Moreover, the reported statistics among males and 
females suggest that there are a lot of asymptomatic or undiagnosed cases in females 
[49, 50]. Due to the x-linked nature of the disease, it is predicted that FD prevalence 
can be twice higher in females compared to Fabry males [51, 52]. The reported global 
prevalence is shown in Table 1.1 but as many other rare diseases the actual prevalence 




Interestingly, a high prevalence of FD has been shown in previous high risk targeted 
screening subjects for instance, 2-5% of patients having left ventricular hypertrophy 
(LVH) showed very low α-gal-A activity, typical of FD [53, 54]. Moreover, other 
screening work showed that 2-5% of males under 55 years of age suffering from a 
stroke were confirmed as Fabry patients. However, previous screening studies in 
chronic hemodialysis patients showed prevalence of FD of 1.2% in males and 0.34% 
















60 2.9 [63] 
UK 
(1980-1995) 






98 2.7 [64] 
Netherlands 
(1970-1996) 
Prenatal and postnatal 
LSD diagnoses labs 
Birth prevalence = 
number of cases born in a 
certain period/total 
number of live births in 
the same period 
27 2.1 [65] 
Australia 
(1980-1996) 
2 centres for enzymatic 
analyses 
Birth prevalence = 
(postnatal + prenatal 
enzymatic diagnoses) / 
number of births 




Prenatal and postnatal 
LSDs diagnoses centre 
Birth prevalence = 
(postnatal + prenatal 
enzymatic diagnoses) / 
number of live births 
1 1.2 [66] 
Turkey 
(1997-2002) 
Two main reference 
centres for diagnosis of 
sphingolipidoses by 
enzyme analysis of 
patients under 5 years 
suspected of LSD 
Birth prevalence = 
number of cases born 
within a certain period / 
total number of live 
births in the same period 
1 0.15 [67] 
North Italy 
(2004-2006) 
Northern Italy Neonatal screening 12 300 [48] 
Taiwan 
(2006-2008) 
Taiwan Neonatal screening 73 800 [68] 
 
Table 1.1 Prevalence of FD: A table shows the frequencies of FD in different 





1.4 THE GENETIC BASIS OF FABRY DISEASE  
 
The deficiency of α-gal-A enzyme activity is caused by mutation in the GLA gene. 
This gene is located in Xq22.1 on the long arm of the X chromosome, which spans 
approximately 13kb of genomic sequence and contains a total of 7 exons spanning 92 
to 291 base pairs in length; the spliced full-length mRNA generates a cDNA that is 
1290 base pairs in length. The gene encodes a polypeptide of 429 amino acids 
including a 31-amino acid signal peptide [17].  
The genetic basis of FD is well established. The α-galactosidae-A gene has been 
sequenced and hundreds of mutations identified [69]. According to the Human Gene 
Mutation Database (last accessed at www.hgmd.cf.ac.uk, May, 23, 2016), more than 
800 mutations in the GLA gene have been described. Cebada and colleagues [70] 
suggested that more than one modification can cause FD, recommending that the 
whole gene should be sequenced to confirm the presence of FD-related mutations. 
 
Mutations can be of various types. In classical FD, affected males possess any one of 
a number of pathogenic allelic defects of the GLA gene [69, 71]. The most common 
and frequent ones are point mutations including missense or nonsense nucleotide 
substitution (approximately 70%), other defects such as small deletions, insertions, 
polymorphism, large and small gene rearrangements and genetic changes that impact 
on mRNA splicing [17, 70, 72, 73]. The missense mutations have one of three effects:  
1- It causes an alteration to the active site of the enzyme.  
2- It can affect correct folding and hence stability of the resultant protein.  
3- It can negatively affect the enzyme function. 
Most of the identified mutations in the GLA gene are family specific and, as such, 
occur in single-family pedigrees [69, 71, 74-77]. Unlike mutations that impact on the 
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protein, mutations involving CpG dinucleotides upstream of the promotor region have 
been found in unrelated families of different ethnicities and geographic backgrounds. 
Haplotype analysis of mutant or variant alleles that have been identified in several 
families has revealed that those families carrying rare alleles are probably related, 
while those identified with mutations involving the CpG islands are not [78]. To date, 
the identification of novel mutations; data is not available regarding the frequency of 
germline mosaicism. 
On the other hand, a number of GLA variants have been identified in atypical late 
onset Fabry patients, such as D313Y, R118C, S126G, IVS0-10C>T, IVS4-16A>G 
and IVS6-22C>T. The variant D313Y is a common variant identified within exon 6 of 
the GLA gene. Compared to wild-type GLA, this variant displays decreased enzymatic 
activity in vitro and reduced activity at neutral pH, the net result being low plasma α-
gal-A activity. This variant has been identified in approximately 0.45% of normal 
individuals (n = 800 alleles). As this variant possesses approximately 60 % of the 
activity of the wild type protein, D313Y, like many of the aforementioned variants, is 
a variant that does not cause typical presentations of FD [79]. Classical phenotypes of 
the disease associated with mutations resulting in complete loss of the gene product’s 
function while the late onset variants phenotypes of the disease potentially associated 
with mutations resulting in amino acid substitutions [80]. 
In Fabry patients carrying cardiac variants, virtually all individuals possess missense 
mutations or mutations that affect mRNA splicing. Unlike mutated forms of GLA 
observed in classical Fabry patients, these so-called cardiac variant proteins possess 
residual enzymatic activity [55]. Representative mutations include I91T, R112H, 
F113L, N215S, M296I, R301Q, and G328R. Interestingly, the N215S mutation has 
been identified in several unrelated individuals carrying the cardiac variant. Unlike 
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cardiac variants, virtually all renal variants identified to date are associated with 
missense mutations [60]. 
 
Despite extensive efforts, attempts to establish a correlation between genotype and a 
particular phenotype have proved challenging. This appears to be due to the variation 
observed in the age of onset, the rate of disease progression and organ involvement 
making the clinical presentations variable even in the same family [81]. 
The heterogeneity of FD suggests that other independent factors such as other genetic 
modifiers and the environmental factors may play an important role in establishing 
disease progression in both genders. Nonetheless, it is not clear yet if there are 
specific factors can have a role in the modification of the disease course. The role of 
X inactivation in females has been suggested, but this alone cannot explain the 
clinical variability. It has been reported that typical Fabry females can have skewed X 
inactivation but inconsistently [80, 82-84]. There are certain mutations which have 
been noted in both classical and cardiac phenotypes such as A112H, A301G, and 
G328A suggesting that other modifying factors are involved in dictating disease 
severity and course. Figure 1.5 shows the chance of transmitting FD from affected 




Figure 1.5 Genetic of Fabry disease: The heterozygous Fabry females have a 50% 
chance during each pregnancy of transmitting the gene to their children (left panel). 
Affected hemizygous Fabry males transmit the disease to all of their daughters and 




1.5 THE BIOCHEMISTRY OF FABRY DISEASE 
 
FD results from an error in the metabolic pathway affecting GSLs degradation; 
mainly Gb3 and its related derivatives. This is due to insufficient/deficient expression 
and/or activity of the hydrolase key enzyme (α-gal-A). Subsequently, GSLs 
accumulate in various tissues and organs. The main substrate GSLs is Gb3, which can 
be substituted into various related derivatives. This is achieved due to either 
modifications in the sphingoid base, generating various analogues of Gb3, or, 
additionally due to variations in the fatty acid chain moieties that form various Gb3 
isoforms. On the other hand, Lyso-Gb3, which can be generated as described 
previously by a deacylation process of the major accumulated substrate, Gb3. In the 
same manner, Lyso-Gb3 can be substituted into various related derivatives due to 
modifications in the sphingoid base, generating various derivatives of Lyso-Gb3 
(termed as Lyso-Gb3 analogues). Therefore, Lyso-Gb3 and its analogues play a role 
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in the diversity of FD. The causative role of several Lyso-Gb3 analogues has been 
postulated to be involved in the aetiology and pathogenesis of FD [85]. 
1.5.1.1 The Human α-Galactosidase-A Enzyme 
 
The human body contains two types of α-Galactosidase enzymes: A and B. The α-gal-
A enzyme is a lysosomal exoglycohydrolase enzyme which is responsible for 
degradation of GSLs; mainly Gb3 and its derivatives such as Lyso-Gb3. Any defect in 
the activity of α-gal-A enzyme will block the degradation pathway and the subsequent 
accumulation of un-catabolised metabolites in various locations in the body. The 
structure of the key-enzyme α-gal-A can be studied either by three-dimensional X-ray 
crystallography [86] or by gel electrophoresis [87]. The α-gal-A enzyme functions as 
a homodimer, comprising two 50 kDa glycosylated subunits. It contains three 
functional N-glycosylation sites. Specifically, α-gal-A enzyme recognizes the GSLs 
substrates in the terminal α-galactose. Therefore, this key enzyme is responsible for 
the hydrolytic cleavage between the galactose residues in GSLs. This enzyme cannot 
act on the other portions of GSLs such as the terminal β-galactose or GSLs containing 
α-N-GalaNAc. 
One of the physical properties of α-gal-A is the requirement of an acidic pH to 
function optimally. It has been demonstrated that GSLs hydrolysed by α-gal-A in 
human lysosomes is achieved at an acidic pH. This finding has been proven by Aerts 
and co-workers in vitro, who showed that the degradation of Lyso-Gb3 was low at 
neutral pH [46]. Moreover, Dean and co-workers [87] have shown that in vitro, the 
catabolism efficiency of Lyso-Gb3 by α-gal-A is 50 fold less compared to Gb3. 
It has been shown that the activity of α-gal-A is commonly absent in symptomatic 
hemizygous Fabry males. Nonetheless, a various residual activity of α-gal-A ranging 
between normal and nearly completely absent, has been shown in both Fabry females 
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and atypical late onset Fabry males[88]. This residual enzyme activity cannot be used 




1.6 PATHOPHYSIOLOGY OF FABRY DISEASE 
 
 
FD is characterised by the complete or partial loss of α-gal-A activity. The loss of 
enzymatic activity, results in the accumulation of neutral GSLs mainly Gb3 and its 
derivatives in the lysosomes of cells. Smooth muscle and endothelial cells of target 
organs are primarily affected resulting to the predominance of vascular complications 
seen. 
The GSLs accumulation compromises cellular function and may lead to cell death. 
This, in turn, can trigger inflammation and the generation of fibrotic responses [80]. It 
has been estimated that GLA variants or mutants that still retain an average of 7.5% of 
residual enzyme activity is sufficient to prevent the accumulation of GSLs and the 
ensuing clinical manifestations [29, 80]. Unlike Fabry hemizygotes, Fabry 
heterozygotes can have significant amounts of residual α-Gal-A activity. Despite this 
they still display a spectrum of clinical disease extending from being asymptomatic to 
severe organ damage. Hence residual α-gal-A activity is a poor predictor of the 
clinical course [29, 80]. 
 
Over time, the aberrant accumulation of GSLs leads to organ dysfunction and the 
clinical manifestation of FD. While the mechanisms involved in mediating tissue 
damage are not fully resolved, they are thought to arise through poor perfusion of 
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oxygen, caused by the accumulation of GSLs in the vascular endothelium lining key 
organs such as the kidneys, heart, nervous system, and skin [29, 80, 90]. 
The accumulation of GSLs in the endothelial cells of the renal vasculature, podocytes 
leads to vascular occlusion, glomerulosclerosis and ultimately renal failure [91, 92]. 
While accumulation of GSLs in mesangial cells has been documented, its contribution 
to renal failure is unclear [93]. 
The accumulated GSLs in all major cell types’ cellular components of the heart 
(endothelial cells, vascular smooth-muscle cells, cardiomyocytes, valvular fibroblasts 
and conduction system cells) play a role in the pathophysiology of cardiac disease in 
Fabry patients. However, other mechanisms such as hypertrophy, apoptosis, necrosis, 
and fibrosis may contribute to cardiac disease as well [80, 94]. 
 
Fabry patients are at increased risk of developing strokes. This may occur through 
cardiogenic embolism or aberrant activation of the coagulation pathway in vessels due 
to heightened reactivity [95]. These factors may be exacerbated in Fabry patients who 
have other underlying prothrombotic risk factors [96]. Abnormalities in the cerebro-
vasculature and its associated effects on cerebral circulation with substantial cerebral 
hyperperfusion in the posterior cerebral circulation, can all contribute to 
neurovascular disease [97, 98].  
The acute pain and acroparesthesia frequently observed in Fabry patients are believed 
to occur due to the accumulated GSLs in neurons, spinal cord and dorsal root ganglia, 
which can lead to atrophy of small unmyelinated nerves [29, 90]. Moreover, poor 





1.7 CLINICAL MANIFESTATIONS OF FABRY DISEASE 
 
The clinical manifestation of FD are heterogeneous with multi-systemic 
manifestations including a wide spectrum of symptoms that are manifest in the skin, 
eye, nervous system, heart, kidneys and other body organs and tissues [29]. Onset of 
organ involvement for classical Fabry patients is age dependent (Table 1.2). 
Generally, in classical X-linked disorders, females act as carriers of a mutation but do 
not show symptoms (e.g. red-green blindness in males). Nonetheless, heterozygous 
Fabry females can present in the same way as their male counterpart perhaps at a later 
age [29, 99-101]. 
 
Male sufferers show symptoms at an early age, while females display symptoms when 
older. Both male and female Fabry patients covered in a study by Mehta [50], showed 
symptoms of the disease at different ages. The study showed that disease severity in 
the affected organs increase considerably with age for both genders. . 
The typical onset of FD manifestations in childhood include angiokeratomas, 
hypohidrosis, corneal opacities and painful acroparesthesias [30, 102]. 
It has been reported that Fabry patients with renal and a cardiac variants that have 
splicing and missense mutations don’t show the classical onset of the disease in 
childhood such as angikeratoma. Fabry patients with the cardiac variant develop 
arrhythmias, LVH and cardiomyopathy. All these manifestations can appear from 40 
years of age onwards. Moreover, Fabry patients with the renal variant who don’t 
develop the typical early symptoms can develop proteinuria and subsequently end-
stage renal disease in the fifth decade of life [30, 48, 53, 60, 103-105]. MacDermok 
[64] has stated that the life span of Fabry patients is reduced on average by 20 years 
compared to normal healthy individuals. On the other hand, previous studies 
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suggested that within an average of a decade later, Fabry heterozygous females can 
develop similar manifestations exactly like Fabry hemizygous males, regarding the 




Symptoms Age at onset 
- Neuropathic pain 
- Ophthalmological abnormalities (cornea   verticillata and 
tortuousretinal blood vessels) 
- Hearing impairment 
- Dyshidrosis (hypohidrosis and hyperhidrosis) 
- Hypersensitivity to heat and cold 
- Gastrointestinal disturbances and abdominal pain 
- Lethargy and tiredness 
- Angiokeratomas 
- Onset of renal and cardiac signs, e.g. micro-albuminuria, 





- Extension of any of the above 
- Proteinuria and progressive renal failure 
- Cardiomyopathy 
- Transient ischaemic attacks, strokes 




- Worsening of any of the above 
- Heart disease (e.g. LVH, angina, arrhythmia and dyspnoea) 
- Stroke and transient ischaemic attacks 





Table 1.2 Typical signs and symptoms of FD [108]: a table shows the various signs 




The clinical manifestations of FD can vary by the type and extent of the organ 
involvement. The clinical manifestations can be classified according to the organ in 




1.7.1 Neurological manifestations 
1.7.1.1 Acroparesthesia 
This painful small fiber neuropathy presents with intermittent bouts of burning and 
tingling pain in the hands and feet. It is the earliest manifestation and most disabling. 
Acroparesthesia can be triggered by factors such as exercise, stress, fever, fatigue and 
changes in the weather or temperature [80]. As with other affected tissues, the 
accumulation of Gb3 in Schwann cells and dorsal root ganglia together with deposits 
in neurons of the CNS disrupt neuronal cell function. However, the effect of Gb3 
accumulation in neuronal cells appears to have little. 
 
1.7.1.2 Cerebrovascular manifestations 
Cerebrovascular manifestations in FD were not recognized in early studies because 
renal and cardiac events were more evident and computerized tomography and 
magnetic resonance imaging (MRI) were not readily available [109, 110]. However, 
in recent years, many cerebrovascular abnormalities, including early onset stroke, 
transient ischemic attacks, hemiparesis, diplopia, dizziness, nystagmus, dysarthria, 
dementia and ataxia have been identified in Fabry patients [71, 111, 112]. Of 
particular concern is the vulnerability of Fabry patients to early ischemic stroke, due 
in part to a thickening of small arteries; an effect which is due to the accumulation of 
associated lipids mainly Gb3 [113]. The formation of such thrombi may be enhanced 
due to inflammation and adhesion of neutrophils and monocytes to endothelial cells 
lining the vessels [114]. In a retrospective study performed by Grewal, ischemic 




The risk of haemorrhagic stroke is increased in Fabry patients because of 
hypertension due to renal failure [113]. Recently, MRI employed in order to quantify 
cerebral vasculopathy in 50 Fabry patients with  an average age of 33 [115]. However, 
only 38% of Fabry patients showed a correlation between the presence of cerebral 
lesions and neurologic symptoms, neurological involvement increased with age, with 
all patients over the age of 54 years displaying some form of cerebrovascular 
involvement [115]. In a study by Mehta and colleagues, who studied 366 Fabry 
patients, cerebrovascular events appeared to be more prevalent in females than males, 
with 27% of 165 Fabry females and 12% of 201 Fabry males experiencing a stroke, 
transient ischemic attack, or prolonged ischemic neurologic deficit [50]. A study of 
white matter lesion (Figure 1.6) in 27 Fabry patients showed a comparable incidence 
(36% of 14 Fabry females and 31% of 13 Fabry males) and the severity level in both 
genders [116]. 
The main involvement of the CNS seems to be attributed to effects on endothelial 
cells within the vasculature which results in Cerebrovasculopathy and an increased 
likelihood of a stroke or transient ischemic attack. Unlike many other LSD effects on 
the CNS appears to be less prominent in FD. However, like other sphingolipid 
disorders, neurological abnormalities are common [71, 117, 118]. Using Proton 
magnetic resonance spectroscopy the presence of diffuse central neuronal 
involvement in cortical and subcortical locations has been identified in Fabry patients 
[119]. The degeneration of both small myelinated and unmyelinated nerve fibres has 
been documented in Fabry patients, a finding which may account for the pain and 
hypohidrosis associated with FD [71, 118]. In a similar vein, the loss of small 
peripheral sensory neurons in the dorsal root ganglia [118] and small fiber 
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dysfunction [120] may be related to autonomic neuropathy, pain and temperature 
sensitivity. 
 
Figure 1.6 Clinical manifestations, White matter: MRI section for a classical Fabry 
patient enrolled in the current study. Brain MRI section shows white matter spots. 




1.7.1.3 Sensory neural hearing loss 
While the clinical manifestations of FD in classical patients involve the kidney, heart, 
and brain, several recent studies have reported that FD patients also experienced some 
form of hearing loss [121-123]. Sakurai and colleagues reported that sudden 
sensorineural hearing loss was common in both male and female patients, although 
the incidence was always higher in affected Fabry males. Furthermore, all patients 
with renal dysfunction also displayed some form of hearing impairment [123]. While 
the exact mechanisms involved are still unclear, studies in the mouse model of Fabry 
disease have identified the presence of densely-stained material in cells of the inner 
ear stria vascularis [124]. Studies performed in Europe and North America, have 
26 
 




1.7.2 Skin manifestation 
1.7.2.1 Angiokeratomas 
One distinct clinical feature of Fabry patients, is the presence of cutaneous vascular 
lesions termed angiokeratomas [126]. These lesions are found almost universally 
among affected Fabry males and in more than half (55%) of Fabry females[106]. 
These clusters of reddish purple, non-blanching lesions are usually distributed 
predominantly on the buttocks, groin, umbilicus, and upper thighs. Their size ranges 
from pinpoint to several millimetres. Their shape can be flat or marginally raised. 
Angiokeratomas lesions are very rare in childhood but they become more common 
starting from adolescence and early adulthood; with age, they become larger and more 
numerous. 
1.7.2.2 Hypohidrosis/Anhidrosis 
Hypohidrosis or anhidrosis is another classic feature of FD, with affected individuals 
displaying an impaired ability to sweat or perspire. This condition leads to dry skin 
and heat intolerance (hot or cold temperature extremes); individuals also frequently 
exhibit exercise intolerance. In classical Fabry patients, this symptom normally 
presents in childhood or adolescence. This condition may result from selective 
peripheral nerve damage [71, 127] or the formation of cytosolic lipid deposits in 
capillaries surrounding sebaceous glands [128]. In almost 50% of cases, the 




1.7.3 Gastrointestinal Tract 
Gastrointestinal disturbances manifest themselves as episodes of diarrhoea, vomiting, 
nausea, weight loos, irritable bowel syndromes and post-prandial bloating and pain 
[49, 130]. The improvement in the baseline diarrhoea in some Fabry patients has been 
reported with a decrease in the severity and frequency abdominal pain after ERT 
administration [131, 132]. 
 
1.7.4 Kidney Manifestations 
Renal pathology is a hallmark of classical FD and appears to be one the most frequent 
causes of death. The effects are progressive and, in most instances occur during the 
third to fifth decade of life. Isosthenuria due to concentration defects is among the 
first manifestations of kidney malfunction; however, in most cases, this does not 
prompt testing for FD diagnosis [133]. During late adolescence, Fabry patients 
develop proteinuria, indicating glomerular dysfunction due to Gb3 accumulation in 
the podocytes, progressive renal failure [71]. 
Azotemia usually occurs by the third to fifth decade of life [71] while renal failure has 
also been reported in younger Fabry patients [134]. Azotemia and progressive 
proteinuria reflect deterioration in renal function. Uremia usually ensues and heralds 
end-stage renal disease. According to data from the Fabry Registry, 430 of 1158 
males and 507 of 1077 females (Genzyme-sponsored Fabry Registry) exhibited 
chronic kidney disease.  
In one study, performed on young hemizygotous Fabry males, diffuse lipid 
accumulation was observed in glomerular, vascular, and interstitial cells, and in distal 
tubules and loops of Henle. With increased age, intimal thickening and degenerative 
changes were also apparent [135]. 
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Collectively, the effects on the kidney manifest themselves as progressive renal 
Insufficiency (proteinuria, isothenuria, azotemia, high plasma creatinine levels) and 
an advanced stage of renal failure; the latter is the main cause of high mortality in FD. 
1.7.5 Heart Manifestations 
The frequency of Cardiac involvement in Fabry patients is variable and increases in 
severity with age like most aspects of FD. The most common cardiac anomalies 
include LVH (Figures 1.7 and 1.8), coronary artery disease, regional systolic 
dysfunction, diastolic dysfunction [136] and conduction abnormalities. These 
disorders precipitate congestive heart failure, arrhythmias and myocardial infarction 
[71, 137, 138]. 
Some of the cardiac structural changes associated with FD may not be related to 
significant loss of cardiac function, but may serve as useful markers of disease 
progression and severity [139]. Defects identified by electrocardiography include 
LVH, ST-T wave changes, conduction abnormalities and arrhythmias [71]. 
Echocardiographic (ultrasound) abnormalities include concentric LVH, aortic root 
dilatation, dilated cardiac chambers, myocardial dysfunction, and valvular disease 
(usually involving the mitral valve) [134, 140, 141]. Aortic root dimension and Left 
ventricular wall thickness usually increase with age [142, 143]. Contrast-enhanced 
MRI shows delayed gadolinium enhancement indicating myocardial fibrosis [144].  
Cardiac events were reported to occur in 23% of both males and females enrolled in 
the Fabry Registry as of December 31, 2007. These cardiac-related events were 
occurred at median ages of 42 years in males and 48 years in females [Genzyme 
Fabry Database]. A prospective study performed by Kampmann and colleagues [145] 
identified a high correlation between the appearance of LVH and patient age in a 
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small cohort of females diagnosed with FD (mean patient age of 39.6 years with a 
range of 6.1 to 70.8 years). In this study, 25 of the women over age 45 were 
diagnosed with LVH [145]. In another study from the same group, 39% of women 
and 30% of men were identified as having right ventricular hypertrophy [146]. 
 
Figure 1.7 Chest X-Ray showing a Permanent Pacemaker Implantation in 
patient with FD: It is inserted for Bradyarrythmia which is a known cardiac 





Figure 1.8 Clinical manifestations, left ventricular hypertrophy (LVH): two MRI 
sections from a male classical Fabry patient enrolled in the current study. MRI 




1.7.6 Pulmonary Manifestations 
Hemizygous Fabry patients may develop airway and pulmonary defects that can result 
in bronchitis and a shortness of breath (dyspnea) [71]. Although not considered as a 
principle feature of FD, patients can experience airway obstruction, an effect that is 
due to airway narrowing due to GSLs deposits in epithelial cells lining the airways. In 
a recent study, 36% of Fabry males were found to have some form of airway 
obstruction [147]. The extent of respiratory symptoms and obstructive impairment has 
been found to correlate with increased age. Interestingly, pulmonary manifestations 
were only observed in patients with either frameshift mutations or the presence of  the 
D264V missense mutation, suggesting a possible genotype/phenotype correlation 
[147]. 
 
1.7.7 Musculoskeletal and Growth Abnormalities 
Although somewhat less common, Fabry hemizygous males can develop permanent 
deformity in their hands. This usually involves the distal interphalangeal joints of the 
fingers, limiting extension of the terminal joints. Other manifestations include a 
general retardation in growth, a delayed onset of puberty, and sparse, fine facial hair 
[71]. 
 
1.8 DIAGNOSIS OF FABRY DISEASE 
 
Due to the non-specific nature of FD, diagnosis can be delayed for years if not 
decades [49, 107, 148]. Classical Fabry hemizygous males normally have the disease 
onset in early childhood or adolescence. The most common signs and symptoms 
include bouts of severe pain in the extremities (acroparesthesias), the appearance of 
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cutaneous vascular lesions (angiokeratomas), and an inability to sweat (anhydrosis, 
hypohidrosis). Affected adults also suffer from unexplained fatigue and intolerance to 
extremes of temperature. Additional symptoms include corneal and lenticular 
opacities and the excretion of protein in the urine (proteinuria). Deterioration of renal 
function progresses during life to complete renal failure and death (end-stage renal 
disease).  
Due to residual α-gal-A activity, Fabry heterozygous females typically have milder 
symptoms and present at a later age of onset than classical Fabry males. While 
affected Fabry females are rarely asymptomatic, they may have symptoms that are 
less severe than those observed in classical Fabry males. Fabry males who possess 
residual a-gal-A activity may display cardiac variant or renal variant phenotypes. 
Affected individuals usually present in the sixth to the eighth decade of life with 
LVH, mitral valve defects or cardiomyopathy. While such patients may show 
proteinuria, there is no evidence to suggest this will progress to end stage renal 
disease. Alternatively, they may display a renal variant phenotype. This is associated 
with end stage renal disease yet rarely experience symptoms such as acroparesthesias 
and angiokeratomas). Hoigne and others [149] have reported that the combination of 
four criteria in patients presenting with cardiac involvement (LVH), acroparesthesia 
or polyneuropathy, anhydrosis, the absence of hypertension, and the presence of 
Sokolow criteria for LVH, proved useful in distinguishing FD from other disorders. 
Pieroni and others [150] noted that Fabry’s cardiomyopathy could be identified by 
ECG and the appearance of a hypoechogenic line described as a subendocardial with 




Once the clinician suspects that the patient may have FD, a diagnosis can be made in 
men by screening plasma or purified leukocytes for α-gal-A activity, or by gene 
sequencing [151]. Although the concentration of Gb3 is often raised in the plasma or 
urine of patients with the classical form of FD, a broad range of values and plasma 
concentrations exist that might be normal in Fabry females. The concentration of Gb3 
is also frequently used to monitor the effectiveness of ERT in Fabry patients with low 
sensitivity. However, the levels of plasma or urinary Gb3 are only of diagnostic use if 
they are sufficiently high before the start of ERT [152]. Unlike the situation in males, 
the diagnosis in Fabry females can only be achieved by gene sequencing, and the 
identification of a disease-associated mutation. 
While increased levels of protein, the presence of red blood cells, desquamated 
epithelial cells, and characteristic Maltese crosses are observed in urinary sediments 
obtained from adolescents, significant signs of deterioration in kidney function are not 
manifest until the patient is older. 
Evidence of renal damage can be obtained using polarization microscopy of urinary 
sediment, which may reveal the presence of birefringent lipid globules with the 
characteristic Maltese cross configuration; so-called “Maltese crosses.” The presence 
of birefringent inclusions in the urinary sediment (i.e. fat-laden epithelial cells or 
mulberry cells) may also be noted on closer examination.  
1.8.1 Current methods of Fabry Disease Diagnosis 
The diagnosis of FD is mainly based on the individual's clinical presentation. 
Currently, the diagnosis is made through a variety of methods, and includes: 
• Measurement of the level of a-gal-A activity by an enzyme assays; usually 
performed on isolated leukocytes from blood. However, this enzyme assay is not 
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reliable for the diagnosis of classical FD in females due to the random nature of X-
inactivation. 
• Molecular genetic analysis of the GLA gene is the most accurate method of 
diagnosis in females, particularly if the mutations have already been identified in male 
family members. Almost 800 mutations have been identified and those which 
predispose to classical or non-classical FD have been recognised.  
• Measurement of plasma or urinary GSLs levels such as Gb3 or Lyso-Gb3 and their 
isoforms/analogues by HPLC or LC-MS/MS.  
• Tissue biopsy taken from the kidney or the heart to confirm the build-up of lipid 
deposits. 
• Various investigations such as kidney function test, ECG and MRI.  







 The GLA gene sequencing assessing for a known familial 
mutation 
Males 
 The α-gal-A enzymatic activity in peripheral leucocytes or 
plasma  
 The GLA gene sequencing and identification of disease-causing 
mutation or testing for all known familial mutations 
Females 
 The GLA gene sequencing and identification of disease-causing 
mutation or testing for a known familial mutation (α-gal-A 
enzymatic activity in peripheral leucocytes is not preferred and 
plasma levels are unreliable) 
 




1.8.2 Challenges and current issues in diagnosis of Fabry disease 
The non-specific nature of the symptoms in FD, coupled with its clinical 
manifestations make the diagnosis of FD difficult [80, 153]. In addition, other factors 
hamper the diagnosis, such as the rarity of FD, the X-linked nature in heterozygous 
Fabry females, the general lack of awareness of the disease, and some early signs of 
FD being shared with other more general pathological conditions. 
 
Measuring the activity of α-gal-A in leukocytes can be useful in the diagnosis of adult 
hemizygous Fabry males [153, 154]. However, the method is inadequate in case of 
heterozygous Fabry females and late onset Fabry patients such as those with cardiac 
variants, where the patients can show residual levels of the enzyme activity similar to 
those in healthy individuals [153, 154]. The molecular analysis procedures could be 
useful as a diagnostic tool for the individuals having FD history in family members. 
On the other hand, all the diagnosis procedures mentioned above are of no use in 
follow up of disease progression and assaying the response to treatment.  
 
Recently, it has been suggested that the accumulation of Gb3 and Lyso-Gb3 and their 
related isoforms/analogues in biological samples such as plasma and urine can be 
used as diagnostic biomarkers with inconsistent sensitivity due to the heterogenotypic 
and heterophenotypic specificities of FD [26, 155]. Despite the biological roles of 
Lyso-Gb3 in deactivation of the key enzyme and stimulation of the proliferation of 
cardiomyocytes and other smooth muscle cells, some roles of Lyso-Gb3 in the 





1.9 TREATMENT OF FABRY DISEASE 
 
 
1.9.1 Enzyme Replacement Therapy 
Enzyme replacement therapy (ERT), using intravenous infusion of recombinant α-gal-
A, has become the standard treatment for symptomatic Fabray patients since 2001 
[35]. Despite its clinical benefit being limited, mainly slowing progression and 
requires a long time to appreciate the benefit, previous studies showed the importance 
of ERT in FD administration. It has been reported early initiation of ERT minimizes 
most of the complications and stabilizes FD progression. It may well be true that 
damaged tissues may not be reversed by ERT [108]. 
Two different types of recombinant α-gal-A (genetically-engineered of the human 
enzyme) have been approved as treatment for symptomatic Fabry patients. The first 
treatment is agalsidase-α (Replagal from Shire HGT) with a dose of (0.2 mg / kg body 
weight / 2 weeks). The second treatment is agalsidase-β (Fabrazyme from Genzyme 
Corp) with a dose of (1.0 mg / kg body weight / 2 weeks) [44, 45, 89]. The consensus 
is that ERT has a limited impact on the long-term outcome of patients with FD. While 
the results from long-term registry studies e.g. Fabry outcome survey (FOS) [50] have 
shown encouraging results, others have shown that the effects of ERT on cardiac, 
renal, and cerebrovascular outcomes are comparable between treated and untreated 
cohorts [156, 157]. 
A recent Cochrane review has also highlighted the poor quality of evidence in favour 
of ERT for the treatment of Fabry patients. Despite this ambiguity, Desnick and co-
workers advocate the use of ERT in all affected males, in Fabry females with 
significant disease, and those with end stage renal disease undergoing dialysis [151, 
158] given that all are at high risk for of developing cardiac, cerebrovascular, and 
neurologic complications such as strokes. 
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Aerts’s team [46] studied the response of plasma Lyso-Gb3 in Fabry patients, to 
elongated ERT using agalsidase-α treatment. The study illustrated a significant 
decrease in the levels of Lyso-Gb3 after ERT with recombinant α-gal-A in the first 
year, but this decrease did not reach the reported levels of healthy individuals. Aerts 
and co-workers [46] suggested that the observed drop in Lyso-Gb3 levels after ERT 
could be a result of intra-lysosomal direct degradation of Lyso-Gb3 or caused by the 
complete clearance of the stored origin source Gb3. 
On the other hand, it has been reported that some hemizygous Fabry patients 
receiving ERT showed a Lyso-Gb3 levels raise following the early drop; which may 
result from treatment resistance due to development of α-gal-A antibodies [46, 159-
162]. 
There are many challenges face applying ERT as an effective treatment for Fabry 
patients. Firstly, ERT is extremely costly [156, 163] for example previous studies 
showed that the average cost of ERT for a single typical Fabry patient can exceed £8 
million per patients life time [156]. Other challenges should be considered such as 
being ERT an invasive procedure, burdensome for the patients where the dose is 
repeated each 2 weeks and it can cause infusion reaction. Moreover, production of α-
gal-A antibodies has been reported in some Fabry patients under ERT course, which 
may cause reverse increasing levels for un-catabolised GSLs substrates [159, 162]. 
Finally, other challenges related to difficulties in the treatment preparation and storage 
should be taken in the consideration. 
The initiation age of ERT in Fabry patients is still debatable. It has been suggested 
that initiation of ERT at early stage of the disease could enhance the efficacy of the 
treatment, secure better outcomes and increase lifespan of the patients. Nonetheless,   
both genders with atypical late onset FD and heterozygous females with typical FD 
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show residual activity of the key-enzyme α-gal-A [88] and the ERT effectiveness in 
these groups of Fabry patients is questionable.  
Some ERT guidelines suggest different criteria for the treatment initiation in Fabry 
hemizygous male and Fabry heterozygous females [158]. Nevertheless, a study by 
Hughes and colleagues [52] suggested that the assessment criteria of ERT in both 
Fabry genders should be similar. 
The levels of Gb3 in biological samples have been measured to monitor the efficacy 
of ERT with limited sensitivity. Gb3 levels in biological samples decrease 
considerably within two weeks after starting ERT but may develop α-gal-A antibodies 
hence Gb3 level may increase again [44, 45, 47, 164]. On the other hand, Lyso-Gb3 
levels in biological samples from Fabry patients markedly decreased after starting 
ERT [165] while the complete normalisation of Lyso-Gb3 levels was not achieved. 
Togawa and co-workers [166] studied the levels of Gb3 and Lyso-Gb3 in Fabry mice 
monitored with recombinant α-gal-A. Considerably, tissue Lyso-Gb3 levels decreased 
more than Gb3 levels especially in kidney suggesting that Lyso-Gb3 could be more 
accurate biomarker compared with Gb3 to monitor ERT. 
 
Smid et al. [167] reported that male Fabry patients on ERT with agalsidase-β showed 
elevated concentrations of plasma Lyso-Gb3 after decreasing the dosage of the 
enzyme or switching to agalsidase-α; however, this elevation proved not to be 
statistically significant. The interpretation of their findings is confounded by the fact 
that only a small numbers of patients were enrolled in the study, The inclusion of two 
apparent outliers with very high plasma Lyso-Gb3 concentrations and the multiple 
changes in the dosage of agalsidase-β made necessary by an unexpected interruption 
in the supply of the medication also had a negative impact on the study. 
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Treatment with ERT is very expensive, and cost-effectiveness of ERT is arguable 
[156, 163] given the high cost of ERT and the efficacy of the treatment in some cases 
such as heterozygous Fabry females and late onset FD patients (e.g. cardiac variants). 
Moreover, the time and age where ERT should be administered usually is not known 
and the effect of production of anti- recombinant α-gal-A antibodies should be 
administrated [162]. Hence, a reliable biomarker for FD that aids diagnosis and 
disease monitoring is fundamental to counter the above challenges and to avoid the 
use of other invasive diagnostic procedures such as cardiac and kidney biopsy. 
 
In order to prove the efficiency of ERT in FD monitoring, many challenges confirm 
the importance of having a reliable biomarker for FD. These challenges are either 
related to the treatment system or related the diagnostic procedures [168]. Examples 
of these challenges are as follows: 
a- Cost-effectiveness of ERT: the reported cost of ERT is very expensive. Moreover, 
it has been suggested that the efficiency of ERT in typical Fabry hemizygotes is 
limited in terms of economic evaluation of the treatment in one side comparing 
with quality of the life, organ necrosis and life expectancy in the other side [156, 
163].  
b- Efficacy of various suggested doses of ERT [169-171]. 
c- Influence of production of α-gal-A antibodies especially in hemizygous Fabry 
males who show typical manifestations of the disease [162]. 
d- It is well-known that the other diagnostic procedures for FD may be invasive such 





1.9.2 Other treatment Strategies for Fabry disease: 
Other therapeutic options of FD are under study including pharmacological 
chaperone, substrate reduction and gene therapy [172-174]. 
 
1.9.2.1 Chaperone 
While large mutations within the GLA gene lead to the absence of protein or 
expression of a catalytically inactive protein, missense mutations often produce an 
aberrant misfolded protein that possesses residual enzymatic activity. Misfolded 
proteins are either degraded, retained in the endoplasmic reticulum or partitioned to 
other intracellular organelles [175, 176]. Pharmacological chaperones have been 
shown to bind and stabilize certain GLA mutants. Chaperone binding promotes correct 
protein folding and trafficking to the lysosome, where the mutant protein can 
function, albeit less efficiently [177]. 
Chaperone therapy has been proposed as a feasible strategy for treating certain LSD 
[177, 178]. Migalastat hydrochloride (1-deoxygalactonojirimycin HCl) has been 
shown to bind and stabilize wild-type and mutant forms of GLA [179, 180]. 
In pre-clinical studies, Migalastat HCl has been shown to reduce the storage of Gb3 in 
vitro and in vivo in a mouse model of FD [181-183]. Recent phase 2 clinical trials in 
patients with amenable GLA mutations have shown that Migalastat HCl increases 
enzymatic activity and reduces the accumulation of Gb3 in the blood, skin, and 
kidneys [184, 185]. Migalastat HCl is currently being evaluated in phase 3 clinical 
trials as a potential treatment for FD. 
In contrast to ERT, pharmacological chaperones are non-invasive, orally available, 
and have a broad tissue distribution, including access to the CNS [186]. While 
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chaperone therapy is genotype-specific, it is estimated that one-third to one-half of 
mutations of the 630 gene mutations identified, may be amenable to currently 
available chaperone therapy [178]. Pre-clinical studies have shown that 
pharmacological chaperones and ERT may be beneficial in the management of FD 
[187], as the chaperones may also enhance the stability, and efficacy of the 
recombinant enzymes. 
 
1.9.2.2 Substrate reduction 
Substrate reduction therapy is a novel therapeutic approach that aims to decrease the 
synthesis of the substrate Gb3, by targeting enzymes involved in its biosynthesis [188, 
189]. One such agent, Miglustat, reduces the biosynthesis of GSLs [190]. While 
Miglustat has shown positive results in the mouse model of FD [191], its lack of 
specificity for glucosylceramide synthase, results in a variety of side effects [192, 
193]. Another glucosylceramide synthase inhibitor, Genz-682452, appears to be more 
specific than Miglustat, where, in pre-clinical studies, Genz-682452 lowered the 
levels of tissue Gb3 in mice. Since the majority of Fabry patients are null for a-gal-A 
activity, using substrate reduction therapy a lone is unlikely to be useful. However, it 
has been demonstrated that combining ERT with SRT is a more efficient alternative 
to ERT alone in reducing Gb3 levels, especially in the liver, kidneys, and urine [174]. 
 
1.9.2.3 Gene therapy 
Gene therapy approaches have been investigated in the Fabry mouse model [194-
196]. Early studies utilised retroviral vectors to introduce the normal GLA gene into 
bone marrow haematopoietic stem cells derived from Fabry patients [197]. In this 
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murine model, α-gal-A was able to reduce levels of accumulated Gb3 in various 
tissues [198]. More long-term enzymatic and functional correction in multiple organs 
of the Fabry mouse has recently been achieved through the use of adeno-associated 
viral vectors to deliver the GLA gene [196, 199, 200]. Moreover, immune tolerance to 
GLA was observed in this study. These findings argue well for the use of gene therapy 
in the treatment of FD. 
 
1.10 BIOMARKERS OF FABRY DISEASE 
 
The biomarkers are vital indicators for any disease in order to evaluate the progress of 
the disease and to study the treatment efficacy. In term of metabolic disorder, the 
biomarkers can play a significant role in increasing or dramatically decreasing the 
concentrations of the specific related metabolites. Subsequently, these biomarkers can 
reveal worthwhile factors including the age of onset of the disease and treatment 
efficacy. Two essential biomarkers have been reported Gb3 and Lyso-Gb3 as 
biomarkers for FD diagnosis and treatment efficacy [46, 201-203]. 
Gb3 and more recently Lyso-Gb3 (the product of an alternative catabolic pathway), 
have been detected at elevated levels in the plasma and urine of Fabry patients using 
mass spectrometric (MS) approaches [46, 164, 201, 202, 204]. Furthermore, a series 
of novel Lyso-Gb3 derivatives (e.g. an oxidised form) have been detected and the 
possibility that the levels of these derivatives are related to the various symptoms 







Globotriaosylceramide (Gb3) also known as ceramide trihexoside (CTH) is the main 
precursor metabolic substrate which pathologically accumulates within the lysosomes 
in the various body tissues due to the defective hydrolase enzyme (α-gal-A). 
1.10.1.1 Chemical, Physical and Biological Properties of Gb3: 
The chemical structure of Gb3 (Figure 1-9) comprised ceramide backbone including 
sphingoid base (sphingosine moiety) and fatty acid chain which vary in mammals 
between C16-C26 and a serial of 3 carbohydrates head-groups (galactose-galactose-
glucose). 
The biological role of Gb3 in the living cells similar to the other GSLs which mainly 
includes the cell surface functions such as cell surface antigens,  receptors for 




Figure 1-9 Chemical structure of globotriaosylceramide (Gb3): The figure shows 
the chemical structure of the main accumulated substrate in FD, 
globotriaosylceramide (Gb3) and the action site of the defective key enzyme α-gal-A. 
Gb3 is comprised ceramide backbone including sphingoid base and fatty acid chain 








1.10.1.2 Accumulation of Gb3 in Biological Samples of Fabry Patients: 
The un-metabolised Gb3 accumulates in plasma, urine and other body tissues of 
Fabry patients. Therefore, previous studies indicated that Gb3 may be used to monitor 
the efficacy of ERT and as a diagnostic biomarker although for FD with limited 
sensitivity. 
It has been shown that the excreted urinary Gb3 by both genders of Fabry patients are 
considerably higher compared with healthy individuals [201, 207]. On the other hand, 
elevated levels of plasma Gb3 can be detected in hemizygous Fabry males, while 
female Fabry patients usually show normal plasma Gb3 levels [207]. 
It has been reported that Gb3 levels in biological samples decrease considerably 
within two weeks after starting ERT but α-gal-A antibodies may develop therefore 
Gb3 level may increase again [171, 208-210]. It has been postulated that Gb3 levels 
correlate with vital factors such as mutation type, ERT outcome and gender of Fabry 
patients [201]. Whitfield et al [160] suggested that urinary Gb3 is a potential useful 
biomarker for FD detection and ERT monitoring only in hemizygous males but not in 
heterozygous females. Nevertheless, Aerts and co-workers [46] suggested that there 
are many indicators enhance the theory of Gb3 does not cause direct or instantaneous 
signs of FD for three linked reasons. Firstly, it has been shown that Gb3 accumulates 
in body tissues before the birth. Secondly, most of hemizygous Fabry males lack to α-
gal-A activity. Lastly, it is well-known that the disease manifestations practically are 
lacking in infantile early childhood [89, 152, 211]. Commonly, the conducted studies 
on the role of Gb3 in FD showed erratic correlation between the Gb3 levels excreted 
by Fabry patients in the biological samples and the clinical manifestations of the 
disease [89, 170, 208, 211]. Additionally, Vedder et al [89] stated that there is no 
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correlation between the clinical manifestations of FD and excreted Gb3 in plasma and 
urine of Fabry patients. 
 
1.10.1.3 Gb3 isoforms and analogues 
Gb3 isoforms are defined as Gb3 derivatives result from a modification in the fatty 
acid chain which linked by amide bond with unmodified sphingosine moiety. 
Nevertheless, Gb3 analogues are defined as Gb3 derivatives result from a 
modification in their sphingosine moiety [212]. 
Auray-Blais and co-workers revealed five urinary Gb3 isoforms/analogues which are 
structurally related to Gb3. These analogues were detected in both gender Fabry 
patients but none in healthy individuals. These Gb3 isoforms/analogues structurally 
vary as follows: Gb3-methylated isoforms, Gb3-saturated fatty acid isoforms, Gb3-
hydrated sphingosine isoforms, Gb3-two double bonds isoforms and Gb3-one double 
bond isoforms. These Gb3 isoforms could help in the differentiation between different 
outcomes of the disease [26]. It has been reported that the levels of Gb3 
isoforms/analogous in biological samples from Fabry patients are decreased after ERT 
providing a positive biological response to the treatment [26, 213]. 
 
1.10.1.3.1 Gb3 methylated isoforms 
Auray-Blais and colleagues revealed seven methylated isoforms related to Gb3 [26, 
212]. The isoforms will be expressed as follows: Gb3(nc:d)(as:e), where n represents 
sphingosine group; c represents number of carbon atoms in sphingosine moiety; d 
represents number of double bonds in sphingosine moiety; a represents fatty acid 
group; s represents number of carbons in the fatty acid moiety and e represents 
number of double bonds in the fatty acid moiety while Me abbreviation stands for 
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methylated. Three Gb3 methylated isoforms were detected in both urine and plasma 
from Fapry patients including Gb3(n18:1)(a22:0)Me; Gb3(n18:1)(a22:1)Me; 
Gb3(n18:1)(a24:1)Me; Gb3(n18:1)(a16:0)Me; Gb3(n18:1)(a18:0)Me; 
Gb3(n18:1)(a24:0)Me and Gb3(n18:1)(a24:0)Me [212]. 
Methylated isoform is not detected in Lyso-Gb3 suggesting a significant role could be 
played by this isoform to work as an intermediate agent in the metabolic pathway of  
Gb3 deacylation process to form Lyso-Gb3 [26, 204, 212, 214]. It has been suggested 
that Gb3 methylated isoforms are possibly promising biomarkers for FD [214]. 
 
1.10.1.3.2 Gb3-saturated fatty acids isoforms:  
Auray-Blais and Boutin [26] revealed six Gb3 isoforms of saturated fatty acids as 
follows: Gb3(n18:1)(a16:0); Gb3(n18:1)(a18:0); Gb3(n18:1)(a20:0); 
Gb3(n18:1)(a22:0); Gb3(n18:1)(a24:0) and Gb3(n18:1)(a26:0). All these isoforms 
detected in urine and plasma samples from Fabry patients and result from 
modifications in the fatty acid chain of the ceramide backbone [26, 212]. 
 
1.10.1.3.3 Gb3-hydrated sphingosine analogues:  
Auray-Blais and co-workers [26] revealed urinary Gb3 hydrated sphingosine 
analogue, Gb3(n18:0)(a24:1)H2O which results from a modification in the 
sphingosine moiety. The fragmentation of this analogue by MS/MS involves the 
formation of a hydroxyl group by adding H2O through the double-bond of 
sphingosine group. The hydrated sphingosine analogue is detected as well in the 





1.10.1.3.4 Gb3 isoform/analogue with two double bonds:  
Canadian researchers revealed Gb3 isoforms/analogue with two double bonds [26, 
212]. Theses isoforms/analogues were detected in urine and plasma of Fabry patients 
as follows: Gb3(n18:1)(a24:2) + Gb3(n18:2)(a22:1); Gb3(n18:1)(a22:2) + 
Gb3(n18:2)(a22:1) and Gb3(n18:1)(a24:2) + Gb3(n18:2)(a24:1). 
 
1.10.1.3.5 Gb3 isoforms/analogues with one double bond: 
It has been revealed six Gb3 isoforms/analogues with monounsaturated fatty acid 
chain as follows: Gb3(n18:1)(a16:1) + Gb3(n18:2)(a16:0); Gb3(n18:1)(a18:1) + 
Gb3(n18:2)(a18:0); Gb3(n18:1)(a20:1) + Gb3(n18:2)(a22:0); Gb3(n18:1)(a22:1) + 
Gb3(n18:2)(a22:0); Gb3(n18:1)(a24:1) + Gb3(n18:2)(a24:0) and Gb3(n18:1)(a26:1) + 
Gb3(n18:2)(a26:0). Gb3 isoforms/analogues with one double bond were detected in 
urine and plasma samples from Fabry patients [26, 212]. 
 
1.10.1.3.6 Short chain-Gb3 isoforms 
Manwaring et al [212] revealed a short chain Gb3 related isoform Gb3(n16:1)(a16:0) 
+ Gb3(n18:1)(a14:0). This isoform was detected in plasma samples only. 
 
1.10.1.3.7 Methylated short chain-Gb3 isoforms: 
Manwaring et al [212] revealed a methylated short chain Gb3 related isoform 






1.10.2 GLOBOTRIAOSYLSPHINGOSINE (LYSO-GB3) 
 
Lyso-Gb3 was introduced for the first time as a hallmark biomarker for FD by Aerts 
et al using plasma samples [46]. Thereafter, Auray-Blais and co-workers showed 
elevated levels of urinary Lyso-Gb3 in Fabry patients [202]. It has been shown that 
Lyso-Gb3 is a potential diagnostic biomarker for FD. Rombach et al [215] reported 
that the plasma Lyso-Gb3 concentration showed significant elevation in all 
hemizygous Fabry males and adult heterozygous Fabry females compared to healthy 
individuals. However, young heterozygous Fabry females may show absence or lower 
elevation in Lyso-Gb3. 
 Rombach and collaborators showed a correlation between the elevated levels of 
Lyso-Gb3 and the severity of the clinical manifestations displayed by Fabry patients 
[215]. Togawa et al [166] suggested that Lyso-Gb3 is expected to be a useful 
biomarker for monitoring ERT in FD demonstrating that Lyso-Gb3 levels in Fabry 
mice, are decreased more than Gb3 levels after ERT with recombinant α-gal-A. It has 
been shown that Lyso-Gb3 is superior to Gb3 as a diagnostic biomarker for FD 
especially in case of heterozygous females where Gb3 levels in females usually 
appears as normal [25]. A previous study revealed that plasma Lyso-Gb3 is superior 
to urinary Lyso-Gb3 as a diagnostic biomarker [25]. The study reported that some 
typical Fabry males showed Lyso-Gb3 levels in plasma about 500 fold greater than 
Lyso-Gb3 levels in urine. Alternatively, it has been reported that urinary Lyso-Gb3 
concentrations in Fabry patients correlate with clinical severity of FD [201, 202]. 
Aerts et al [46] introduced plasma Lyso-Gb3 as a promising diagnostic and 




Various biochemical methods have been developed in order to measure Lyso-Gb3 
levels in biological samples in Fabry patients as shown in Chapter 3 (section 3-1). 
 
1.10.2.1 Biochemical and physical properties of Lyso-Gb3 
It is crucial to understand and highlighting the biochemical properties of Lyso-Gb3 in 
order to study its etiologic roles in FD. The chemical structure of Lyso-Gb3 is shown 
in (Figure 1.10). Lyso-Gb3 results from a deacylation process of Gb3 by a 
sphingolipid deacylase [17]. As shown in Figures 1.9 and 1.10, the acyl-amide group 
is replaced by free amine making Lyso-Gb3 a more polar and more water-soluble than 
its diacyl parent (Gb3). Therefore, this chemical structure of Lyso-Gb3 which 
characterised by having a free amine group allows applying some extraction 
procedures such as derivatization process using OPA. 
Moreover, the structure of Lyso-Gb3 shows the hydrophilic nature of this compound 
facilitating its extraction from biological samples using liquid-liquid extraction. On 
other hand, Gb3 is absolutely totally soluble in lipoprotein [46]. Hence, we believe 
that applying a single liquid-liquid extraction procedure (e.g. Bligh and Dyer) to 
extract both Lyso-Gb3 and Gb3 at the same time is attainable where Lyso-Gb3 being 
harvested from the upper phase while Gb3 is harvested from the lower phase.  
Moreover, the free amine reflects the avidity of Lyso-Gb3 to be protonated (H
+
 ion) 
allowing LC-MS analysis on positive mode. Generally, these biochemical and 
physical characteristics allow HPLC mediated purification linked to mass 






Figure 1-10 Chemical structure of globotriaosylsphingosine (Lyso-Gb3): The 
figure shows the chemical structure of globotriaosylsphingosine (Lyso-Gb3) and 
action site of the defective key enzyme α-gal-A. Lyso-Gb3 is resulted from a de-
acylation process of the precursor compound Gb3. So Lyso-Gb3 consisted from 




1.10.2.2 Biological effect of Lyso-Gb3 
Dutch researchers [46] investigated the role of Lyso-Gb3 in vascular remodelling, 
presenting the biological effect of Lyso-Gb3. The team found that in vitro,using levels 
of Lyso-Gb3 similar to that excreted by symptomatic Fabry patients could 
significantly stimulate smooth muscle proliferation, which enhances the thickness of 
carotid-intima media resulting from vascular remodelling [216, 217]. Lyso-Gb3 role 
in enhancement the proliferation of cardiomyocytes and vascular smooth muscle cells 
has been postulated in human [215] and in vitro [218]. Moreover, the biological role 
of Lyso-Gb3 has been suggested in glomerular injury [219] and enhancement the 
toxicity of the viper venom verotoxin 2, a protein which binds to the natural 
membrane-anchored Gb3 receptor [220]. 
On the other hand, contrary to Lyso-Gb3, the other GSLs compounds specially the 
product of Lyso-Gb3 degradation (lactosylsphingosine) and its diacyl-parent (Gb3) 





1.10.2.3 The mechanism of Lyso-Gb3 catabolism 
Aerts and co-workers [46] studied the degradation mechanism of Lyso-Gb3 in vitro. It 
has been revealed that Lyso-Gb3 requires the catabolic hydrolase α-gal-A in order to 
be degraded into lactosylsphingosine. The study showed a weak degradation of Lyso-
Gb3 by recombinant α-gal-A in vitro at neutral pH due to the optimal acidic pH of 
hydrolases enzymes in the cellular lysosomes in vivo. The study reported that Gb3 
degradation efficiency in vitro using recombinant α-gal-A is 50 times higher 
compared with Lyso-Gb3 degradation using the same hydrolysis actors and at the 
same physical conditions. 
Many previous studies showed that Lyso-Gb3 concentrations in biological samples 
from Fabry subjects are elevated proportionally with the elevation in Gb3 levels and 
therefore, it is suggested that Lyso-Gb3 plays a significant biological role in inhibition 
of the key enzyme α-gal-A activity [46].  Aerts and co-workers [46] revealed that the 
activity of recombinant α-gal-A on Gb3 substrate was inhibited by presence of Lyso-
Gb3. A considerable accumulation of Gb3 has been shown in healthy cultured 
fibroblasts after adding Lyso-Gb3 proving the inhibitory role of Lyso-Gb3 on α-gal-A 
activity and subsequently promoting Gb3 storage. It has been postulated that the 
inhibitory capacity in vitro was markedly lower than in vivo by 200 fold which could 
be due to the physical properties of Lyso-Gb3 in human lysosomes which 
characterised by acidic pH and absorptive character of Lyso-Gb3 intra-membranes. 
On the other hand, Canadian researchers [202] suggested that the cellular elevation of 
Gb3 possibly due to increase in the Gb3 synthesis and it is not necessary to be due to 




1.10.2.4 Accumulation of Lyso-Gb3 in biological samples of Fabry patients 
The quantitation and potential use of Lyso-Gb3 as a biomarker in plasma [46, 215] 
and urine [202] for FD detection and monitoring have been demonstrated. It has been 
reported in a study conducted on Fabry mice that Lyso-Gb3 level is decreased more 
than Gb3 level after ERT with recombinant α-gal-A [166]. Auray-Blais and co-
workers suggested a  significant correlation between urinary Lyso-Gb3 and mutation 
type, ERT outcome and gender of Fabry patients [202]. On the other hand, a 
considerable correlation has been shown between plasma Lyso-Gb3 concentrations 
and left ventricular mass in heterozygous Fabry females and cerebrovascular white 
matter lesions in hemizygous Fabry males [215]. 
The urinary excretion of Lyso-Gb3 and Gb3 in untreated Fabry patients has been 
compared by a Canadian study  [202]. The study revealed that Fabry patients excrete 
lower amounts of urinary Lyso-Gb3 compared to urinary Gb3 by 1000 fold less in 
heterozygous females and by 6000 fold less in hemizygous males. 
It has been reported that Fabry patients with late onset cardiac variant mutations and 
renal variant mutations show normal level or slight increase in their urinary Lyso-Gb3 
and Gb3 excretion. For example Fabry patients with mutations R363H and R118C  
did not excrete urinary Lyso-Gb3 but showed normal urinary Gb3 [202, 221]. 
Moreover, it has been suggested that the use of urinary Lyso-Gb3 may be not the best 
predictive biomarker for Fabry patients with late onset renal variant where there is no 
correlation between urinary Lyso-Gb3 exertion and some kidney functions mainly 
estimated glomerular filtration rate (eGFR) [89, 202]. 
 
It has been reported that both symptomatic hemizygous Fabry males and adult 
heterozygous Fabry females show elevated levels of plasma Lyso-Gb3 while young 
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heterozygous females show no or a lesser elevation [71]. Moreover, adult 
heterozygous females show lower levels of plasma and urinary Lyso-Gb3 compared 
to hemizygous males [46, 164, 204, 222]. 
On the other hand, it has been shown that Fabry patients with late onset cardiac 
variant mutations such as R112H [223] show normal plasma Gb3 and very low level 
of plasma Lyso-Gb3 [46]. Rombach and co-workers reported that no elevated levels 
of Lyso-Gb3 are displayed by cardiac variant Fabry patients with R112H and P60L 
mutations [215]. Moreover, it has been demonstrated that Fabry patients with cardiac 
variant mutation (N215S) show normal levels or low elevation in plasma Lyso-Gb3 
and its analogues with normal levels of Gb3 [206]. 
Niemann and co-workers reported that some Fabry patients show late onset clinical 
manifestations in a single organ only such as heart or kidney referring to cardiac 
variant and renal variant [224]. The researchers suggested that measuring Gb3 and 
Lyso-Gb3 levels are insufficient for the identification of FD severity and the clinical 
manifestations in both genders, hypothesizing that assessing a degradation product of 
the accumulating GSLs can help in the definition of clinically relevant FD [224]. 
 
1.10.2.5 Lyso-Gb3 analogues 
Lyso-Gb3 analogues are Lyso-Gb3 related molecules result from modifications in the 
sphingosine moiety [204]. Canadian studies [85, 206, 225, 226] identified eight novel 
modified derivatives of the sphingosine moiety of Lyso-Gb3 (termed as Lyso-Gb3 
analogues) in plasma and urine samples from Fabry patients using an LC-MS 
approach. These analogues vary in the mass compared to Lyso-Gb3 by the exact 
amount predicted by modification. Lyso-Gb3 analogues will be expressed as follows: 
Lyso-Gb3 (n)/(m), where n represents m/z difference between Lyso-Gb3 and its 
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analogue and m represents the empirical formula of the modification corresponding to 
the m/z difference between Lyso-Gb3 and its analogue. A total of five analogues were 
detected in plasma and urine samples from Fabry patients as follows: Lyso-Gb3 (-28 
Da)/(-C2H4); Lyso-Gb3 (-2 Da)/(-H2); Lyso-Gb3 (+14Da)/(-H2+O); Lyso-Gb3 
(+16Da)/(+O); Lyso-Gb3(+34Da)/(+H2O2) and Lyso-Gb3 (+50 Da)/(+H2O3) [85, 
226]. The remaining Lyso-Gb3 analogues: Lyso-Gb3 (-12 Da)/(-C2H4+O) and  Lyso-
Gb3 (+14Da)/(-H2+O) were detected in urine samples only [85, 225] while the 
analogue Lyso-Gb3 (+18Da)/(-H2+O) was detected in plasma samples only [206, 
226]. 
The main fragment (daughter ion) of Lyso-Gb3 by MS/MS is at m/z 282. Other Lyso-
Gb3 fragments include the following m/z (768, 624, 606, 462, 444, 426, 300 and 264). 
However, Lyso-Gb3 analogues have the same fragments with the consideration of the 
mass shifts each time (Chapter-3). 
Auray-Blais and co-workers [85] stated that the profiles of three Lyso-Gb3 analogues 
in urine with mass shifts of (-12 Da, +16 Da and +50 Da) showed split peaks which 
may indicate the presence of isomers. Some urinary Lyso-Gb3 analogues e.g. Lyso-
Gb3 (+16 Da)  have higher concentrations than Lyso-Gb3 itself in a hemizygous 
Fabry male suggesting that these analogues could be used as strong specific and 
reliable biomarkers for FD in addition to Lyso-Gb3 [225]. However, plasma Lyso-
Gb3 concentrations in Fabry patients are higher than its analogues [206]. 
A considerable correlation has been shown between Fabry patients’ gender and 
urinary concentrations of Lyso-Gb3 analogues. Hemizygous Fabry males had 
considerably higher concentrations of Lyso-Gb3 analogues, than heterozygous Fabry 
females [85, 225]. The relative distribution of Lyso-Gb3 analogues vary between 
Fabry patients. It has been revealed findings suggesting that most Fabry patients with 
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specific disease symptoms and clinical manifestations showed elevated urinary 
concentrations of at least one of three main Lyso-Gb3 analogues: Lyso-Gb3 (+16 Da); 
Lyso-Gb3 (+34 Da) and Lyso-Gb3 (+50 Da). Nevertheless, some Lyso-Gb3 
analogues were found with levels below limit of quantitation in Fabry females (e.g. 
Lyso-Gb3 (-2 Da) and Lyso-Gb3 (-28 Da) analogues). Hence, these findings suggest 
that the presence and the urinary levels of specific Lyso-Gb3 analogues are associated 
with clinical features of the disease. 
It has been reported that the sphingosine structure could be varied based on its origin 
tissue [227]. This could help in comparing different Lyso-Gb3 analogues and 
subsequently matching with variant disease outcomes. Hence, an indicator could lead 
to the origin tissue of Gb3 [204, 227]. 
The biological samples from healthy individuals are lacking of Lyso-Gb3 analogues 
except small traces amounts of one analogue with m/z value of 836 (Lyso-Gb3 + 50 
Da) [225]. These findings give indications for the importance of urinary Lyso-Gb3 
analogues which could benefit in FD detection and monitoring especially in case of 
mutation analysis enzymatic activity test results being ambiguous as in heterozygous 
Fabry females, or in case of Fabry patients with late onset manifestations of FD who 
show residual enzyme activity. 
It has been reported that plasma and urinary Lyso-Gb3 analogous are decreased after 
ERT providing a positive biological response to the treatment [205, 225]. 
Lavoie and collaborators [225] studied the urinary levels of Lyso-Gb3 and its 
analogues in Fabry patients under ERT course. The study reported that hemizygous 
Fabry males showed a considerable correlation between the response to ERT and 
male urinary Lyso-Gb3 (-28 Da) and Lyso-Gb3 (+50 Da) analogues. Nevertheless, the 
remaining urinary Lyso-Gb3 analogues revealed reasonable response to ERT. In 
55 
 
terms of heterozygous Fabry females, only urinary Lyso-Gb3 (-28 Da) analogue 
showed a significant correlation with ERT. On the other hand, no considerable 
correlation was given between the response to ERT and urinary Lyso-Gb3 
concentrations highlighting the importance of using Lyso-Gb3 analogues which could 
be more fundamental than using Lyso-Gb3 itself in FD detection and monitoring 
[225]. It has been suggested that the urinary levels of Lyso-Gb3 analogues in Fabry 
patients correlate with clinical severity of FD [204, 225]. 
 
1.10.2.6 Lyso-Gb3 analysis using Dried Blood Spots  
Currently, the dried blood spots (DBS) are used worldwide in the newborn screening 
for different metabolic disorders. It has been shown that the chance of applying and 
the use of DBS to measure Lyso-Gb3 in Fabry patients to be applicable [228-230]. 
This service involves measuring the levels of plasma Lyso-Gb3 where a single blood 
spot being collected in a filter paper is sufficient determine Lyso-Gb3 concentration. 
Alternatively, Johanson et al [229] demonstrated that using DBS for Lyso-Gb3 
analysis in Fabry patients can be worthwhile in case of symptomatic patients such that 
in adult hemizygous males and some heterozygous females. However, the procedure 
is not suitable for newborn screening and late onset heterozygous females. 
 
1.11 SCREENING OF FABRY DISEASE 
 
 
Commonly, the newborn screening for metabolic disorders is considered a 
fundamental in order to administrate the disease progression, prevent the damage of 
affected organ and decrease the advanced various worse manifestations. 
Many previous papers demonstrated that newborn screening for LSD and FD is 
attainable and can reduce the age of diagnosis and subsequently enhance the disease 
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monitoring [231-234]. Auray-Blais and co-workers suggested a protocol for high risk 
screening for FD in patients with renal and vascular disease [235]. Maruyama et al 
[236] revealed plasma Lyso-Gb3 to be a promising secondary screening target. This 
biomarker can be used to confirm the initial molecular analysis diagnosis or to detect 
new cases of Fabry patients. 
 
1.12 SEPARATION TECHNIQUES FOR BIOLOGICAL SAMPLES 
 
1.12.1 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
The complexity of biological samples means that is usually necessary to employ some 
sort of separation process prior to analysis. A common method is the use of high 
performance (pressure) liquid chromatography (HPLC) because this method is very 
adaptable, robust and advances in instrumentation and columns allows for excellent 
resolution and reproducibility.  
Two approaches are possible, normal phase where the column (stationary phase) is 
more polar than the mobile phase (solvent) and reverse phase where the relative 
polarities are switched. Unmodified silica is usually the choice of stationary phase in 
normal phase separation and silica modified with long chain hydrocarbons (typically 
8 or 18 carbons long) is used in reverse phase work. HPLC columns are made up 
small particles or beads (2.7µm or less) and the uniformity of the bead size is an 
important factor in the quality of separation and the pressure required to pump solvent 
through the column. 
Reverse phase HPLC is the most common method. Here, the sample (e.g. Lyso-Gb3) 
is loaded in a solvent that is more polar than the hydrocarbon-modified silica which 
leads to analytes binding to the column. The elution of analytes from the column is 
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often brought about by decreasing the polarity of the solvent in a step-wise or gradient 
manner. Details of the reverse phase HPLC protocol employed in this work are given 
in Chapter 3. 
 
1.13 MASS SPECTROMETRY 
Mass spectrometry (MS) is one of the most powerful analytical techniques in 
biological sciences. An upturn in the utilization of MS has occurred in the last 20 
years or so because of technological developments in computers and the actual mass 
spectrometers. Subsequently protocols for the analysis of oligosaccharides, lipids, 
peptides and proteins in a wide range of sample types have been developed to take 
advantage of the analytical power offered by MS [237]. 
Mass spectrometers function by generating gas phase ions from analytes which are 
then subjected an analysis that determines the mass to charge ratio (m/z) and 
abundance of the ions [237]. In order to do this all mass spectrometers are made up of 
three components; the ion generation system (termed the ion source), a mass analyser 
and a detector [237, 238]. 
 
1.13.1 Ion sources: 
Ion source is the first part of the MS where the samples are converted to beams of 
gaseous ions. The most common ionization methods are electro spray ionization (ESI) 
and matrix assisted laser desorption ionization (MALDI), which are both capable of 
generating gas phase ions from relatively large, heat labile, non-volatile molecules, 
which is essential for the analysis of biological samples [237]. 
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1.13.1.1 Electrospray ionisation (ESI): 
Electrospray ionisation (ESI) is a soft ionisation procedure which involves 
transferring ions from the liquid phase to the gas phase, facilitating the analysis and 
keeping the molecule of interest fully intact [239]. This technique was firstly 
suggested by Malcolm Dole in the 1960s and applied in practice in the 1980s by John 
Fenn [240, 241].  A solution of an analyte, containing volatile, polar buffer is pushed 
into the ion source through a highly-charged capillary, usually of stainless steel, 
producing a nebula of droplets and solvated ions in the gas phase. These ions pass 
through a desolvation device under vacuum and are then injected into the analyser. 
Multiply-charged ions are produced from large molecules through ESI. 
As shown in Figure 1.11, there are three main steps in ESI process [239]: 
a) Charged droplets are produced at the ES capillary tip by applying a high voltage up 
to 6 kV at the end of the capillary. Ions travel toward the analyser, pulling the sample 
along until the charge at the capillary tip is higher than surface tension, resulting in 
the formation of the droplet.    
b) The charged droplets are shrunk by solvent evaporation and repeated droplet 
disintegrations due to coulomb repulsion, finally resulting in tiny, highly-charged 
droplets until the Rayleigh limit is reached when coulomb repulsion is equal to the 
surface tension, resulting in producing of gas phase ions. 
c) Gas phase ions are produced from these droplets. The role of establishing the gas 
phase ion is played by various models including charge residue pattern, through the 
evaporation of the solvent leaving a bare gas phase ions; ion evaporation pattern as 
the charges left on the surface of the droplets acquire the required energy, jumping 
into the gas phase and finally; ion emission pattern, in which the gas phase ion is 
59 
 
formed directly from the capillary due to the applied high voltage. ESI is considerably 
faster, more sensitive, and offers greater accuracy than previous techniques of mass 
determination for biological molecules such as gel electrophoresis. 
 
 
Figure 1.11 Electrospray ionisation (ESI) process: Essential features of the 
electrospray ionisation and the droplet production in the electrospray interface. 
 
1.13.1.2 Matrix-assisted laser desorption ionisation 
Matrix-assisted laser desorption ionisation (MALDI) is an ionisation procedure that 
involves mixing an analyte with a suitable matrix absorbing at the required laser 
wavelength. Usually, this is of the order of a 1,000 to 10,000 molar access of matrix 
to analyte. After the evaporation of the solvent, this process results in a co-
crystallisation of both matrix and the analyte. The combination, of the analyate 
molecules and the lattice structure of the matrix, enhances the precondition that the 
laser desorption/ionisation process will work. 
Thereafter, the crystallised surface of the sample is exposed to concentrated short 
waved laser pulse in the high vacuum area in the ion source of MS. The coupling of 
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the energy is performed on UV radiation by resonant excitation of the matrix 
molecule (Figure 1.12). 
 
Figure 1-12 MALDI procedure: A schematic highlighting key aspects of the 
MALDI process. Matrix/analyte crystals are deposited onto a MALDI target plate and 
are then pulsed with a laser. Matrix molecules absorb energy from the laser and 
transfer this to the analyte species, facilitating desorption and ionisation. The resultant 




1.13.2 Mass analysers: 
The most common mass analysers used in biological work are time of flight (TOF), 
quadrupoles and the modified quadrupole, an ion trap [237].  
With TOF a package of ions is generated in an ion source (usually by MALDI or ESI) 
and the whole package is accelerated through a fixed potential at the same time down 
a flight tube until they reach the detector. As every ion will have the same kinetic 
energy under these conditions the smaller the ions the faster they will travel. The 
actual speed attained is related, inversely, to the square root of the m/z. When 
electrical components that operated quickly enough to detect all of the ions contained 
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in each pulse of ions were developed in the 1990s TOF use increased considerably. 
More modern instruments incorporate a reflectron in the flight path which is an 
electrostatic mirror that improves the reliability of the mass analysis [237], (Figure 
1.13). This functions by deflecting the ions such that they travel back down the flight 
tube.  This corrects for small deviations in the kinetic energy dispersions of ions with 
the same m/z (ions with greater kinetic energy will be travelling faster and therefore, 
will move further into the reflectron before being deflected thereby travelling further 
to compensate for the increased speed) and by increasing the length of the flight path 
considerably. 
Quadrupoles are made of four parallel (usually round) rods where each opposing pair, 
are electrically coupled. A radio frequency (rf) electrical field is applied to the pairs in 
combination with a direct current (DC) off-set. In this way an m/z specific 2-
dimensional stability region along the plane of the poles is established such that ions 
with the correct trajectory can pass through the quadrupole. By varying the rf (at a 
constant ratio to the DC voltage) ions over an m/z range can pass, allowing 
considerable flexibility in the use of the quadrupole. For example, not only it can be 
used as a mass analyser but it can also act as a filter to allow ions of a specified m/z to 
pass. This can be useful when a particular molecule is being investigated.   
Ion traps are specialized versions of quadrupoles where a 3 dimensional stable zone is 
established (rather than the 2 dimensional in standard quadrupoles) by having charged 
end caps where the DC is applied. In this way ions can be trapped and scanned out by 
changing the rf. This allows the ions to be either analysed conventionally or specific 
m/z to be isolated within the same space. When specific ions are isolated using 
conventional quadrupoles a second quadrupole has to be employed to contain the 
isolated ions [237]. 
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1.13.2.1 MicrOTOF-II Mass Spectrometer 
The use of a quadrupole orthogonal time-of-flight mass spectrometer (Q-TOF) was 
first described by Morris et al. in 1996 [242]. A schematic illustration of the 
instrument is depicted in Figure 1.13. The Q-TOF technique was developed as a 
variation of the triple quadrupole mass spectrometer (QQQ). Using collision-activated 
decomposition or so called collision-induced dissociation (CID), the Q-TOF 
technique was applied to sequence a biopolymer, in this case, components of the 
major histocompatibility (MHC) antigen complex. The substitution of the third 
quadrupole with a time-of-flight (TOF) mass analyser improved the signal-to-noise 
ratio of obtained MS/MS spectra, providing mass accuracies in their study of product 
ions ‘within 0.1 Dalton [242]. This modification enabled the determination of isotope 
patterns in MS/MS spectra and significantly improved the ability to assign charge 
states to fragmented ions, a particularly important factor in the analysis of biological 
analytes [242]. 
The Q-TOF mass spectrometers have the ability to generate a high signal-to-noise 
ratio facilitating the accurate prediction of the analysed ion mass. Moreover, these 
instruments can provide a high resolution which can exceed 3000 (FWHM). 
Importantly, Q-TOF instruments have the ability to analyse very low concentrations 
of an analyte in a sample, generating MS/MS spectra of the analysis [242]. While the 
Q-TOF mass spectrometer was first introduced with ESI as an ion source, currently 
Q-TOF instruments are available with various ion sources, such as MALDI [243, 
244]. A comprehensive review about Q-TOF mass spectrometers has been introduced 




Figure 1.13 Components of micrOTOF-II Mass Spectrometer: A schematic 
illustration shows the various components of micrOTOF-II Mass Spectrometer. This 
instrument was devised in the study in order to measure plasma and urinary 




1.13.3 Tandem Mass Spectrometry 
Tandem mass spectrometry (MS/MS) is the technique in which the ions of interest are 
fragmented through a dissociation process such as CID, facilitating the study of these 
fragments in order to identify the parent ion. MS/MS for chemical molecules (e.g. 
GSLs, amino acids and acylcarnitine) analysis is used in metabolic disorders 
screening as an excellent tool for use with compound sharing fragment ions or neutral 
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molecules [246, 247]. It is possible to analyse different chemical families in a single 
analysis in approximately two minutes. This offers a broad spectrum analysis and 
high throughput, and is therefore a comparatively inexpensive instrument for analysis. 
Hence, from a clinical perspective, it is practical to use it to screen for a number of 
diseases [238]. 
There are different dissociation methods such as CID and high energy C-trap 
dissociation (HCD). CID is a tandem mass spectrometry dissociation method in which 
the parent ions are fragmented as a result of their collision with a neutral gas. An 
electric field is applied to accelerate these parent ions and to induce bond cleavage 
through their collision with a neutral gas (e.g. argon, helium or nitrogen) in the 
collision cell. The collision energy breaks down the parent ions and thereby the 
daughter ions result [248]. 
HCD: is a new developed dissociation technique. In this procedure, C-trap is used to 
store and fragment the ions; thereafter, these ions are transferred to orbitrap [248]. 
MS/MS is the main tool that used in newborn screening laboratories worldwide [247]. 
 
1.13.4 The role of MS in newborn screening for IEM 
Newborn screening is a test or investigation for a disorder in the early stages of 
human life, allowing the management of disease before it becomes advanced [247]. 
It has been reported that the detection of congenital diseases at an early stage is 
fundamental for health protection. An example of such diseases are metabolic 
disorders (inborn errors of metabolism), which were identified by Sir Archibald 
Garrod at the beginning of the twentieth century [249]. Metabolic disorders comprise 
disorders of organic acid, amino acids and fatty acid metabolism, urea cycle disorders 
and lysosomal storage disorders, in addition to other diseases [247]. 
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Tandem mass spectrometry (MS/MS) was first applied to newborn screening in 1990 
at Duke University Medical Centre in the USA. Before this, Fast Atom Bombardment 
(FAB) ionisation MS/MS was used for acylcarnitine analysis of urine and plasma 
samples for infants with suspected metabolic disorders. FAB was later modified to 
develop Fast Ion Bombardment (FIB). This modification enhanced the advantages of 
this version of MS/MS, made it simple to use and improved the sensitivity of the 
instrument. Moreover, butyl ester derivatisation was selected over methyl ester 
derivatisation, which helped in decreasing interference, particularly with amino acids 
[246]. 
In 1993, blood spot samples were used to develop the analysis of acylcarnitine, 
together with phenylalanine for phenylketonuria diagnosis [250]. Following this, an 
expansion occurred in the detection of many amino acids at the same time in a single 
analysis after discovering the common structural loss (neutral loss of 102) [251, 252].                                                                                                                                                                                                                          
According to Chace and Naylor [246], routine newborn screening for metabolic 
disorders using MS/MS started in late 1992 at Magee Women’s Hospital in 
Pittsburgh. By 1999, approximately 25,000 samples were screened. Between 1992 
and 1994 different methods were studied to develop the automation of MS/MS to 
semi-automated sample preparation and dynamic or continuous flow FIB ionisation. 
One of these studies was carried out by Rashed and co-workers using ESI [253]. 
These new methods of ionisation were applied to newborn MS/MS analyses. The ESI 
technique offers considerable advantages, as it is a fully automated system with 
improved FIB-MS/MS [246].  
In the majority of advanced countries, every new-born is screened for many metabolic 
diseases using MS/MS and a drop of blood is enough to measure multiple metabolites, 
confirming the prediction of Chace [254]. Chace [254] stated that the application of 
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MS/MS is crucial to help differentiate between numerous compounds according to 
their fragmentation pattern, such as identifying a small shoulder from a minor 
component in a chromatogram.  
Currently, metabolic disorders such as phenylketonuria, hypothyroidism, cystic 
fibrosis and medium-chain acyl-CoA dehydrogenase deficiency are covered by the 
newborn screening programme in the UK. 
 
1.14 THE SCIENTIFIC JUSTIFICATION FOR THE RESEARCH 
The diffuse range of symptoms displayed by Fabry patients makes diagnosis 
problematic. Whilst the enzyme activity of α-gal-A is useful in this process, this assay 
does not allow the treatment regime/efficacy to be monitored or help in understanding 
the disease process. The post/during-treatment monitoring available currently are the 
patient’s symptoms and well-being or the level of Gb3, which is thought to be a poor 
indicator of patient status. Monitoring the level of Lyso-Gb3 and its related analogues 
prior to and during treatment will allow us to ask the questions which will be outlined 
in the research objectives (section 1.15). We hope to develop a post treatment 
monitoring process that will enhance patient treatment and further our understanding 
of the disease. 
 
1.15 RESEARCH OBJECTIVES 
The aim of this study was to develop an assay to measure Lyso-Gb3 and associated 
analogues in biological samples taken from Fabry patients and to assess its utility in 
FD diagnosis and monitoring patient response to therapy. This required the 
development of methods to extract GSLs from the biological fluid, and the use of a 
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sensitive HPLC-MS/MS-based assay with sufficient sensitivity to measure the 
metabolites of interest. 
 
The project aims to measure both plasma and urinary Lyso-Gb3 in  a large cohort of 
Fabry patients (obtained from Birmingham Sheffield and London) and follow changes 
in their levels of Lyso-Gb3 over a two-year period to determine whether Lyso-Gb3 
measurements are useful in monitoring the efficacy of ERT and studying disease 
progression and/or regression. For the first time, we set out to compare the levels of 
Lyso-Gb3 in both plasma and urine to determine the best biological fluid used for 
analyte measurement. With these aims in mind, we have set out to ask the following 
specific questions: 
 
 Can plasma/urinary levels of Lyso-Gb3 be used to diagnose FD in hemizygous 
males and heterozygous females?  
 Can the levels of plasma Lyso-Gb3 be used to monitor the efficacy of ERT in 
Fabry patients?  
 What is the best biological sample or source for analyte measurement? We 
will compare Lyso-Gb3 and analogue measurements in both plasma and urine 
samples from Fabry patients.  
 We will examine the significance of the various Lyso-Gb3 analogues with 
respect the target organ damage using patients presenting with classical and 
non-classical (cardiac variants) forms of FD. 
 Finally, establish a method for measuring the level of total urinary Gb3 using 
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All human research conducted was in accordance the ethical standards of the Helsinki 
declaration and was approval by an NHS Research Ethics Committee [North West 5 
Research Ethics Committee, Haydock Park, represented by Human Biomaterials 
Resource Centre (HBRC), University of Birmingham, reference: 09/H1010/75).  
 
2.2 SUBJECTS 
FD diagnosis was confirmed in all enrolled Fabry patients by mutation analysis and/or 
by the α-gal-A enzyme activity test in white blood cells of classical hemizygous Fabry 
males where the heterozygous Fabry females and Fabry patients with late onset FD 
(e.g. cardiac variants and renal variants) can show residual enzyme activity within the 
reference range of healthy control subjects. A total of 100 Fabry patients and 109 age 
and gender matched control individuals have been enrolled in this project (Subject 
details are shown in Table 2-1). All Fabry patients and healthy control individuals 
who enrolled in this study gave written consent before collection of their biological 
samples. Fabry patients were categorised into two groups’ classical Fabry patients (n= 
62) and late onset cardiac Fabry patients (38). The classical Fabry are defined as 
having typical Fabry disease manifestations and known classical mutations with the 
deficiency of α-gal-A enzyme activity (<1%) while cardiac Fabry patients were 
confirmed by mutation analysis. Blood samples were collected from the patients and 
healthy individuals in EDTA tubes, centrifuged and the plasma stored at -80 ⁰C. Urine 
samples were collected from the patients and healthy individuals in urinary universal 






Table 2.1 Anthropometric data of 209 Fabry patients and control subjects: a table 





2.3 CHEMICALS AND MATERIALS 
 
2.3.1  General equipment and reagents 
 




# Consumable Supplier 
1 Cap w/PTFE/Silicone Seal for 9mm Screw Vial Thermo Scientific–UK 
2 Cryo-Tube Vials Thermo Scientific–UK 
3 Oasis MCX 1cc (30mg) LP extraction cartridges Waters-USA 
4 0.65mL low binding microfuge tubes Dutscher  Scientific-UK 
5 1.7mL low binding microfuge tube Dutscher  Scientific-UK 
 










  Fabry patients Control subjects 
classical cardiac variant 
male female 
male female male female 
Number 23 39 20 18 63 46 
Age 
(y) 
mean 42.0±13.5 56.0±16.3 55.7±16.1 46.9±17.8 51.1±20.4 52.8±15.9 
median 49.0±3.1 60.0±2.7 58.6±3.7 41.6±4.2 54.9±2.9 56.1±5.5 
range 19-62 24-82 18-86 25-85 20-82 23-80 
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2.3.1.2 Glass consumables: the glass consumables used in the current study are 
shown in Table 2.3. 
 
# Consumable Supplier 
1 
Certified glass inserts mandrel precision point 200µL, 
6×29mm with plastic spring 
Supelco Analytical-
USA 
2 Screw Top Vials 2 mL clear 9 mm Thermo Scientific-UK 
3 Disposable culture tubes - borosilicate glass (13×100mm) Fisher Scientific-UK 
4 Disposable culture tubes - borosilicate glass (16×150mm) Fisher Scientific-UK 
5 Pasteur pipettes short glass Sigma Aldrich-UK 
 




HPLC grade water and acetonitrile (ACN) were purchased from VWR international. 
HPLC grade methanol (≥99.9%), formic acid (≥98%), hydrochloric acid (HCl, 37%) 
and ammonium hydroxide (NH4OH, 28%) were purchased from Sigma Aldrich, UK. 
1-β-D-glucosylsphingosine (GSG) internal standard (source: semisynthetic bovine 
buttermilk), 1-β-D-glucosylsphingosine (GSG) internal standard (source: plant) and 
globotriaosylsphingosine (Lyso-Gb3) standard (source: semisynthetic porcine RBC) 
were purchased from Matreya (Pleasant Gap, PA). Human plasma (pooled from 6 
mixed-gender individuals, charcoal stripped twice, filtered 0.2µm and sodium heparin 
preservative) was purchased from Sera lab, UK. All the chemicals used in the current 
study are shown in Table 2.4. 
 
2.3.3 Solutions, standards and reagents 
The compositions of the solutions, buffers and reagents that were used in the study are 
given in table 2.5. 
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# Consumable Supplier 
1 HPLC-grade water (H2O) VWR-UK 
2 HPLC-grade methanol (MeOH, ≥99.9%), Sigma Aldrich-UK 
3 Acetonitrile gradient grade VWR-UK 
4 HPLC-grade chloroform (CHCl3, ≥99.9%) Sigma Aldrich-UK 
5 Formic acid puriss (98%) Sigma Aldrich-UK 
6 Hydrochloric acid Sigma Aldrich-UK 
7 Phosphoric acid Sigma Aldrich-UK 
8 Ammonium hydroxide (28% NH3 in H2O) Sigma Aldrich-UK 
9 HPLC grade Propan-2-ol Fisher Scientific-UK 
10 Acetone Fisher Scientific-UK 
11 Potassium hydroxide (pellets, 85%) Sigma Aldrich-UK 
12 Ammonium formate Sigma Aldrich-UK 
13 Ammonium acetate Sigma Aldrich-UK 
14 5-chloro-2-mercaptobenzothiazole (5C2M) Sigma Aldrich-UK 
15 2- mercaptobenzothiazole Sigma Aldrich-UK 
16 6-aza-2-thiothymine Sigma Aldrich-UK 
17 2-(4-hydroxyphenylazo) benzoic acid Sigma Aldrich-UK 
18 2,5-dihydroxy benzoic acid (DHB) Sigma Aldrich-UK 
19 Super-DHB Sigma Aldrich-UK 
20 Sinapic acid Sigma Aldrich-UK 
21 2,4,6-trihydroxyacetophenone monohydrate Sigma Aldrich-UK 
22 2,5- dihydroxy acetophenone Sigma Aldrich-UK 
23 α-cyano-4-hydroxycinnamic acid acid Sigma Aldrich-UK 
24 Picolinic acid Sigma Aldrich-UK 
25 9-aminoacridine hemihydrate Sigma Aldrich-UK 
26 Ceramide/sphingoid internal standard mixture I Avanti polar lipids-USA 
27 Lyso-Gb3 standard Matreya - Pleasant Gap, PA 
28 GSG (plant) internal standard Matreya - Pleasant Gap, PA 
29 GSG (bovine) internal standard Matreya - Pleasant Gap, PA 
30 Gb3 standard (source: porcine RBC) Matreya - Pleasant Gap, PA 
31 N-Heptadecanoyl ceramide trihexoside standard Matreya - Pleasant Gap, PA 
32 ESI - Low concentration tuning mixture Agilent Technologies-USA 
33 
Human plasma, Sodium heparin, mixed gender,  
pooled, 0.2µm  filtration 
Sera lab-UK 
 




# Solution/reagent/standard Composition 
1 HPLC mobile phase A 0.1%FA / H2O 
2 HPLC mobile phase B 0.1%FA / ACN 
3 HPLC mobile phase C 20%ACN / H2O 
4 Lyso-Gb3 standard stock solution [1272 µM] 1mg Lyso-Gb3+1mL MeOH (stored at -20°C) 
5 Lyso-Gb3 standard working solution [20 nM] Prepared by a serial dilution using (20%ACN / H2O) and stored at -20°C 
6 GSG standard stock solution [100 µM] 5mg GSG + 108.45mL of (0.1%FA/50%MeOH) stored at 4 °C 
7 GSG standard working solution [0.8 nM] By a serial dilution  using MeOH (stored at -20°C) 
8 Gb3 standard stock solution [200 ng/µL] 10mg Gb3+1mL MeOH:CHCl3(2:1, v/v) then adding 49ml MeOH (stored at -20°C). 
9 Gb3 standard working solution [80 ng/µL] By a serial dilution  using MeOH (stored at -20°C) 
10 Gb3 IS stock solution [50 ng/μL] 0.5mg Gb3+1mL MeOH: CHCl3 (2:1) then adding 9ml MeOH (stored at -20°C). 
11 Gb3 IS working solution [2 ng/µL] By a serial dilution  using MeOH (stored at -20°C) 
12 SPE Conditioning solution 1 MeOH 
13 SPE Conditioning solution 2 2% H3PO4 in H2O 
14 SPE Conditioning solution 3 HCl (1N) 
15 SPE wash-1 solution 2% FA in H2O 
16 SPE wash-2 solution 2% FA in MeOH 
17 SPE elution solvent 2% NH3 in MeOH 
28 SPE reconstitution solvent 20% ACN in H2O 
 
Table 2.5 Composition of solutions: a table shows the composition of solutions and various reagents used in the project. 
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2.3.4 HPLC and MS equipment and parts 
Table 2.6 shows the parts and columns of HPLC system used in the study. 
 
# Consumable Supplier 
1 Halo C18 column (2.7µm, 50mm×200µm) Hichrom Limited-UK 
2 Thermo C18 column (3.0µm, 150mm×75µm) Thermo Scientific-UK 
3 Ascentis Express C18 (2.7µm, 50mm×200µm) Supelco Analytical-UK 
4 C18 nano/Capillary (3µm, 250mm×75µm) Fisher Scientific–UK 
5 












µ-Precolumn Trap C18 Cartridge (5µm, 
5mm×1000µm) 
Thermo Scientific-UK 
9 HPLC C8 column (5µm, 5mm×300µm) Fisher Scientific–UK 
10 HPLC C4 column (5µm, 5mm×300µm) Fisher Scientific–UK 
11 
Dionex™ nano-Viper™ UHPLC Flexible Connection 
Tubing (50µm×650mm) 
Thermo Fisher Scientific–UK 
12 
Dionex™ nano-Viper™ UHPLC Flexible Connection 
Tubing (50µm×350mm) 
Thermo Fisher Scientific–UK 
13 
Dionex™ nano-Viper™ UHPLC Flexible Connection 
Tubing (20µm×350mm) 
Thermo Fisher Scientific–UK 
14 
Dionex™ nano-Viper™ UHPLC Flexible Connection 
Tubing (30µm×100mm, 1/32inch) 
Thermo Fisher Scientific–UK 
15 Peek SIL connection tubing (50µm×50mm) Agilent Technologies-UK 
16 Peek SIL connection tubing (50µm×100mm) Agilent Technologies-UK 
17 Peek SIL connection tubing (50µm×200mm) Agilent Technologies-UK 
18 Peek SIL connection tubing (50µm×500mm) Sigma Aldrich-Germany 
19 Ferr Rheodyne VWR-UK 
 









2.4 EXTRACTION OF GLYCOSPHINGOLIPIDS FROM CLINICAL 
SAMPLES 
Plasma samples were processed by solid phase extraction (SPE) using mixed-mode 
cation-exchange cartridges (Oasis, MCX 1 cc, 30 mg, 60 µm, Waters Corp). Each 
cartridge was conditioned using 1 mL of methanol, then 1 mL of phosphoric acid (2% 
H3PO4 in H2O). The sample was prepared by mixing 200 µL of plasma, 500 µL of 
phosphoric acid (2% H3PO4 in H2O) for acidification, 20 µL of 0.1%FA/20%ACN 
and 500 µL of GSG internal standard (0.8nM) in methanol. When standard curves 
were prepared the 20 µL of 0.1%FA/20%ACN contained the appropriate amount of 
lipid required to generate the curve. The sample was vortexed shortly and then 
transferred to the MCX cartridges using glass pipettes and allowed to drip through the 
column. Each cartridge was washed twice, firstly with 1 mL of 2%FA/H2O and then 
with 1mL of 0.2% FA/methanol. Thereafter, each cartridge was eluted using 500 µL 
of basic buffer (2%NH3/methanol). The extract was dried and then resuspended using 
50 µL of 0.1%FA/20%ACN. Thereafter, 10 µL of this extract was subjected to an 
MRM mass spectrometric analysis following resolution of the lipids by reverse phase 
HPLC as set out below.  
Urine samples were prepared by mixing 500 µL of urine, 500 µL of GSG (0.8 nM), 
100 µL HCl (1.0 M) and 20 µL of 0.1%FA/20%ACN. When standard curves were 
prepared the 20 µL of 0.1%FA/20%ACN contained the appropriate amount of lipid 
required to generate the curve. Extraction was performed using the same procedure of 
plasma extraction except using of 1.0 mL HCl (1.0 N) in the conditioning of MCX 
cartridges, instead of phosphoric acid (2% H3PO4 in H2O). The resolution of the lipids 




2.5 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
A reverse phase-HPLC system (Ultimate 3000, Dionex) was utilized using mobile 
phase A (0.1%FA in H2O), mobile phase B (0.1%FA in ACN) and a Halo C18 
column (50mm×200μm, 2.7μm, from Hichrom limited-UK). Samples were loaded at 
20% mobile phase B for 3 minutes and then eluted isocratically at 50% mobile phase 
B for 4 minutes. The column then was washed with 100% mobile phase B for 3 
minutes then equilibrated with 100% mobile phase A for 2 minutes. The flow rate was 
3μL/min (Table 2.7). 
HPLC (Ultimate 3000 – Dionex) 
Mobile phase A 0.1%FA/H2O 




Column (particle size) 2.7µm 
Column (length×I.D) 50mm × 200µm 
Column (temperature) 30 ⁰C 
Auto-sampler temperature 7 ⁰C 
Injection volume 10µL 
Injection mode Full loop 
 
Table 2.7 Final optimized HPLC parameters. 
 
 
2.6 ANALYSIS OF GLYCOSPHINGOLIPIDS USING MASS 
SPECTROMETRY 
A micrOTOF-II mass spectrometer (Bruker-Germany) was used in this study. Positive 
ion mode electrospray ionisation (ESI) was employed. A multiple reaction monitoring 
(MRM) acquisition mode, an MS technique, was used to identify and quantify 
different metabolites with N2 as the collision gas. Table 2.8 shows the different MS 
parameters and Table 2.9 shows MRM transitions and the applied collision energies 
for each metabolite. In order to prevent the system contamination, HPLC divert valve 
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was programmed to direct the sample solvents toward the MS only between 3-7 




Ion source Electrospray ionisation (ESI) 
Polarity Positive mode 
Acquisition mode  Multiple Reaction Monitoring (MRM) 
Dry temperature 180 ⁰C 
Capillary voltage 3.5 Kv 
Nebuliser 0.6Bar 
Dry gas 4.0 I/min 
Spectra rate 0.5 Hz 
Rolling average 3 
Mass range 50-1000 m/z 
 
Table 2.8 Final optimised parameters of micro-ToF-II mass spectrometer which was 







Metabolite Transition Collision energy 
Lyso-Gb3 (-28 Da) 758.3 >>> 254.3 38 
Lyso-Gb3 (-12 Da) 774.3 >>> 252.3 38 
Lyso-Gb3 (-02 Da) 784.3 >>> 280.3 38 
Lyso-Gb3 786.4 >>> 282.3 38 
Lyso-Gb3 (+14 Da) 800.3 >>> 334.3 38 
Lyso-Gb3 (+16 Da) 802.3 >>> 280.3 38 
Lyso-Gb3 (+34 Da) 820.3 >>> 334.3 38 
Lyso-Gb3 (50 Da) 836.3 >>> 350.3 38 
GSG (internal standard) 460.3 >>> 280.3 25 
 










2.7 STATISTICAL ANALYSIS 
All data in this thesis were analysed using SPSS software (Version 21, IBM software, 
UK) or Microsoft Excel 2010 unless otherwise specified. Normality of data 
distribution was determined by Kolmonogrov test and by visual inspection of values 
in case of small number of data points. The statistical tests used for each experiment 
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Metabolomics is an emerging approach dealing with the scientific study of a large 
numbers of small molecules less than 1500 Da (metabolites) including the study of 
their chemical processes and their different profiles leading to identification and 
quantification of these metabolites in biological fluids [253-257]. The study of 
metabolome highlights the important details of biochemical pathways and their 
modifications which associated with various disorders [256]. Hence, Metabolomics 
has been applied in many clinical researches due to its clinical informative allowing 
early diagnosis of various disorders and following up the progression and regression 
of these diseases [258]. 
Various biochemical methods have been developed in order to measure Lyso-Gb3 
levels in biological samples in Fabry patients. Originally, Dutch researchers extracted 
Lyso-Gb3 by a derivatization process using orthophthaldialdehyde (OPA). Thereafter, 
the separation and detection of the lipids were achieved using high performance liquid 
chromatography (HPLC) and fluorescence detection respectively [46, 165, 215]. The 
method was valuable and fair enough to measure Lyso-Gb3 levels in hemizygous 
Fabry males. Alternatively, the method lacked the required sensitivity where it can’t 
measure low levels of Lyso-Gb3 such that in case of heterozygous Fabry females, late 
onset cardiac variant Fabry patients nor healthy controls levels. Moreover, another 
drawback for this method was interference of the used derivatization agent OPA with 
other OPA-reactive compounds of plasma. 
The same Dutch team developed a new method where the lipids were extracted using 
liquid-liquid extraction then analyzed using LC-MS/MS. In this method Glycine-
Lyso-Gb3 was synthesized and used as an internal standard [164]. This method 
doesn’t require derivatization, decreases the processing time and has low detection 
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limits allowing measurement Lyso-Gb3 levels in Fabry females, atypical Fabry 
patients and healthy controls. 
Gold et al [25] developed a new method based on using stable isotopic [5,6,7,8,9] 
13
C5-labelled Lyso-Gb3 internal standard. The lipids were extracted from the 
biological samples using liquid-liquid extraction before being separated, fragmented 
and detected using ultra performance liquid chromatography linked to electrospray 
ionization tandem mass spectrometry (UPLC-ESI-MS/MS) respectively [25]. The 
study measured Lyso-Gb3 and another compound was called Lyso-ene-Gb3 which 
later is known as Lyso-Gb3 (-2 Da) analogue. This method has advantages of being 
rapid [25]. 
In the last decade, Auray-Blais and collaborators showed advanced steps in terms of 
establishment many advanced metabolomics studies facilitating the measurement of 
chemical biomarkers of FD and revealing novel biomarkers (e.g. various 
isoforms/analogues of Gb3 and Lyso-Gb3) [26, 201, 202, 204-206, 213].  
The worked presented here was performed to establish, optimise and validate an 
HPLC-MS approach to measure plasma and urinary Lyso-Gb3 and related analogues. 
The stages examined were the extraction of the lipids from the biological samples, the 




3.2.1 Lipid extraction 
A reliable extraction method is an essential aspect of any lipid analysis. Here, the 
approach developed utilizes the addition of a known amount of a synthetic Lyso-Gb3 
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standard and 1-β-D-glucosylsphingosine (GSG) to samples. GSG standard is used as 
an internal standard, in order to quantify the lipid level reliably. 
 
3.2.1.1 Choice of Internal Standard 
Two sources of GSG were compared in this work, one derived from bovine buttermilk 
and the other of plant origin (Figure 3.1). The only difference between the two lipids 
is the presence of 2 double bonds in the sphingosine moiety of the plant lipid 
compared to 1 in the bovine lipid, meaning that they differ in mass by 2 Da. In both 
cases 5 mg of pure, commercially available lipid was dissolved in methanol to give a 
stock solution of 100µM which was stored at -20 
°











Figure 3.1 Chemical structures of GSLs: The figure shows the chemical structure of 
four GSLs. (a) Globotriaosylceramide (Gb3), α-gal-A key-enzyme is responsible for 
the hydrolytic cleavage between the galactose residues. (b) Globotriaosylsphingosine 
(Lyso-Gb3). (c) 1-β-D-glucosylsphingosine (GSG in human and bovine) which has 
similar structure of sphingosine moiety of Lyso-Gb3 resulting in similar MS/MS 
fragmentation pattern. (d) 1-β-D-glucosylsphingosine (GSG- plant source) where 





3.2.1.2 Preparation of Lyso-Gb3 Standard 
Pure, commercially available Lyso-Gb3 (porcine) was used initially for method 
development and subsequently to prepare standard curves that were run with each 
batch of samples. The Lyso-Gb3, 1 mg, was dissolved in methanol to give a stock 
solution of 1.27 mM, which was stored at -20 
°
C until used as a working solution (20 
µM) following serial dilution with 0.1%FA/20%ACN. 
 
3.2.2 Resolution of Glycosphingolipids using Reverse Phase High Performance 
Liquid Chromatography 
A range of parameters that affect the resolution of lipids by RP-HPLC were examined 
to establish a robust and reproducible method that is suitable for the analysis of 
clinical samples. The initial aspects of this work were carried out using commercially 
available lipids. 
3.2.2.1 Choice of Tubing Connectors 
The junctions in HPLC systems can have a significant effect on the resolution of 
compounds.  This occurs when “dead space” or gaps are generated which result in a 
poor peak shape. In this work, the method development aimed at employing the 
optimal HPLC tubing connectors in order to improve the chromatography. Two 
different brands of HPLC connection tubing were tested: standard HPLC connection 
tubing and nano-Viper fittings connection tubing. 
3.2.2.2 Choice of Chromatography Stationary Phase 
The stationary phase in HPLC is the reverse-phase resin in the trap/guard column and 
the resolving column.  For GSLs separation a silica support with an 18 carbon 
aliphatic chain is the universal choice. There are many commercially available high 
resolution columns; here three different brands were tested to compare the separation 
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of GSLs with respect of area under the curve (AUC), peak intensity, shape and tailing.  
In addition the background contamination of the MS spectra with each column was 
compared.  These columns tested were: Halo C18 column (2.7µm, 50mm × 200µm, 
Hichrom Limited-UK), Ascentis Express C18 (2.7µm, 50mm × 200µm, Supelco 
Analytical-UK) and Thermo C18 column (3.0µm, 150mm × 75µm, Thermo 
Scientific-UK). 
The trap columns employed (recommended by Dionex, the Manufacturer of the 
HPLC system) were C18 µ-Precolumns (silica support modified with 18 carbon 
aliphatic chains). These are supplied in cartridges that are fitted into the system with 
no dead space.  Three sizes were (5µm, 5mm × 300µm, 5µm, 5mm × 500µm and 
5µm, 15mm × 500µm) compared to ensure sufficient, but not excess capacity was 
used. 
3.2.2.3 Optimisation of Flow Rate 
The rate at which the mobile phase flows through the trap and resolving columns is an 
important parameter that can affect binding and elution characteristics. The flow rate 
was varied and significant factors such as retention time, peak intensity, AUC and 
shape were measured. 
 
3.2.2.4 Optimisation of Binding and Elution Conditions 
In reverse phase chromatography hydrophobic analytes bind to the stationary phase 
under relatively polar conditions, so the loading solvent contains a low percentage of 
organic solvent and a large amount of water.  The actual percentage of organic solvent 
used for binding should be the highest possible that results in complete binding of the 
analyte. In this way the lowest background contamination binding to the column 
should occur. The elution of the bound lipids is performed by increasing the 
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percentage of organic solvent in the liquid that is pumped through the column.  This 
can be done using a gradual increase (termed gradient elution) or by a stepped 
increase which is then held constant (termed isocratic elution). An appraisal of the 
elution conditions that are suitable for a reliable analysis of Lyso-Gb3 in Clinical 
samples was performed. 
 
3.2.3 Analysis of Glycosphingolipids using Mass Spectrometry 
A micrOTOF-II mass spectrometer (Bruker-Germany) was selected to be employed in 
the study. There are many parameters that can affect the accuracy, reliability and 
reproducibility of mass spectrometers and all of these were optimised in this work. 
Positive ion mode ESI was employed as an ion source to convert the sample from 
liquid phase to gas phase. The identity of each metabolite was confirmed using a 
multiple reaction monitoring (MRM) acquisition mode. MRM is an MS technique 
used to identify and quantify different metabolites with N2 as a collision gas. The 
different MS parameters (Table 2.8), MRM transitions and the applied collision 
energies for each metabolite (Table 2.9) were tested and optimised. In order to 
prevent contamination in the HPLC-MS system, the HPLC effluent is discarded to the 
waste between (0-3 min) and (7-12 min) using the HPLC divert valve. 
The identity of each metabolite is confirmed using an MRM mode where the ion of 
interest, identified by the accurate m/z, is isolated within the collision cell of the MS, 
where it is subsequently fragmented by collision with an inert gas (N2) using a 
specified energy level. This gives rise to characteristic daughter ions where the 
presence of the daughter ions conclusively identifies the parent ion, and the intensity 
and AUC of the daughter ion are considered as an accurate measure of the parent ion 
concentration. This is termed an MRM transition. Here, the intensity of the most 
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abundant specific daughter ion, the dehydrated sphingosine moiety (m/z 282.3) 
derived from the Lyso-Gb3 parent ion (m/z 786.4) was recorded and AUC determined 
using a function available in the manufacturer’s software package. Every assay 
contained the internal standard GSG-plant source (m/z 460.4) or GSG-bovine source 
(m/z 462.4) which contain the sphingosine moiety, (Figure 3.1, c and d) was also 
isolated and fragmented in an identical fashion to the lipids under investigation and 
the intensity and AUC of the m/z 280.3 (for vegetal GSG) or m/z 282.3 (for the animal 
source GSG) daughter ion derived from the GSG determined. Any losses during any 
part of the assay procedure, from the point where the GSG was added to the samples, 
can therefore be accounted for by dividing the measured AUC of the daughter ion 
derived from the lipid of interest by the recorded AUC of the daughter ion derived 
from GSG internal standard. 
 
3.3 RESULTS 
3.3.1 Extraction Protocols 
3.3.1.1 Extraction of Lyso-Gb3 and Analogues 
Two approaches for the extraction of Lyso-Gb3 have been developed previously. The 
SPE protocol used here [204] and a liquid-liquid extraction based on the method 
developed by Bligh and Dyer [255, 256] where the lyso-lipids partition into an upper 
water/methanol phase. Initially, a brief comparison of these methods was performed 
and although the sensitivities of the methods was comparable due to the lower 
reproducibility, the more complex procedure, and the requirement to use halogenated 
solvents (chloroform) the Blighe and Dyer method was considered inferior. Data to 
support this conclusion is not presented as no patient samples were analysed using 
Bligh and Dyer extraction method. 
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3.3.1.2 Extraction Efficiency of Lyso-Gb3 from Urine and Plasma 
The extraction efficiency of Lyso-Gb3 from urine and plasma using SPE was tested. 
This was done by performing 2 sets of extractions; the first where 1.0 picomole of the 
synthetic Lyso-Gb3 standard was added to either urine (500µL) or plasma (200µL) 
samples prior to addition to the MCX columns (as described previously) or secondly 
where 1.0 picomole of the synthetic Lyso-Gb3 standard was added to the solvent used 
to resuspend the extraction residue (post extraction) and will therefore have no 
extraction related losses. In this way the extraction efficiencies can be calculated by 
comparing the Lyso-Gb3 levels detected in these 2 sets of samples (Equations 3.1 and 
3.2). The efficiency of extraction from urine was found to be more than 90% and for 
plasma to be 65-70%. The lower extraction efficiency from plasma is probably due to 
the Lyso-Gb3 binding to (or associating with) the much more abundant proteins 
and/or lipids in plasma. A range of other factors are thought to affect the amount of 
analyte that is detected in this type of protocol, especially when the analyte 
concentrations are low as they are here. For example, non-specific losses due to 
adsorption to any surface that the analyte is exposed to during the entire analytical 
process or in the case of an MS-based analysis factors that enhance or suppress 
ionisation of the analyte will also play a role. 
 
Response ratio = (Lyso-Gb3AUC/GSG AUC)*100% …………………….. Equation 3.1 
 
 
Extraction recovery = (Lyso-Gb3 response ratio before extraction/ Lyso-Gb3 









Several of the most important factors that limit the quality of data when using HPLC 
based methods were optimised in this work. Figure 3.2 shows that the elution peak of 
Lyso-Gb3 and GSG lasts 30-40 seconds in this work. The flow rate is 3µL/min 
meaning that elution volume is approximately 1.5-2µL. This narrow shape leads to a 
high peak intensity which is a significant help in lowering the limit of detection and 
quantitation.  Anything that causes the peak shape to broaden or tail will diminish the 
peak intensity and compromise the quality of the assay and anything that helps to 
narrow the peak will help to improve the analysis. The final different optimisation 









Figure 3.2 Detection of Lyso-Gb3 using MRM mode: (a) Extracted ion 
chromatogram of Lyso-Gb3 standard (Red) and GSG internal standard (Blue). (b) 
Extracted ion chromatogram of Lyso-Gb3 in urine sample from a Fabry hemizygous 





3.3.2.1 Choice of Tubing Connectors 
During the early stages of this project, Dionex, the manufacturer of the HPLC system 
developed a new zero dead volume tubing connector. Dead volumes at manually 
prepared conventional unions and junctions are very difficult, if not impossible, to 
avoid as small imperfections or irregularities will occur when the tubing is cut to form 
the union/junction. Even small dead spaces can be problematic because the peak 
volume is only 1.5-2µL. A comparison between an analysis where conventional and 
nano-Viper fittings were used was carried out. There is a minimum of five 
junctions/unions in the liquid path in the HPLC (from the autosampler to the mass 
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spectrometer) we employed. Figure 3.3 shows that peaks eluted slightly earlier; were 
narrower, sharper and more intense when nano-Viper fittings were used. The use of 
nano-Viper fittings decreased the limit of detection of Lyso-Gb3 from 40 fmols to 10 








Figure 3.3 Chromatography developments: Extracted ion chromatograms of the 
main fragment ion (m/z 282.3) derived from Lyso-Gb3 using: (a) nano-Viper 
connection tubing designed to give zero-dead space displaying sharper peak (lower 
peak width), higher peak intensity and earlier retention time of detection. (b) Standard 









3.3.2.2 Choice of Chromatography Stationary Phase 
Three different brands of C18 columns were tested for MS background, 
reproducibility, peak shape and tailing in order to select the most appropriate 
resolving column. Although all 3 columns were satisfactory the Halo C18 column 
(2.7µm, 50mm×200µm, Hichrom Limited-UK) was chosen as the background 
contamination MS peaks were slightly lower in initial tests and was employed for the 
whole study. 
A trap column was employed in this work to protect (guard) the main column. 
Samples flow through the trap column under conditions where the analyte binds 
whilst the unbound material passes straight through and is discarded to waste (Figure 
3.4). Any particles or poorly dissolved material will collect at the start of the trap 
column. It is important that the trap column has sufficient capacity to bind all of the 
analyte under study but an overly large column can lead to long run times, non-
specific losses (due to excessive surface area) and peak broadening. My initial studies 
showed that a trap column with the dimensions of 5µm, 5mm × 300µm was optimal. 
This trap column has 5µm particles, compared to 2.7µm for the main C18 column and 
is 5mm in diameter compared to 200µm (or 0.2mm which means that the trap column 
has 25 times greater diameter or 625 times greater cross sectional area) to the main 
C18 resolving column. This allows the trap column to be loaded with sample at 
15µL/min. The larger particle size and massively increased surface area means that 
the trap column can be loaded at higher flow rates to save time,  is far less prone to 
blocking/plugging and acts as a very effective guard, which extends the useful life of 







Figure 3.4 HPLC valve operation and usage: The diagram represents the 10 port 
valve that was fitted to the Dionex 3000 HPLC system used in this work. The valves 
work by having channels within them that connect each port to one of the two ports 
on either side of them and when the valve switches the connection is redirected to the 
port on the other side. For example, if port 5 was connected to port 4 in position A it 
would change to port 6 after switching to position B and port 4 would then be 
connected to port 3. In the schematic shown the sample line, from the autosampler, is 
connected to port 5, and whilst loading this is connected to port 6. The sample 
(resuspended in 20%ACN/0.1%FA in water) then exits port 6 and flows through the 
trap column.  The GSLs bind to the trap column and the unbound material flows onto 
port 9, which is connected to port 10, which then directs the flow to waste. During 
this time the flow into port 7 comes from the HPLC elution line and then onto the 
resolving column via port 8. During the sample loading the flow through this line 
contains 20% ACN/0.1%FA in water. After the sample is loaded (3min at 15µL/min) 
and the trap column washed the valve switches so that the flow into port 6, which is 
connected to the trap column, comes from the solvent elution line. The solvent 
composition is changed at exactly the same time to 50%ACN/0.1%FA in water to 
elute the analytes from the trap column. After the valve switch port 9 is connected to 
port 8 (rather than port 10) so that the eluate from the trap column flows onto the 
resolving C18 column via port 8. The GSLs are resolved on this column and 
eventually are sprayed directly into the mass spectrometer for analysis. All the flow 
rates, valve switches and solvent composition changes/timings etc. are written into the 










Figure 3.5 HPLC optimization, the final optimized HPLC gradients: The different 
concentrations of ACN were generated by the HPLC mixing the required proportions 
of solvent A (0.1% FA in water) and solvent B (0.1% FA in ACN). The sample was 
resuspended in 20%ACN/0.1%FA in water. Then, the sample was loaded into the trap 
column using 20% of mobile phase B for 3 min at loading flow rate of 15µL/min and 
then eluted at flow rate of 3µL/min using 50% of mobile phase B for 4 min. 
Thereafter, the column was washed with 100% of mobile phase B for 3 min. and 
finally, the HPLC system was equilibrated using 20% of mobile phase B for 2 min to 
be ready for the next sample. During the washing and equilibration steps, the eluate 















3.3.2.3 Binding and Elution Conditions 
3.3.2.3.1 Flow Rate 
The flow rate used in this type of analysis is, like many parameters, a compromise 
where the quality of the data, the time it takes to perform the analysis and the back 
pressure of the HPLC should be considered. For example, higher flow rates lead to 
shorter analysis times but if it is too high the analyte binding to the trap column may 
be affected and the back pressure could reach unacceptable levels. A range of flow 
rates were tested and 15 µL/min for loading the trap column and 3 µL/min for elution 
of the resolving C18 column generated an acceptable back pressures, complete 
binding of the analytes and good peak shapes and  were used for all the subsequent 
work. Higher flow rates generated too much back pressure. 
 
3.3.2.3.2 Solvent Composition 
The conditions used to ensure reliable binding of analyte to the stationary phase are 
again a compromise. A high polarity (low organic solvent content) acidic solvent 
would be expected to increase binding of GSLs but would also cause more 
background lipids/contaminants to bind as well. This may lead to a high background 
contamination that can lead to poor quality data. Therefore, it is more usual to use a 
less polar solvent (higher organic content) that results in complete binding of the 
analyte whilst minimising the binding of other compounds. Another factor to be 
considered is the solubility of analytes in the solution used to resuspend the residue 
produced following extraction from the sample. Lipids are often kept in solution in 
biological samples by being bound to proteins, located in lipoproteins, vesicles, or as 
a component of micellar type structures. When the samples are extracted these 
structures will be destroyed and the solubility of many lipids in an aqueous solvent 
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will be limited. Therefore, a less polar solvent is often used to resuspend extract 
residues. The lipids of interest here are lyso-lipids (one acyl chain) that are less 
hydrophobic than lipids that contain 2 acyl chains (like Gb3) so relatively polar 
solvents can be used. Our initial studies showed that a solvent containing 0.1% FA 
and 20% ACN in water was suitable to both resuspend the extracted lipids and to 
ensure complete binding of analytes to the solid phase without increasing background 
MS contamination to unacceptable levels. 
Gradient elution is often used when large numbers of compounds in very complex 
mixtures are being identified, for example, in a shotgun proteomic protocol but it is 
quite common to use an isocratic elution when a small number of specific analytes are 
being quantified. Therefore, a series of isocratic elutions, using Lyso-Gb3 standards, 
using increasingly percentages (35, 40, 45, 50, 55 and 60% in 0.1% FA in water) of 
ACN were performed and the elution characteristics of the Lyso-Gb3 recorded. The 
retention times, peak intensities and AUC were recorded and are shown in Figure 3.6.  
The peak shapes and the level of background contamination were also monitored. The 
AUC and peak intensities of the Lyso-Gb3 increased as the proportion of ACN 
increased, as the extent of elution increased. However, the background contamination 
also increased at the same time. The retention time decreased as the ACN increased, 
which allows for a shorter analysis time, which is an important factor when 
developing a routine assay. As a compromise between increased AUC/peak intensity 
and background issues all samples were analysed with an isocratic elution using 50% 









Figure 3.6 HPLC optimaisation – the optimised solvent composition used for the 
stationary phase elution: Isocratic elution of Lyso-Gb3 using a range of mobile 
phase B (1%FA/ACN) concentrations was performed and (a) AUC, (b) intensity and 
(c) retention time (RT) recorded and the peak shape and background contamination 
observed. Increasing the concentration of ACN decreased RT and increased the AUC 
and intensity but at concentrations above 50% ACN the background was problematic 
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3.3.3 Optimisation of the Mass Spectrometer 
The sensitivity and stability of the mass spectrometer in this work is of fundamental 
importance therefore, a great deal of care was taken to monitor, maintain and optimise 
the instrument performance. 
 
3.3.3.1 Tuning and calibration of MS 
The software supplied with the micrOTOF-II mass spectrometer used in this work has 
an automatic tuning and calibration function. In order to do this a commercially 
available calibrant (ESI-L low concentration tuning mixture – Agilent Technologies – 
USA, calibrants at m/z of 118.09, 322.05, 622.03, 922.01, 1221.99, 1521.97, 1821.95, 
2121.93, 2421.91 and 2721.89) was  infused directly into the MS and a 
comprehensive optimisation of all variables related to the ion optics and detector 
performed. Modern mass spectrometers are extremely complex and all instruments 
are now tuned in this way to ensure that optimal conditions are obtained. The 
instrument was also calibrated once the tuning was complete (Figure 3.7). This test 
was done every day and the calibrant mass accuracies and intensities recorded to 
monitor instrument long term performance. The ion source was optimised manually, 
prior to and after the tune/calibration procedure was carried out, using calibrant 






Figure 3.7 MS tuning and calibration: A mass spectrum generated from microToF 
MS showing the final optimised calibrants to follow the instrument performance. The 
figure shows 9 peaks of the mixed calibrants at m/z of 322.05, 622.03, 922.01, 
1221.99, 1521.97, 1821.95, 2121.93, 2421.92 and 2721.89. The signal intensities and 
mass accuracies were tested and optimised by MS tuning and calibration before each 
analytical run. This way allows us to follow the performance of the instrument for 
long term. 
   
 
3.3.3.2 Dry Gas Temperature 
Another important factor in the ionisation process is the temperature of the ion source.  
This is important because the hot gas infused into the MS source evaporates the 
solvent (from the HPLC) that contains the eluted analyte to allow ionisation in the gas 
phase. Therefore, the gas needs to be hot enough to remove the solvent effectively, 
but if it is too hot it can lead to premature fragmentation of the analyte, compromising 
the assay. A range of dry gas temperatures between 50 and 200 °C were tested and 







3.3.3.3 Optimum Spectral rate  
The spectral rate in an MRM based analysis is also a compromise. The spectral rate is 
essentially; if the rate is low the analyte is allowed to accumulate in the collision cell 
for longer, increasing the sensitivity of the analysis. However, since the GSLs elute 
from the resolving column over a narrow 30-40 second peak a low spectral rate will 
mean that less data points will be collected across the peak which will limit the ability 
to reliably calculate the AUC. In order to assess the effect of changing the analytical 
rate different amounts of Lyso-Gb3 were extracted and analysed using the optimised 
procedures outlined above at spectral rates of 0.5, 1, 2 and 5 Hz. The findings showed 
that a rate of 0.5 Hz was the optimal condition to be used in the study (Figure 3.8) due 




Figure 3.8 Optimisation of the MS spectral rate: MS spectra rate of 0.5Hz gives 
lower limit of detection, higher intensity and AUC so it has been selected as the 



































3.3.3.4 Lyso-Gb3 fragmentation profile by MS/MS 
In order to accurately quantify Lyso-Gb3 and other metabolites, MRM mode was 
used.  The metabolites detected at the predicted masses were isolated and fragmented 
and the masses and intensities of the daughter ions recorded using an MRM based 
protocol. This procedure eliminates contaminant peaks giving a clean fragmentation 
spectrum (Figure 3.9). The fragmentation mechanism of Lyso-Gb3 in the collision 
cell of a mass spectrometer like the micrOTOF-II used here is outlined in Figure 3.10 
while Figure 3.9 shows the actual fragmentation spectrum where the protonated Lyso-
Gb3 molecule [(a), m/z 786.4] loses the 3 carbohydrates (galactose, galactose and 
glucose) [(c, e and g), m/z 624.4, 462.3 and 300.3 respectively] represented by losing 
162 Da each time. The loss of these 3 carbohydrates results in formation of a 
sphingosine ion [(g), m/z 300.3]. Moreover, peaks [(b, d, f, h and i), m/z 768.4, 606.4, 
444.4, 282.4 and 282.4 respectively] are generated by the loss of a water molecule 
from the sphingosine moiety at each stage. Subsequently, this mono-dehydrated 
sphingisine molecule [(h and i), both have the same m/z 282.4] is fragmented by 
another dehydration process resulting in peak [(j), m/z 264.4]. Therefore the peak of 
m/z 282.29 is used for identification and quantitation of Lyso-Gb3 by measuring AUC 




















Figure 3.9 MS/MS of Lyso-Gb3: This mass spectrum data was generated using microToF-MS, and shows the fragmentation (MRM transitions) of the Lyso-
Gb3 precursor ion (m/z 786.4) into a range of fragments (daughter ions). There are 3 losses of 162 Da represented in the loss of the 3 sugar groups resulting in 
sphingosine molecule (m/z 300.3). Subsequently, a mono-dehydration process occurs at each stage. The ion m/z 282.3 has two channels (it could result from a 
mono-dehydration process of sphingosine molecule and/or the loss of glucose molecule from the ion m/z 444.3. The most abundant daughter ion (m/z 282.3) 
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Figure 3.10 Theoretical fragmentation procedure of Lyso-Gb3: The structures of the ions generated in the MRM transition of Lyso-Gb3 
precursor ion (m/z 786.4) to the most abundant daughter ion (dehydrated sphingosine, m/z 282.3) are shown along with intermediate structures of 
all the fragments, explaining the mechanism. A total of 3 losses separated by 162 Da which represent the loss of the 3 carbohydrates (c, e & g) 
generating a sphingosine molecule (g). At each stage, a mono-dehydration process is achieved resulting in the peaks (b, d, f, h & i). 
Subsequently, (h & i) are fragmented by another dehydration generating peak (j). 
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3.3.3.5 MRM Analysis of Lyso-Gb3 Analogues  
Recent work by Aurey-Blais et al [85, 206, 225, 226] has identified analogues of Lyso-Gb3 
in samples from Fabry patients and there is the potential that these analogues could be 
clinically relevant biomarkers. Here plasma from an untreated classical Fabry hemizygote 
(Figure 3-11) was found to contain analogues with m/z 758.4, 784.3, 802.3, 804.4, 820.4 and 
836.4, which differ from Lyso-Gb3 by m/z -28, -2, +16, +18, +34 and +50 Da respectively. 
With urine from a Fabry patient seven analogues were detected with m/z of 758.4, 774.4, 
784.3, 800.4, 802.3, 820.3 and 836.3 resulting from a modification in the sphingosine moiety 
of m/z –28, -12, -2, +14, +16, +34 and +50 Da respectively. Figure 3.12 shows the extracted 
ion chromatograms for the urine derived analogues from an untreated classical Fabry 
hemizygote. When these analogues are isolated and fragmented in the collision cell of the 
mass spectrometer they display a series of daughter ions (fragments) that differ from Lyso-
Gb3 fragments, by exactly the same m/z as the parent ion varies from Lyso-Gb3 (Figure 3-
13). Therefore, the analogues have the same tri-carbohydrate group as Lyso-Gb3 and a 
modified sphingosine moiety. The analogues can be quantified in the same way as Lyso-Gb3 
using the area response of the analogue to GSG internal standard by calculating the AUC of 
the modified sphingosine moiety and dividing this by the AUC of the sphingosine derived 
from the GSG internal standard as shown in the following equation (Equation 3-3): 





Figure 3.11 Plasma Lyso-Gb3 analogues in untreated Fabry hemizygote: Extracted ion 
chromatograms of Lyso-Gb3 and its analogues in plasma sample from a hemizygous Fabry 
male: (a) Lyso-Gb3 (m/z 786.4), (b) Lyso-Gb3 (-28 Da, m/z 758.4), (c) Lyso-Gb3 (-2 Da, m/z 
784.3), (d) Lyso-Gb3 (+16 Da, m/z 802.3), (e) Lyso-Gb3 (+18 Da, m/z 804.4), (f) Lyso-Gb3 






Figure 3.12 Urinary Lyso-Gb3 analogues in untreated Fabry hemizygote: Extracted ion 
chromatograms of Lyso-Gb3 and its analogues plasma sample from a hemizygous Fabry 
male: (a) Lyso-Gb3 (m/z 786.4), (b) Lyso-Gb3 (-28 Da, m/z 758.4), (c) Lyso-Gb3 (-12 Da, 
m/z 774.4), (d) Lyso-Gb3 (-2 Da, m/z 784.3), (e) Lyso-Gb3 (+14 Da, m/z 800.4). (f) Lyso-Gb3 






Figure 3.13 MS/MS fragmentation of Lyso-Gb3 analogues: MS spectra show MS/MS fragmentation of (a) Lyso-Gb3; (b) Lyso-Gb3 (-2 Da); 
(c) Lyso-Gb3 (-28 Da); (d) Lyso-Gb3 (+34 Da); (e) Lyso-Gb3 (+16 Da) and (f) Bovine-GSG internal standard. The modified derivative of the 
sphingosine moiety of Lyso-Gb3 was detected in plasma of an untreated Fabry male using HPLC-micrOTOF-MS approach. This analogue 




3.3.4 Choice of Internal Standard 
GSG derived from bovine, buttermilk was used initially, which has an m/z of 462.4 which is 
exactly the same as one of the MS/MS fragments of Lyso-Gb3 (Lyso-Gb3 -2 carbohydrates). 
The structures of MS/MS fragmentation of GSG-bovine origin and Lyso-Gb3 are identical 
giving the most abundant daughter ion m/z 282.3 (Figure 3.14 a). Alternatively, GSG-plant 
origin varies from GSG-bovine origin and human-GSG by having an additional double-bond 
in the sphingosine moiety decreasing the m/z by 2 Da (Figure 3.14 b). This results in variation 
in MS/MS fragmentation where GSG-plant origin is fragmented giving the most abundant 
daughter ion m/z 280.30, 2 Da less than human-GSG giving easily distinguishable peaks. 
 
Figure 3-14 Method development- GSG Internal standard: MS spectrum view window 
shows MRM transitions of the parents and daughters ions of GSG from bovine buttermilk (a) 
and GSG from plant (b) where the plant origin-GSG has 2Da less in the parent ion and 




3.3.5 Role of the Internal Standard 
A clinically relevant concentration range of Lyso-Gb3 was added to either control urine (0-8 
nM sample concentration or 0-0.8 pmol/MS run) or charcoal stripped plasma (0-200 nM 
sample concentration or 0-8.0 pmol/MS run) samples along with GSG. The samples were 
subjected to the optimised extraction and analytical protocols given above. The AUC data of 
the m/z 282.3 daughter ion derived from the added Lyso-Gb3 for the urine samples and 
plasma samples. Lyso-Gb3 standard curves were generated using Lyso-Gb3 area alone vs. 
Lyso-Gb3 injected amount or by using area response ratio of Lyso-Gb3 vs. Lyso-Gb3 
injected amounts. Using Lyso-Gb3 AUC alone, a considerable deviation from a good fit with 
r
2
 values of 0.9068 and 0.9279 was observed. When this AUC data is expressed relative to 
the AUC data of the m/z 280.3 daughter ion derived from the GSG internal standard from the 
same sample the r
2
 values increase to 0.9999. This demonstrates that the GSG internal 
standard very effectively compensates for variability in the entire analytical process and that 
the assay is applicable to the samples of interest over the entire clinically relevant 






Figure 3.15 Lyso-Gb3 standard curves using GSG IS: Lyso-Gb3 extracted from urine (a) 
and plasma (b). The standard curves were plotted using Lyso-Gb3/GSG response of AUC. 
The standard curves show a linear response with GSG. A constant amount of GSG is used 
with different amounts of Lyso-Gb3 (covering the clinical ranges) showing a reproducible 
stable response for Lyso-Gb3 to GSG each time (Note: The used GSG internal standard is 
derived from plant). 
 
3.3.6 Assay Performance Characteristics 
Once the relevant variables of the extraction, HPLC resolution and MS analysis were 
optimised it was a priority to demonstrate that the assay is valid over the concentration range 
of Lyso-Gb3 seen in Fabry patients plasma and urine and to determine the lowest level of 
Lyso-Gb3 that can be detected and quantified reliably as well as the variability of the assay. 
 
3.3.6.1 Lyso-Gb3 Quality Controls 
As the intention of this work was to establish an assay for the analysis of large numbers of 
clinical samples over an extended period of time it was important to demonstrate that the 
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assay was reproducible over time. Urine and plasma quality controls (QCs) would be suitable 
for this purpose but they are not available commercially and the ethics in place for this 
project would not allow use of patient samples for this purpose. Therefore, we prepared our 
own QCs by adding Lyso-Gb3 to bulk samples before freezing aliquots that were assayed, 
identically to the clinical samples, with every batch processed. 
Two 250mL samples of the same charcoal stripped (twice) and filtered (0.2µm) plasma from 
healthy controls had Lyso-Gb3 added to give a low concentration (2.5nM) and a high 
concentration (50 nM). After thorough mixing the samples were aliquoted and frozen at -
80⁰C until used.  For urine 2 identical samples from a healthy individual (500mL) was spiked 
with Lyso-Gb3 to give a low (0.5 nM) or high (6 nM) concentration. Again after extensive 
mixing aliquots were frozen at -80⁰C until used. These samples were processed regularly 
throughout the batches of samples and the results recorded in order that the consistency of the 
assay could be monitored. 
Samples prepared in this way have significant limitations, for example, patient samples will 
contain variable amounts of metabolites and analogues related to Lyso-Gb3. Such related 
molecules could have effects on the extraction efficiency of the Lyso-Gb3/GSG or modify 
the extent of ionisation of the analytes in the MS analysis.  However, even with these 
limitations the QC samples will allow an assessment of consistency, if not the accuracy, of 
the entire analytical process over time. 
 
3.3.6.2 Lyso-Gb3 stability test 
A stability test was used in order to study the stability, reproducibility and repeatability of the 
HPLC-MS system prior any analysis of biological samples. The stability test solution was 
prepared by mixing 25nM of Lyso-Gb3 standard with 8nM GSG internal standard (1:1, v:v) 
and stored at -20
⁰
C until used. The stability test solution was analysed 6 times at the 
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beginning of each run and the intensities, AUC and retention times recorded. The AUC 
response of Lyso-Gb3 to GSG internal standard and the retention time for the six run should 
be identical before analysing any clinical samples. This test allows following the instruments 
performance in each single run. Figure 3.16 shows extracted ion chromatogram of Lyso-Gb3 
and GSG internal standard used in stability test. 
 
Figure 3-16 Stability test: extracted ion chromatogram of Lyso-Gb3 and GSG internal 
standard in stability test to study the instrument performance in each single day analysis. 
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3.3.6.3 Lyso-Gb3 Intra-Assay and Inter-Assay  
Plasma QCs and urinary QCs were analysed in quadruplicate on the same day to calculate the 
intra-assay variability and this was repeated on four independent occasions on different 4 
days to calculate the inter-assay variability. The following formula was used to calculate the 
intra-assay variability:  
 
 
The inter-assay variability was calculated using the following formula: 
 
 
Intra-assay variability (CV %) was calculated for plasma QCs as: 5.13%. Inter-assay 
variability (CV %) was calculated as: 8.79%. 
Intra-assay variability (CV %) was calculated for urine QCs as: 1.93%. Inter-assay variability 
(CV %) was calculated as: 2.46%. The acceptable intra- and inter-assays variability is ≤15%. 
 
3.3.6.4 Limits of Detection and Quantitation 
A range of concentrations of synthetic Lyso-Gb3, were added to either healthy control urine 
or pooled human plasma stripped twice with charcoal samples which were extracted and 
analysed using the optimised methods given above. The concentration ranges used were 0, 
0.125, 0.25, 0.5 and 1.0 nM for plasma and 0, 25, 50, 100, 200, 400 pM for urine. Limit of 
detection (LOD) and limit of quantitation of both plasma and urinary Lyso-Gb3 were 
determined using (Equation 3.6) and (Equation 3.7) respectively, where f = 3.3 and 10 for 
Inter-assay variability = [(Stdev of LQC area response means / mean of LQC mean area 
response*100) + (Stdev of HQC area response means / means of HQC area response 
means*100)] / 2 ……………………………………….……….…………….…. (Equation 3.5) 
Intra-assay variability= [(Stdev of LQC area response / mean of low QC area 
response*100) + (Stdev of HQC area response / mean of HQC area response*100)] / 2               
……………………………………….……….…………….….…….…………….. (Equation 3.4) 
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LOD and LOQ respectively, 𝑠𝑡𝑑𝑒𝑣 = standard deviation and 𝑏: Slope of the regression line 
(Figure 3.10 b and c) respectively. 
𝐿𝑂𝐷 = f × 𝑠𝑡𝑑𝑒𝑣/𝑏 ……………………………………….……….…………….…. (Equation 3.6) 
𝐿𝑂𝑄 = f × 𝑠𝑡𝑑𝑒𝑣/𝑏 ……………………………………….……….…………….…. (Equation 3.7) 
For plasma LOD was 0.13 nM and LOQ was 0.25 nM. However, for urine LOD was 50 pM 




We have developed an HPLC-MS/MS approach for analysis of plasma and urinary Lyso-Gb3 
and its analogues. Our pilot data on method optimisation has shown a clear advantage of SPE 
extraction, HPLC separation and MS/MS assays. 
SPE was preferred over liquid-liquid extraction (Bligh and Dyer extraction), because of its 
simple procedure, shorter processing time and comparable recoveries. Moreover it does not 
require halogenated solvents (e.g. chloroform) where laboratories avoid the use of chloroform 
and other halogenated solvents for environmental reasons. 
The MRM acquisition mode used here has the advantage that the selection of the parent ion 
before fragmentation removes any contaminants (other unwanted peaks) from the MS 
spectrum giving very clean spectra and allowing accurate and sensitive quantitation. 
The use of a suitable internal standard in quantitative mass spectrometry approaches is 
essential. Stable isotopes versions are typically used as they are chemically identical to the 
parent but vary in mass by a known amount. However, as no isotopic form of Lyso-Gb3 is 
commercially available and although synthetic protocols have been developed they are 
complex and require specialist knowledge [25, 257]. Therefore GSG was selected as internal 
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standard since it is closely related to Lyso-Gb3 and behaves in an identical fashion in the 
extraction, HPLC and MS protocols utilized here. 
GSG derived from plant was superior over GSG-bovine origin as an internal standard. While 
the later gives rise to exactly the same fragment likes Lys-Gb3 m/z 282.3 which could cause 
carry over and/or confusion, the plant GSG contains an extra double-bond in the sphingosine 
moiety giving a fragment of m/z 280.3. The use of GSG-plant origin removes any potential 
carry over, and used in all project studies. 
Similarly, to optimize the analytical process, I have tested the use of the newly developed 
nano-Viper fittings and found to be superior in terms of quantitation of Lyso-Gb3 and other 
metabolites. The use of nano-Viper fittings connection prevents any chromatography dead 
space and improves the limit of detection of the tested lipids. 
As this project deals with clinical samples, it was critical to ensure the instrument 
performance is stable. So, we have prepared our own in-house Lyso-Gb3 QCs to monitor the 
performance. MS performance displayed high stability with acceptable intra- and inter-assay 
variability.    
In conclusion, this chapter illustrates the optimization conditions of this research project. 
GSG-plant source internal standard and instrumentation have been chosen with optimal 
quality control benchmarks achieved. We have established a mass spectrometry based assay 
for Lyso-Gb3 and other metabolites. We have validated the assays using samples from Fabry 
patients. This assay is cheap and employs a virtually non-invasive method to collect body 
fluids such as urine and plasma facilitating regular monitoring. The relevant metabolites were 
extracted using SPE then separated by HPLC before being linked online to MS. The detected 
mass alone does not definitely identify the metabolite. Therefore the ions are fragmented 
using MS/MS giving a characteristic fragmentation pattern of daughter ions. GSLs 
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concentrations were measured using Lyso-Gb3 standard calibration curve after measuring the 
area response ratio of the examined analyte to GSG internal standard. Having optimised the 
assays to detect and quantify Lyso-Gb3 and its associated analogues, this protocol was used 
to examine and quantify the levels of these metabolites in plasma and urine samples obtained 


































CHAPTER - 4 
THE CLINICAL UTILITY OF PLASMA LYSO-GB3 
AND ITS ANALOGUES IN THE DIAGNOSIS AND 
















Fabry disease (FD) results from mutations in the α-gal-A gene. The human genome mutation 
database has identified approximately 800 mutations thus far, some of which result in a 
complete loss of enzymatic activity while others result in diminished activity. As outlined in 
Chapter-1, the α-gal-A enzyme activity test shows the deficiency of enzymatic activity in 
Fabry patients. This deficiency can identify classical Fabry patients especially in hemizygous 
males, where the enzyme activity is considerably reduced or absent (<1%). Nevertheless, 
classical heterozygous Fabry females and both genders of late-onset variant Fabry patients 
can show residual enzymatic activity. 
Currently, mutation analysis and the α-gal-A enzyme activity test along with clinical signs 
are used to establish the diagnosis of FD. A subgroup of Fabry patients lack the classical 
features of FD and present with single organ involvement (e.g. LVH and kidney disease) and 
are classified as atypical variants [79, 224, 258]. They usually present later in life than 
classical Fabry patients and tend to have symptoms which are not specific to FD making 
them a diagnostic challenge. The correct diagnosis in atypical variant Fabry patients usually 
takes many years if not decades. At the other end of the spectrum, increased awareness of FD 
has led to screening studies resulting in identification of patients with mutations of unknown 
significance which has led to over diagnosing FD in some patients [259]. 
Lyso-Gb3 has been increasingly suggested as a promising diagnostic biomarker and some 
evidence suggest that Lyso-Gb3 may be of value in monitoring FD [46, 162, 215]. Patel et al 
[260] reported that FD is associated with a high burden of cardiac morbidity and mortality. 
Adverse cardiac outcomes are associated with age, global disease severity and advanced 
cardiac disease but not the presence of cardiac genetic variants. 
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The work presented in this chapter aims to measure the levels of plasma Lyso-Gb3 and its 
analogues and to study the clinical utility of these GSLs as biomarkers for the diagnosis and 
monitoring of FD in both classical and cardiac variant Fabry patients. 
 
4.2    SAMPLE COLLECTION FROM FABRY PATIENTS 
Blood samples were collected from 100 Fabry patients. Plasma samples were generated after 
centrifugation at 3500 rpm/10mins to pellet and remove contaminating blood cells. Plasma 
samples were stored at -80⁰C until required for processing. All Fabry patients were diagnosed 
either by screening for the presence of GLA gene mutation and/or by α-gal-A enzymatic 
activity assay. Of the 100 Fabry patients enrolled in the study, 56 patients were from London, 
and 44 were from the West Midlands and Sheffield. Samples were obtained from 33 healthy 
volunteers and an additional 76 non-Fabry patients; the latter was obtained from 5 clinics at 
the Queen Elizabeth Hospital, Birmingham, UK; the latter were receiving treatment for 
diseases unrelated to FD. Table 4.1 shows the subgroups of the control subjects and the 









Control Group Subjects number 
Healthy volunteers 
33 
Renal clinic patients 
15 
Adrenal clinic patients 
15 
Inflammatory bowel disease (IBD) patients 16 
Autoimmune liver disease patients 15 
Vascular disease patients 15 
Total control subjects 109 
 





4.3.1    Control groups: 
Blood samples were collected from 76 non-Fabry patients obtained from 5 different clinics. 
As far as possible, these were age and gender matched. These included patients receiving 
treatment for renal, adrenal, inflammatory bowel disease (IBD), autoimmune liver disease 
and vascular disease. Plasma samples generated from this group were analysed for the levels 
of Lyso-Gb3and its analogues. This analysis was performed to determine whether Lyso-Gb3 
constitutes a specific biomarker for Fabry disease patients. The mean concentration of Lyso-
Gb3 was 0.88 nM, with a median of 0.73 nM and range of (0.28-2.30) nM. The results of this 
analysis revealed that all non-Fabry patients from the five clinics had comparable levels of 
plasma Lyso-Gb3 that were similar to those of healthy control subjects. Similarly, the healthy 
control volunteers (n=33) showed mean concentration of Lyso-Gb3 of 1.3 nM, with a median 
of 1.3 nM and range of (0.9-2.1) nM. Hence, all 76 non-Fabry patients data was pulled 




Figure 4.1 Plasma Lyso-Gb3 levels: Figure showing the levels of Lyso-Gb3 in plasma 
samples generated from classical Fabry patients, cardiac variant Fabry patients and non-Fabry 
patients recruited from the five different clinics (renal, adrenal, inflammatory bowel disease 
(IBD), autoimmune liver disease (L. autoimmune), and vascular disease), in addition to 
healthy control individuals (HC). Those non-Fabry patients enrolled in the study as controls 
with the healthy control individuals elevating the number of control subjects from 33 to be 
109 subjects. 
 
4.3.2 Plasma Lyso-Gb3 levels in classical Fabry patients 
To determine whether the levels of plasma Lyso-Gb3 could be used as a diagnostic tool to 
diagnose patients with classical FD, it was necessary to compare the levels of Lyso-Gb3 in 
Fabry patients and control subjects. A total of 62 Fabry patients were categorized as classical 
and the remaining 38 patients were as cardiac variants Fabry patients. The diagnosis of 
classical Fabry patients was initially confirmed by screening for the presence of known 
typical α-gal-A mutations (Table 4.2), the presence of typical FD manifestations, and the 




Table 4.2 Mutations list for classical Fabry patients. 
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The levels of plasma Lyso-Gb3 in treatment-naïve classical Fabry patients [male (n = 8) and 
female (n = 12)] were compared to treated classical Fabry patients [males (n = 15) and 
females (n = 27)] and control subjects [male (n=63) and female (n = 46)]. 
As predicted, higher levels of Lyso-Gb3 were observed in treatment-naïve classical Fabry 
males compared to the other groups. The concentration of plasma Lyso-Gb3 in untreated 
classical Fabry males (mean ± SEM = 117.8 ± 18.8) was significantly higher compared to 
treated classical Fabry males (mean ± SEM = 61.3 nM ± 4.4) (p < 0.01), and control males 
(mean ± SEM = 0.9 nM ± 0.5) (p < 0.0001). Significant differences were also noted between 
treated Fabry males and control males (p < 0.0001). A comparison of untreated Fabry males 
and females showed nearly ten-fold higher levels of Lyso-Gb3 in Fabry males. The difference 
observed was highly statistically significant (p <0.0001). 
In the female subgroup, the concentration of plasma Lyso-Gb3 was twelve-fold higher in 
classical Fabry females (mean ± SEM = 15.2 nM ± 3.7) pre-ERT, and (mean± SEM = 11.4 ± 
0.9) post-ERT compared to control females (mean± SEM = 0.8 nM, ± 0.07) (p < 0.0001). 
However, the variation in the levels of plasma Lyso-Gb3 in classical Fabry females’ pre-ERT 
and post-ERT was not statistically significant (p > 0.05). Furthermore, the difference between 
plasma Lyso-Gb3 levels in the two control genders was not statistically significant (p > 0.05) 
(Figure 4-2). 
These results confirm that the levels of plasma Lyso-Gb3 are significantly higher in untreated 
hemizygous Fabry males and appear to drop in treated hemizygous Fabry males. There was 
no overlap between the levels of plasma Lyso-Gb3 in untreated classical Fabry males and 
females. Furthermore, there was no overlap in the levels of Lyso-Gb3 in classical Fabry 
patients and control subjects. Plasma Lyso-Gb3 levels in classical Fabry patients were found 
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to be associated patient’s gender (Pearson correlation p value of < 0.0001), and treatment 
status (Pearson correlation p value of < 0.05). 
Figure 4.2 The levels of plasma Lyso-Gb3 in classical Fabry patients: Data were pooled 
from the patients and control subjects and presented as Whiskers-box plots. The 
concentrations were measured using Lyso-Gb3 calibration curve. Data were analysed using 
SPSS. The subjects were divided to 6 groups as follows: untreated Fabry male (UTFM), 
treated Fabry male (TFM), untreated Fabry female (UTFF), treated Fabry female (TFF), 
control male (CM) and control female (CF). For each group: n = number of subject; M = 
Mean; m = median; the range of minimum and maximum values in brackets; box= maximum 
and minimum quartiles; line inside the box = median; whiskers = maximum and minimum 
non-outlier values; ο = outlier values. Various groups were compared against each other 
using Mann-Whitney U tests. The differences were considered statistically significant if the p 
value < 0.05 (**=p<0.01and ****=p<0001). 
 
In order to assess the diagnostic accuracy of plasma Lyso-Gb3 levels in diagnosing classical 
FD in males, Receiver Operator Characteristic (ROC) analysis performed. Plasma Lyso-Gb3 
levels in 7 confirmed untreated classical Fabry males and 63 control males were assessed. 
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ROC curves were generated using SPSS software. A statistically significant result was 
generated with favourable area under the curve (1.000, p value <0.0001). Plasma Lyso-Gb3 
value equal to or higher than 2.7 indicated the presence of FD with a sensitivity of 100% and 
specificity of 100% (Figure 4.3). 
The diagnostic accuracy of Plasma Lyso-Gb3 levels in diagnosing classical FD in females 
was assessed using ROC analysis. Plasma Lyso-Gb3 levels in 12 confirmed untreated 
classical Fabry females and 46 control females were assessed. The ROC curve generated 
showed a statistically significant result with high area under the curve (1.000, p value 
<0.0001). Plasma Lyso-Gb3 levels equal to or higher than 2.6 nM indicated the presence of 
FD with a sensitivity of 100% and specificity of 100%. This implies that females with plasma 




Figure 4-3 ROC curve plasma Lyso-Gb3 levels in untreated hemizygous classical Fabry 
males vs. control males, the reference line is in green (left panel), cut-off value of 2.7 nM. 
ROC curve plasma Lyso-Gb3 levels in untreated heterozygous classical Fabry females vs. 
control females, reference line is in green (right panel), cut-off value of 2.6 nM. Graphs 
were generated using SPSS software. 
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4.3.3 Plasma Lyso-Gb3 levels in cardiac variant Fabry patients 
 
A total of 38 Fabry patients were diagnosed as carrying cardiac variants. The diagnosis was 
confirmed by mutation analysis of the α-gal-A gene. Among this group, 34 patients were 
shown to harbor a sequence change (N215S) in the GLA gene (an established mutation in 
cardiac FD variants). The other 4 patients had sequence changes of R118C, A301G, R301Q 
and P490T in the α-gal-A protein (Table 4.3). 
Mutation Cardiac variants’ Fabry patients 
protein Sequence Change nucleotide change male female total subjects 
N215S c.644 A>G 20 14 34 
R118C c.352 C>T 0 1 1 
A301G c.902 G>A 0 1 1 
R301Q c.902 G>A 0 1 1 
P490T not available 0 1 1 
Total subjects 20 18 38 
 




Cardiac variant Fabry patients showed lower levels of plasma Lyso-Gb3 (1.2-19.5 nM) 
compared to classical Fabry patients (3.0-210.8 nM) (Figure 4.1). Plasma Lyso-Gb3 
concentration in untreated cardiac variant Fabry males (n = 7, mean ± SEM = 10.1 nM ± 2.1) 
was significantly higher than in control males and in untreated cardiac variant Females [(n = 
63, mean ± SEM = 0.9 nM ± 0.05), p value <0.0001], [(n =13, mean ± SEM = 5.3 nM ± 
0.95), p value <0.05] respectively. However, there was no significant variation in the 
concentration of plasma Lyso-Gb3 between cardiac variant Fabry males pre-ERT and post-
ERT [n =13, mean ± SEM = 9.4 nM ± 1.1), p value >0.05]. Treated cardiac variant Fabry 
males showed significantly higher levels of plasma Lyso-Gb3 than control males (p value 
<0.0001). Both untreated cardiac variant Fabry females (n = 63, mean ± SEM = 0.9 nM ± 
0.05) and treated cardiac variant Fabry females (n = 5, mean ± SEM = 5.7 nM ± 1.8) showed 
significantly higher levels of plasma Lyso-Gb3 compared to control females (n =46, mean ± 
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SEM = 0.8 nM ± 0.07) with p values of <0.0001 and <0.001 respectively. Similarly, the 
variation in Lyso-Gb3 concentration in females’ pre-ERT and post-ERT did not reach the 
statistical significance (p value >0.05), (Figure 4.4). 
 
Figure 4.4: The levels of plasma Lyso-Gb3 in cardiac variant Fabry patients: Data were 
pooled from the patients and control subjects and presented as Whiskers-box plots. The 
concentrations were measured using Lyso-Gb3 calibration curve. Data were analysed using 
SPSS. The subjects were divided to 6 groups as follows: untreated Fabry male (UTFM), 
treated Fabry male (TFM), untreated Fabry female (UTFF), treated Fabry female (TFF), 
control male (CM) and control female (CF). For each group: n = number of subject; M = 
Mean; m = median; the range of minimum and maximum values in brackets; box= maximum 
and minimum quartiles; line inside the box = median; whiskers = maximum and minimum 
non-outlier values; ο = outlier values. Various groups were compared against each other 
using Mann-Whitney U tests. The differences were considered statistically significant if the p 
value < 0.05 (**=p<0.01, ***=p<0.001 and ****=p<0001). 
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The diagnostic accuracy of plasma Lyso-Gb3 in diagnosing cardiac variant form of FD in 
males assessed. Plasma Lyso-Gb3 levels in 7 males with cardiac variant FD and 63 control 
males were assessed. Similar to classical Fabry males, the ROC curve analysis showed 
excellent diagnostic accuracy. Plasma Lyso-Gb3 levels equal to or higher than 2.7 nM carried 
a diagnostic sensitivity and specificity of 100% (AUC=1, p value <0.0001). This implies that 
all individuals with plasma Lyso-Gb3 levels >2.7 nM are expected to be positive for cardiac 
variant FD (Figure 4.5). 
 
In order to assess the diagnostic accuracy of plasma Lyso-Gb3 levels in diagnosing cardiac 
variant FD in females, ROC analysis performed. Plasma Lyso-Gb3 levels in 13 confirmed 
untreated cardiac variant Fabry females and 46 control females were assessed. ROC analysis 
showed a statistically significant result with high area under the curve (0.965, p value 
<0.001). Plasma Lyso-Gb3 value equal to or higher than 2.7 nM indicated the presence of FD 
with a sensitivity of nearly 77% and specificity of 100%. Moreover, the cut-off value 
corresponding to 100% sensitivity was 2.4 nM. However, specificity at this point was only 
80.4%.  This implies that, depending on whether the test is aimed to be used as a screening 
test or a confirmatory test, an optimum cut-off value with the highest sensitivity or specificity 






Figure 4.5 ROC curve plasma Lyso-Gb3 levels in untreated hemizygous cardiac variant 
Fabry males vs. control males (left panel), cut-off value of 2.7 nM. ROC curve plasma Lyso-
Gb3 levels in untreated heterozygous cardiac variant Fabry females vs. control females (right 
panel), cut-off value of 2.4 nM. Graphs were generated using SPSS software. 
 
 
4.3.4 Levels of plasma Lyso-Gb3 analogues in classical Fabry patients 
The relative concentration of various Lyso-Gb3 analogues was analysed in our cohort of 
classical Fabry patients. This data is presented in the form of Whiskers box plots (Figure 4.6).  
This comparison included both untreated and treated male and female Fabry patients and 
control subjects. As shown in Figure 4.6, the relative concentration of each Lyso-Gb3 
analogues in classical Fabry patients varied considerably. While levels of Lyso-Gb3 (-2 Da) 
analogue in males, were found at the highest concentration (0.1-50.7 nM), levels of Lyso-
Gb3 (+18 Da) analogue were somewhat lower (1.6-17.5 nM), while levels of Lyso-Gb3 (-28 
Da) varied between (0.4-5.5 nM). The levels of Lyso-Gb3 (+34 Da) varied between (0.9-13.8 
nM), while the concentration of Lyso-Gb3 (+16 Da) was extremely low (0.1-2.2 nM). The 
levels of Lyso-Gb3 (+50 Da) were virtually undetectable. In all cases, the levels of each 
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analogue were undetectable in control male and female subjects. Again, differences were 
observed in the levels of all Lyso-Gb3 analogues between male and female classical Fabry 
patients, with female Fabry patients having concentrations that were lower than classical 
Fabry males but marginally elevated compared to control subjects. In response to ERT 
treatment, the concentration of each Lyso-Gb3 analogue decreased in male Fabry patients 
(Figure 4.6). 
  
The relative distribution of plasma Lyso-Gb3 and its analogues in the untreated classical 
Fabry patients is shown in Figure 4.7.  In both male and female Fabry patients, the levels of 
plasma Lyso-Gb3 constituted the highest percentage of total Lyso-Gb3 (males 76% vs 
females 79%) while small trace amounts of Lyso-Gb3 analogues were detected. In both male 
and female cases, the levels of Lyso-Gb3 (-2 Da), Lsyo-Gb3 (+18 Da), Lyso-Gb3 (+34 Da) 
and Lyso-Gb3 (-28 Da), which arise through modification of the sphingosine moiety, were 
broadly similar in both male and female cases, comprising 12% and 11% for Lyso-Gb3 (-2 
Da), 5% for Lsyo-Gb3 (+18 Da), 4% and 2% for Lyso-Gb3 (+34 Da), 2% for Lyso-Gb3 (-28 
Da), and 1% for Lyso-Gb3 (+16 Da), in males and females respectively. 
 
Figure 4.8 shows a ROC analysis of plasma Lyso-Gb3 and its 6 analogues. The results show 
that plasma Lyso-Gb3 and three analogues including Lyso-Gb3 (-28 Da), Lyso-Gb3 (+16 Da) 
and Lyso-Gb3 (+18 Da), show high sensitivity and specificity as a diagnostic predictor for 
FD. While Lyso-Gb3 has been proven to have a potential diagnostic utility, caution should be 
taken with regards to the use of the aforementioned analogues given their extremely low 
abundance and variability in detection between Fabry patients, even though they are absent in 





Figure 4.6 The levels of plasma Lyso-Gb3 analogues in classical Fabry patients: Data 
were pooled from the patients and control subjects and presented as Whiskers-box plots. The 
concentrations were measured using Lyso-Gb3 calibration curve. Data were analysed using 
SPSS. The subjects were divided to 6 groups as follows: untreated Fabry male (UTFM), 
treated Fabry male (TFM), untreated Fabry female (UTFF), treated Fabry female (TFF), 
control male (CM) and control female (CF). For each group: n = number of subject; M = 
Mean; m = median; the range of minimum and maximum values in brackets; box= maximum 
and minimum quartiles; line inside the box = median; whiskers = maximum and minimum 
non-outlier values; ο = outlier values. Various groups were compared against each other 
using Mann-Whitney U tests. The differences were considered statistically significant if the p 




Figure 4.7: The relative distribution of plasma Lyso-Gb3 and its analogues in untreated 
classical Fabry males (n=8, left panel) and untreated classical females (n=12, right panel). 
All classical Fabry males and females showed high percentage of Lyso-Gb3 in their plasma 








Figure 4.8: ROC analysis for diagnostic accuracy of plasma Lyso-Gb3 analogues to 
predict Fabry disease in classical Fabry patients: (a) untreated hemizygous classical Fabry 
males vs. control males. (b) Untreated heterozygous classical Fabry females vs. control 






4.3.5 Levels of plasma Lyso-Gb3 analogues in cardiac variant Fabry patients: 
Building on the analysis outlined above, I set out to determine the levels of various Lyso-Gb3 
analogues in cardiac variants Fabry patients. Again, this comparison included both untreated 
and treated male and female Fabry patients carrying the cardiac variant mutations and normal 
control subjects. As shown in Figure 4.9, the relative concentration of each Lyso-Gb3 
analogue varied considerably and, compared to classical Fabry patients were an order of 
magnitude lower. As with classical Fabry patients, the levels of Lyso-Gb3 (-2 Da) were found 
at the highest concentration (0-4 nM), while levels of Lyso-Gb3 (+18 Da) were somewhat 
lower (0-2 nM), and levels of Lyso-Gb3 (-28 Da) very low (0-1 nM). The levels of Lyso-Gb3 
(+34 Da) varied between (0-0.5 nM) while the concentration of Lyso-Gb3 (+16 Da) was 
extremely small (0-0.9 nM). The levels of Lyso-Gb3 (+50 Da) were undetectable. In all 
cases, the levels of each analogue were undetectable in control male and female subjects. 
Unlike classical Fabry patients, there was less of a distinction between male and female 
Fabry patients carrying the cardiac variant on the levels of all Lyso-Gb3 analogues. In 
response to ERT treatment, a reduction in the concentration of specific Lyso-Gb3 analogues 
was only observed in male patients, with reductions in the concentrations of Lyso-Gb3 (-28 
Da), Lyso-Gb3 (+16 Da) and, to a lesser extent in Lyso-Gb3 (-2 Da). The concentrations of 
Lyso-Gb3 (+18 Da) were moderately affected, while the concentrations of Lyso-Gb3 (+34 
Da) and Lyso-Gb3 (+50 Da) were virtually undetectable. 
 
The relative distribution of plasma Lyso-Gb3 and its various analogues was examined in the 
untreated cardiac variant Fabry patients. This data is presented in the form of a pie chart 
(Figure 4.10). In keeping with findings from classical Fabry patients, the levels of plasma 
Lyso-Gb3 constituted the highest percentage of total Lyso-Gb3 in both male and female 
patients (males 77% vs. females 72%). Again, small trace amounts of Lyso-Gb3 analogues 
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were detected in both male and female cases at broadly similar levels. The levels of Lyso-
Gb3 (-2 Da), Lsyo-Gb3 (+18 Da), Lyso-Gb3 (+34 Da) and Lyso-Gb3 (-28 Da), which arise 
through modification of the sphingosine moiety, were broadly similar in both male and 
female cases, comprising 7% and 9% for Lyso-Gb3 (-2 Da); 9% and 6% for Lyso-Gb3 (+18 
Da); 5% and 3% for Lyso-Gb3 (+34 Da); 4% and 3% for Lyso-Gb3 (-28 Da); and 3% and 
2% for Lyso-Gb3 (+16 Da) in males and females respectively. 
 
Figure 4.11 shows a ROC analysis of plasma Lyso-Gb3 and its 6 analogues in cardiac variant 
Fabry patients. The results show that plasma Lyso-Gb3 and the analogue Lyso-Gb3 (+18 Da) 
show high sensitivity and specificity as a diagnostic predictor for FD. The results proven that 
Lyso-Gb3 has a potential diagnostic utility. Despite some healthy control subjects didn’t 
show any detectable levels of the analogue Lyso-Gb3 (+18 Da), caution should be taken with 
regards to the use of the aforementioned analogues due to the extremely low abundance and 












Figure 4.9 Plasma Lyso-Gb3 analogues levels in cardiac variant Fabry patients: Data 
were pooled from the patients and control subjects and presented as Whiskers-box plots. The 
concentrations were measured using Lyso-Gb3 calibration curve. Data were analysed using 
SPSS. The subjects were divided to 6 groups as follows: untreated Fabry male (UTFM), 
treated Fabry male (TFM), untreated Fabry female (UTFF), treated Fabry female (TFF), 
control male (CM) and control female (CF). For each group: n = number of subject; M = 
Mean; m = median; the range of minimum and maximum values in brackets; box= maximum 
and minimum quartiles; line inside the box = median; whiskers = maximum and minimum 
non-outlier values; ο = outlier values. Various groups were compared against each other 
using Mann-Whitney U tests. The differences were considered statistically significant if the p 






Figure 4.10 The relative distribution of plasma Lyso-Gb3 and its analogues in cardiac 
variant Fabry patients: untreated cardiac variant Fabry males (n=7, left panel) and females 
(n=13, right panel). All cardiac variant Fabry males and females showed a high percent of 











Figure 4.11: ROC analysis for diagnostic accuracy of plasma Lyso-Gb3 analogues to 
predict Fabry disease in cardiac variant Fabry patients: (a) untreated hemizygous cardiac 
variant Fabry males vs. control males. (b) Untreated heterozygous cardiac variant Fabry 





4.3.6 Plasma Lyso-Gb3 levels in classical Fabry patients following ERT  
We next set out to examine the effects of ERT treatment on the levels of plasma Lyso-Gb3 in 
classical Fabry patients. Blood samples were collected from three patients and the levels of 
Lyso-Gb3 analysed from plasma as described previously. In the three cases blood sample 
were available pre and post treatment. In the classical Fabry male patient (Figure 4-12 a), 
elevated levels of plasma Lyso-Gb3 were found pre-ERT (154 nM). However, in response to 
the treatment by ERT, the levels of Lyso-Gb3 were reduced by almost two-fold one month 
after treatment (83 nM). 10 months after treatment the levels of Lyso-Gb3 had reduced again 
to (62 nM). By 18 and 22 months, post-ERT the levels of Lyso-Gb3 increased slightly, but 
were still almost two fold lower compared to the levels observed pre-ERT. While the pre-
ERT levels of Lyso-Gb3 were 77.1 nM in the other Fabry male patient (Figure 4-12 b). 
However, the levels of Lyso-Gb3 were reduced 5 months post-ERT, and continued to drop at 
11, 26 months in response to continual treatment. Here, the concentrations of Lyso-Gb3 were 
almost 2.6 fold lower 26 months post-ERT compared to starting point (pre-ERT). For the 
classical Fabry female patient (Figure 4-12 c), the levels of Lyso-Gb3 were elevated pre-ERT 
(43.9 nM), and decreased by almost two fold (20.1 nM) at the first time point post-ERT (after 
2 months from the initiation of ERT). At the second time point (after 7 months from the 
initiation of ERT), the levels of Lyso-Gb3 had increased slightly (25.0 nM), yet were still 
almost two – fold lower than levels observed pre-ERT. 
Building upon the above findings, the levels of Plasma Lyso-Gb3 in Fabry patients following 
ERT treatment was extended to include a larger cohort of patients. As shown in Figure 4.13, 
the levels of plasma Lyso-Gb3 were measured in an additional 8 classical Fabry patients 
following treatment by ERT. Patient samples 1,2 and 3 were previously described in Figure 
4-12). In broad agreement with the previous findings, the overall levels of Lyso-Gb3 were 




Figure 4.12 Following up ERT management in classical Fabry patients: Figure showing 
the levels of plasma Lyso-Gb3 levels in 3 classical Fabry patients’ pre- and post-ERT. The 




Figure 4.13 Plasma Lyso-Gb3 levels through ERT monitoring in classical Fabry 
patients: A figure shows the variations in plasma Lyso-Gb3 levels in 12 classical Fabry 
patients’ were undergone to ERT. The time points of sample collection were varied from a 







4.3.7 Plasma Lyso-Gb3 levels in cardiac variant Fabry patients following ERT  
Continuing with the theme of the previous section, the levels of Plasma Lyso-Gb3 were also 
measured in Fabry patients carrying cardiac variants pre and post-ERT treatment. As shown 
in Figure 4.14, the levels of plasma Lyso-Gb3 were lower than those observed in classical 
Fabry patients, yet in in a number of cases; the levels of Lyso-Gb3 were reduced in patients 
following treatment with ERT.  
 
 
Figure 4.14 Plasma Lyso-Gb3 levels through ERT monitoring in cardiac variant Fabry 
patients: Plasma Lyso-Gb3 levels in cardiac variant Fabry patients’ pre and post-ERT.
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In order to follow FD progression without ERT treatment, the levels of Lyso-Gb3 were 
available at 2 different time-points for only 3 cardiac variant Fabry patients. The results show 
slight increase in the levels of Lyso-Gb3 with time (Figure 3-15). 
 
 
Figure 4.15 Plasma Lyso-Gb3 levels vs. time in cardiac variant Fabry patients without 
any ERT management: Plasma Lyso-Gb3 concentrations in 3 cardiac variant Fabry patients 
with the nonsense mutation N215S. Plasma samples were collected from the patients at 2 
different time-points where the patients were not undergone for any type of ERT at both the 2 
time-points. 
 
4.3.8 Correlation between the levels of plasma Lyso-Gb3 and its various analogues in 
Fabry patients: 
 We next set out to explore whether the concentrations of specific Lyso-Gb3 analogues 
correlated with the levels of Lyso-Gb3 in plasma samples from Fabry patients. As shown in 
Figure 4.16, a strong correlation was observed between the levels of Lyso-Gb3 and its 
analogues: Lyso-Gb3 (+18 Da) and Lyso-Gb3 (+34 Da); and to a lesser extent with the other 
analogues in plasma samples from Fabry patients. In all cases, the correlations between the 
levels of plasma Lyso-Gb3 and its analogues were statistically significant with Pearson Chi-





Figure 4.16 Correlation between plasma Lyso-Gb3 and its analogues: The graphs show a 
strong correlation between the levels of plasma Lyso-Gb3 and its analogues in Fabry patients. 
The correlation was statistically significant with Pearson Chi-Square p value < 0.0001 in all 









4.3.9 Correlation between the levels of plasma Lyso-Gb3 and age of Fabry patients: 
The correlation between the levels of plasma Lyso-Gb3 and the age of Fabry patients did not 
reach the statistical significance (Figure 4.17). 
 
Figure 4.17 Correlation between plasma Lyso-Gb3 levels and the age: The graphs show 
the correlation between the levels of plasma Lyso-Gb3 and the age of Fabry patients. The 














There is a lack of available biomarkers that can be used to diagnose the various forms of FD, 
or to establish disease severity and monitor disease progression. As stated previously, two 
GSLs have been identified which constitute promising biomarkers that may aid the diagnosis 
and monitoring of the disease in Fabry patients. These are Gb3 and Lyso-Gb3; the latter is 
very similar to Gb3 but lacks the fatty acid chain. 
Several recent publications advocate the use of Lyso-Gb3 as a diagnostic biomarker for FD 
[46, 166, 222, 224]. The concentrations of plasma Lyso-Gb3 have shown utility in diagnosing 
the condition and, at least in one study, shown to correlate with disease severity [215]. 
Findings presented in this Chapter further substantiate these claims and support the utility of 
measuring plasma Lyso-Gb3 levels in the diagnosis of classical and cardiac variant forms of 
the disease. 
Results presented in this chapter set out to explore the utility of Lyso-Gb3 as a potential 
biomarker in the diagnosis and monitoring of FD. Findings presented in the first part of the 
chapter demonstrate that Lyso-Gb3 may serve as a useful biomarker in the detection of 
classical Fabry males, while it is still useful in diagnosing classical Fabry females despite 
their residual enzyme activity. 
There was no overlap between any classical Fabry patients and control males. Also, there was 
no overlap between cardiac variant Fabry males and control males. However, it is important 
to highlight that the levels of Lyso-Gb3 in some cardiac variant females overlapped or were 
very close to the levels in control females and hence caution is advised interpreting plasma 
Lyso-Gb3 levels in this subgroup. Based on the results of the remaining subgroups of Fabry 
patients (classical males, classical females and cardiac variant males) Lyso-Gb3 has a 
potential value to be used as a diagnostic tool for FD. 
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In clinical practice this implies that in males, positive plasma Lyso-Gb3 is likely to be 
diagnostic and a negative Lyso-Gb3 should reliably exclude FD as a diagnosis. In females 
positive plasma Lyso-Gb3 levels again should be considered diagnostic but negative results 
cannot exclude FD with certainty. As discussed previously, Fabry females continue to pose a 
diagnostic dilemma in FD. It is likely that use of plasma Lyso-Gb3 in many of these 
situations, especially when the levels are high, help to establish the diagnosis. 
Another area where we suggest plasma Lyso-Gb3 is likely to be of benefit is in patients with 
mutations of unknown significance. In male patients with mutations of unknown significance 
a positive or negative results should help in confirming or excluding the diagnosis of FD. 
However in female patients a positive result can reliably confirm the diagnosis of FD but a 
negative result cannot exclude it. To expand the argument further most of female patients 
including cardiac variants had levels above control females. Hence in situations where the 
suspicion of FD is low, a negative result of plasma Lyso-Gb3 will add some confidence along 
with other clinical information in attempting to exclude FD. 
 
In terms of monitoring of FD, plasma Lyso-Gb3 may be useful as a biomarker in classical 
Fabry males, where plasma Lyso-Gb3 levels were found to drop in response to ERT therapy. 
Subsequent to the initial drop, increases in the levels of Lyso-Gb3 were observed in only two 
cases from a total of twelve classical Fabry patients examined during their follow-up. This 
phenomenon has previously been suggested to be due to development of an immune response 
to ERT [46, 159-162]. It is not clear whether this increase in Lyso-Gb3 levels after the initial 
decline, correlates with a worsening of symptoms and disease progression. 
In essence, these finding suggest that Lyso-Gb3 may serve as a useful biomarker in 
monitoring Fabry patients’ response to ERT. Moreover, in agreement with a study by van 
Breemen and colleagues [165], we have shown that the levels of plasma Lyso-Grb3 are 
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reduced in classical Fabry males receiving ERT and may, therefore, have utility in 
monitoring a patients’ response to ERT. 
While a correlation was observed between the levels of plasma Lyso-Gb3 and the presence of 
selected Lyso-Gb3 analogues, the overall concentrations of these analogues were deemed too 
low to be of use as selective biomarkers in Fabry Patients. 
The results show that plasma Lyso-Gb3 and its analogues: Lyso-Gb3 (-28 Da) Lyso-Gb3 
(+16 Da) and Lyso-Gb3 (+18 Da) show high sensitivity and specificity as diagnostic 
predictors for classical FD in males. However, plasma Lyso-Gb3 and only the analogue 
Lyso-Gb3 (+18 Da) show high sensitivity and specificity as a diagnostic predictor for 
classical FD in females and for cardiac variant form of FD in both genders.   
While Lyso-Gb3 has been proven to have a potential diagnostic utility, caution should be 
taken with regards to the use of the aforementioned analogues given their extremely low 
abundance and variability in detection between Fabry patients, even though they are absent in 






















CHAPTER - 5 
THE CLINICAL UTILITY OF URINARY LYSO-GB3 



















The deficiency of α-gal-A activity in Fabry patients results in the intracellular accumulation 
of Gb3 and Lyso-Gb3 in various organs. It has been suggested that the genetic and epigenetic 
modifications contribute to residual enzyme activity. 
While less serious clinical manifestations of FD include pain in the hands and feet, more 
serious complications include diseases of the kidney, heart and brain. Fabry nephropathy is 
the involvement of the kidneys in Fabry patients. Over time, the progressive accumulation of 
Gb3 and Lyso-Gb3 and their related isoforms and analogues in cells that form the distal 
tubule and the loop of Henle, disrupts cell function and leads to renal pathologies. These 
manifest as proteinuria and reduced eGFR and can lead to chronic kidney disease and 
progression to renal decline [261-263]. 
The longitudinal databases on FD collected by The Fabry Registry (Genzyme) [49, 264, 265] 
and The Fabry Outcome Survey (FOS; Shire) [27], have shown a long delay in the diagnosis 
of FD after the onset of initial symptoms [261]. It has been shown that before renal dialysis 
and renal transplants became widely available, the life span of male Fabry patients was 
markedly reduced with an average age at death of 42 years [266-268]. However, the 
availability of renal dialysis and renal transplants worldwide in the past decades have 
extended the lifespan of Fabry patients [266]. 
As outlined in previous chapters, it is now well established that the diagnostic procedures 
(mutation analysis and α-gal-A enzyme activity test), while useful in the initial diagnosis of 
FD, have no utility for disease monitoring. This fact underscores the importance of 
identifying other methods that not only aid diagnosis, but can be used to monitor Fabry 
patients receiving treatment. 
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Plasma Lyso-Gb3 has progressive gained more importance as biomarker in Fabry in recent 
years but as explained in previous chapters it has its limitation as a diagnostic and monitoring 
biomarker especially in female variant patients. Having another biomarker to compliment 
plasma Lyso-Gb3 may provide some more diagnostic confidence in groups like cardiac 
variants and patients with genetic variant of unknown significance. 
In this chapter we aimed to measure the levels of urinary Lyso-Gb3 and its analogues and to 
determine the clinical utility of these GSLs as biomarkers for the diagnosis of FD. 
 
 
5.2    SAMPLE COLLECTION FROM FABRY PATIENTS 
Urine samples were collected from 42 Fabry patients. Samples were collected in universal 
urine tubes and stored at -80⁰C without prior purification or centrifugation until further 
processing. A total of 42 patients were sourced from the West Midlands or Sheffield. All the 
patients provided matching plasma samples at the same time of collection. All patients were 
diagnosed as FD sufferers either by mutation screening of the GLA gene or by the α-gal-A 
enzymatic activity test. Samples were obtained from 23 healthy volunteers and an additional 
25 non-Fabry patients; the latter, who were receiving treatment for diseases unrelated to FD, 
were obtained from renal and adrenal clinics at the Queen Elizabeth Hospital, Birmingham, 




Table 5.1 Anthropometric data of Fabry patients and control subjects: Table showing 




5.3.1 Control groups: 
Our control population consisted of 23 healthy volunteers and 25 non-Fabry patients. Urine 
samples were obtained from 25 non-Fabry patients attending two different clinics at the 
Queen Elizabeth hospital, Birmingham, UK. As far as possible, these were age and gender 
matched. These included patients receiving treatment for renal (n=15) or adrenal (n=10) 
diseases. Urine samples generated from this group were analysed for the levels of Lyso-Gb3 
and its analogues by LC-MS/MS, as outlined in section 2.4, 2.5 and 2.6 of Chapter 2. This 
analysis was performed to determine whether urinary Lyso-Gb3 might constitute a specific 
biomarker for FD and whether it is prevalent in other disease conditions. The results of this 
analysis revealed that all non-Fabry patients from both clinics had comparable levels of 
urinary Lyso-Gb3 that were broadly similar to those of healthy control subjects. The levels of 
Lyso-Gb3 were virtually undetectable in both non-Fabry patients (from renal and adrenal 
clinics) and healthy volunteers (n= 23), where the levels of Lyso-Gb3 typically below the 
limit of detection in urine samples. All 25 non-Fabry patients were enrolled in the study as 
controls alongside healthy volunteers, increasing the number of control subjects from 23 to be 
48 (Figure 5-1). Urinary Lyso-Gb3 was detected in classical Fabry patients (mean ± SEM = 
105.8 pmol/mmol creatinine ± 20.8). Moreover, Lyso-Gb3 was also detected in most of 
  Fabry patients Control subjects 
classical cardiac variant 
male female 
male female male Female 
Number 13 7 11 11 22 26 
Age 
(y) 
mean 39.8±15.1 58.7±16.1 49.6±12.9 51.6±19.9 46.7±14.9 59.4±18.3 
median 45.5±4.8 62.0±6.1 54.0±3.9 46.5±6.3 57.2±5.6 56.8±7.4 
range 19-55 32-80 18-65 29-85 20-82 29-80 
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Fabry patients carrying cardiac variant mutations of the α-gal-A gene, although in this case, 
substantially lower levels (approximately 6 fold) of Lyso-Gb3 were present (mean ± SEM = 
16.9 pmol/mmol creatinine ± 4.9). 
 
Figure 5-1 Urinary Lyso-Gb3 levels in Fabry patients and control subjects: The figure 
shows the levels of Lyso-Gb3 in urine samples generated from classical Fabry patients, cardiac 
variant Fabry patients and non-Fabry patients from the two different clinics (renal diseases clinic and 
adrenal diseases clinic), in addition to healthy control individuals (HC). The results revealed that there 
are no differences in the levels of Lyso-Gb3 between healthy controls and non-Fabry patients from 
renal and adrenal groups. All non-Fabry groups showed undetectable Lyso-Gb3 levels exactly like 
healthy control volunteers where their urinary Lyso-Gb3 was undetectable. Consequently, those non-
Fabry patients were pulled together to form large control. For each group: n = number of 
subject; M = Mean; m = median; the range of minimum and maximum values in brackets; 
box= maximum and minimum quartiles; line inside the box = median; whiskers = maximum 
and minimum non-outlier values; various groups were compared against each other using 
Mann-Whitney U tests. The differences were considered statistically significant if the p value 




5.3.2 Urinary Lyso-Gb3 levels in classical Fabry patients 
To determine whether the levels of urinary Lyso-Gb3 could be used as a diagnostic tool to 
diagnose patients with classical FD, it was necessary to compare the levels of urinary Lyso-
Gb3 in Fabry patients to those of control subjects. The levels of urinary Lyso-Gb3 in 
hemizygous male (n = 12) and heterozygous female (n = 7) classical Fabry patients were 
compared to each other and to control male (n = 22) and control female (n = 26) subjects. 
The levels of urinary Lyso-Gb3 were significantly higher in classical Fabry males (mean ± 
SEM = 135.0 ± 30.8) compared to classical Fabry females (mean ± SEM = 64.3 ± 18.1, p 
value < 0.05), with a noticeable overlap in urinary Lyso-Gb3 levels between genders. 
Nonetheless, the concentrations of urinary Lyso-Gb3 in male and female classical Fabry 
patients were significantly higher than those of male and female control subjects, where the 
levels of urinary Lyso-Gb3 were undetectable (p value < 0.0001). 
There was no overlap between the levels of urine Lyso-Gb3 in classical Fabry males and 
control male subjects. Nevertheless, of a total of seven heterozygous classical Fabry females, 
only one patient did not show any detectable level of urinary Lyso-Gb3. 
These results confirm that the levels of urinary Lyso-Gb3 were significantly higher in 
hemizygous classical Fabry males and, to a lesser extent in heterozygous classical Fabry 
females, and point to the potential utility of urinary Lyso-Gb3 in the diagnosis of classical FD 
in both male and female subjects however caution is advised interpreting a negative result in 
classical females. 
In order to assess the diagnostic accuracy of urinary Lyso-Gb3 levels in diagnosing classical 
FD in males, ROC analysis performed. Urinary Lyso-Gb3 levels in 4 confirmed untreated 
classical Fabry males and 22 control males were assessed. A statistically significant result 
was generated with favourable AUC (1.000, p value <0.01). Urinary Lyso-Gb3 levels equal 
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to or higher than 9.4 pmol/mmol creatinine indicated the presence of FD with a sensitivity of 
100% and specificity of 100% Figure (5-3).  
On the other hand, ROC analysis performed to assess the diagnostic accuracy of urinary 
Lyso-Gb3 levels in diagnosing classical FD in females. Urinary Lyso-Gb3 levels in 4 
confirmed untreated classical Fabry females and 26 control females were assessed. ROC 
curve showed a statistically significant result with AUC (0.875, p value <0.05). Urinary Lyso-
Gb3 value equal to or higher than 12.8 pmol/mmol creatinine indicated the presence of FD 
with a sensitivity of 75% and specificity of 100% (Figure 5-3).  
 
 
Figure 5-2 Urinary Lyso-Gb3 levels in classical Fabry patients: Data were pooled from 
the patients and control subjects and presented as box plots. The concentrations were 
measured using Lyso-Gb3 calibration curve. Data were analysed using SPSS. The subjects 
were divided to 4 groups as follows: Fabry male (FM), Fabry female (FF), control male (CM) 
and control female (CF). For each group: n = number of subject; M = Mean; m = median; the 
range of minimum and maximum values in brackets; box= maximum and minimum quartiles; 
line inside the box = median; whiskers = maximum and minimum non-outlier values; various 
groups were compared against each other using Mann-Whitney U tests. The differences were 





Figure 5.3 ROC analysis for diagnostic accuracy of urinary Lyso-Gb3 to predict Fabry 
disease in classical Fabry patients: Urinary Lyso-Gb3 levels in hemizygous classical Fabry 
males vs. control males (left panel), reference line is in green. ROC curve urinary Lyso-Gb3 
levels in untreated heterozygous classical Fabry females vs. control females (right panel), 




5.3.3 Urinary Lyso-Gb3 levels in cardiac variant Fabry patients 
 
A total of 22 Fabry patients for whom we have urinary samples have a diagnosis of cardiac 
variant. The diagnosis was confirmed by mutation analysis of the GLA gene. Among this 
group, 19 patients were shown to harbor a sequence change (N215S) in the α-gal-A gene (an 
established mutation in cardiac FD variants). The other 3 patients had sequence changes of 
R118C, A301G and R301Q in the GLA protein. Urinary Lyso-Gb3 levels in cardiac variant 
Fabry patients [(mean ± SEM = 16.9 pmol/mmol creatinine ± 4.9) with range of (0.0-74.9 
pmol/mmol creatinine)] were significantly lower than the levels in classical Fabry patients 
[(mean ± SEM = 105.8 pmol/mmol creatinine ± 20.8) with range of (0.0-320.4 pmol/mmol 
creatinine), p value < 0001] (Figure 5.1). The average urinary Lyso-Gb3 concentration in 
cardiac variant Fabry males (n = 11, mean ± SEM = 14.5 pmol/mmol creatinine ± 5.7) was 
significantly higher than in control males [(n = 22, mean ± SEM = 0.0 pmol/mmol creatinine 
± 0.0), p value< 0.0001]. Moreover, cardiac variant Fabry Females showed significantly 
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higher levels of urinary Lyso-Gb3 [(n = 11, mean ± SEM = 21.0 pmol/mmol creatinine ± 
9.9)] compared to control females [(n = 26, mean ± SEM = 0.0 pmol/mmol creatinine ± 0.0), 
p value< 0.0001]. Nevertheless, there was no significant variation in the average 
concentration of urinary Lyso-Gb3 between the two genders of cardiac variant Fabry patients 
(p value> 0.05) (Figure 5-4). 
 
Figure 5.4: Urinary Lyso-Gb3 levels in cardiac variant Fabry patients. Data were pooled 
from the patients and control subjects and presented as box plots. The concentrations were 
measured using Lyso-Gb3 calibration curve. Data were analysed using SPSS. The subjects 
were divided to 4 groups as follows: Fabry male (FM), Fabry female (FF), control male (CM) 
and control female (CF). For each group: n = number of subject; M = Mean; m = median; the 
range of minimum and maximum values in brackets; box= maximum and minimum quartiles; 
line inside the box = median; whiskers = maximum and minimum non-outlier values; ο = 
outlier values. Various groups were compared against each other using Mann-Whitney U 





ROC analysis performed to assess the diagnostic accuracy of urinary Lyso-Gb3 levels in 
diagnosing cardiac variant FD in males. Urinary Lyso-Gb3 levels in 6 confirmed untreated 
cardiac variant Fabry males and 22 control males were assessed. ROC curve showed a 
statistically significant result with AUC (0.833, p value <0.05). Urinary Lyso-Gb3 value 
equal to or higher than 1.4 pmol/mmol creatinine indicated the presence of FD with a 
sensitivity of 67% and specificity of 100% (Figure 5.5). 
The diagnostic accuracy of urinary Lyso-Gb3 levels in diagnosing cardiac variant FD in 
females was tested. Urinary Lyso-Gb3 levels in 7 confirmed untreated cardiac variant Fabry 
females and 26 control females were assessed. ROC curve showed a statistically significant 
result with AUC (0.857, p value <0.01). Urinary Lyso-Gb3 levels equal to or higher than 2.6 
pmol/mmol creatinine indicated the presence of FD with a sensitivity of 71% and specificity 




Figure 5.5: ROC analysis for diagnostic accuracy of urinary Lyso-Gb3 to predict Fabry 
disease in cardiac variant Fabry patients: urinary Lyso-Gb3 levels in hemizygous cardiac 
variant Fabry males vs. control males (left panel). ROC curve urinary Lyso-Gb3 levels in 
heterozygous cardiac variant Fabry females vs. control females (right panel). Graphs were 





5.3.4 The levels of urinary Lyso-Gb3 analogues in classical Fabry patients 
The relative concentration of various urinary Lyso-Gb3 analogues was analysed in our cohort 
of classical Fabry patients. This data is presented in the form of box plots (Figure 5.6).  This 
comparison included both male and female classical Fabry patients and normal control 
subjects. As shown in Figure 4.6, the relative concentrations of Lyso-Gb3 analogues varied 
considerably in classical Fabry males. While the levels of Lyso-Gb3 (+16 Da) analogue were 
found at the highest concentration (77.2-1607.7 pmol/mmol creatinine), levels of Lyso-Gb3 
(+34 Da) analogue were somewhat lower (12.2-698.6 pmol/mmol creatinine), while levels of 
Lyso-Gb3 (-2 Da) analogue varied between (33.8-231.8 pmol/mmol creatinine). The 
concentrations of Lyso-Gb3 (+50 Da) ranged between (0-62.1 Da), while the levels of Lyso-
Gb3 (-12 Da), Lyso-Gb3 (-28 Da) and Lyso-Gb3 (+14 Da) analogues varied between (0-41 
pmol/mmol creatinine).  
In all cases, the levels of each analogue were undetectable in control male and female 
subjects. Again, differences were observed in the levels of all Lyso-Gb3 analogues between 
male and female classical Fabry patients, with female Fabry patients having concentrations 
that were marginally elevated compared to control subjects (Figure 5.6).  
 
The relative distribution of urinary Lyso-Gb3 and its various analogues was analysed in our 
cohort of classical Fabry patients. This data is presented in the form of a pie chart (Figure 
5.7). In both male and female Fabry patients, the levels of urinary Lyso-Gb3 constituted only 
small percentage of Lyso-Gb3 (males 12% vs females 21%) while the large remaining 
amounts were distributed between Lyso-Gb3 analogues which arise through modifications of 
the sphingosine moiety. 
The levels of Lyso-Gb3 (+16 Da) constituted the highest percentage of the total measured 
metabolites (males 44% vs females 36%).While the levels of Lyso-Gb3 (+34 Da)  were 
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approximately two fold lower (males 25% vs females19%), the analogue Lyso-Gb3 (-2 Da) 
was somewhat lower with relative percentages of 13% for males and 15% for females.  
However, the levels of Lyso-Gb3 (+50 Da), Lyso-Gb3 (-28 Da), Lyso-Gb3 (+14 Da) and 
Lyso-Gb3 (-12 Da) were broadly similar in both male and female cases, comprising 1% and 
7% for Lyso-Gb3 (+50 Da), 2% for Lsyo-Gb3 (-28 Da), 2% and 0% for Lyso-Gb3 (+14 Da), 
1% and 0% for Lyso-Gb3 (-12 Da) in males and females respectively. 
 
Figure 5.8 shows ROC analysis of urinary Lyso-Gb3 and its analogues in classical Fabry 
patients. The results showed that urinary Lyso-Gb3 and the analogues Lyso-Gb3 (-28 Da, -2 
Da, +14 Da, +16Da and +34 Da), in addition to the total pool of Lyso-Gb3, all showed high 
sensitivity and specificity. As such, they may constitute a useful diagnostic predictor for FD 
in males. Unlike the case for Fabry males, only the total pool of urinary Lyso-Gb3 and 
analogues showed high sensitivity and specificity in Fabry females. In this case, analysis of 
the total pool of Lyso-Gb3 can be used as a diagnostic predictor for FD in females. While 
control subjects did not show detectable levels of urinary Lyso-Gb3 analogues, caution 
should be taken with regards to their use individually for diagnostic purposes due to their low 








Figure 5.6: The levels of urinary Lyso-Gb3 analogues in classical Fabry patients. Data 
were pooled from the patients and control subjects and presented as box plots. The 
concentrations were measured using Lyso-Gb3 calibration curve. Data were analysed using 
SPSS. The subjects were divided to 4 groups as follows: Fabry male (FM), Fabry female 
(FF), control male (CM) and control female (CF). For each group: n = number of subject; M 
= Mean; m = median; the range of minimum and maximum values in brackets; box= 
maximum and minimum quartiles; line inside the box = median; whiskers = maximum and 
minimum non-outlier values; ο = outlier values. Various groups were compared against each 
other using Mann-Whitney U tests. The differences were considered statistically significant if 




Figure 5.7: The relative distribution of urinary Lyso-Gb3 and its analogues in classical 
Fabry patients. Classical Fabry males (n=13, a) and in classical Fabry females (n=7, b). All 
classical Fabry males and females showed low percentage of Lyso-Gb3 in their urine 
compared to the total measured metabolites. Nonetheless, larger amounts were converted to 
Lyso-Gb3 analogues attributed to modifications in the sphingosine moiety. 
 
 
Figure 5.8: ROC analysis for diagnostic accuracy of urinary Lyso-Gb3 analogues to 
predict Fabry disease in classical Fabry patients: untreated hemizygous classical Fabry 
males vs. control males (left panel). Untreated heterozygous classical Fabry females vs. 
control females (right panel). Graphs were generated using SPSS software. 
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In order to test the utility of using total urinary Lyso-Gb3 and its analogue as a biomarker for 
the diagnosis and monitoring FD, the total metabolites has been used and the statistical 




Figure 5.9: The levels of urinary total Lyso-Gb3 and its analogues in classical Fabry 
patients. Data were pooled from the patients and control subjects and presented as box plots. 
The concentrations were measured using Lyso-Gb3 calibration curve. Data were analysed 
using SPSS. The subjects were divided to 4 groups as follows: Fabry male (FM), Fabry 
female (FF), control male (CM) and control female (CF). For each group: n = number of 
subject; M = Mean; m = median; the range of minimum and maximum values in brackets; 
box= maximum and minimum quartiles; line inside the box = median; whiskers = maximum 
and minimum non-outlier values; ο = outlier values. Various groups were compared against 
each other using Mann-Whitney U tests. The differences were considered statistically 
significant if the p value < 0.05 (*** = p<0.001 and **** = p<0001). 
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5.3.5 Levels of urinary Lyso-Gb3 analogues in cardiac variant Fabry patients 
Building on the analysis outlined above, I set out to determine the levels of various urinary 
Lyso-Gb3 analogues in cardiac variants Fabry patients. Again, this comparison included both 
male and female Fabry patients carrying the cardiac variant mutations and normal control 
subjects. As shown in Figure 5.10, the average concentration of each Lyso-Gb3 analogue 
varied considerably and, compared to classical Fabry patients were an order of magnitude 
lower. The levels of Lyso-Gb3 (+34 Da) were found at the highest concentration (0.0-355.5 
pmol/mmol creatinine) for males and (7.0-181.1 pmol/mmol creatinine) for females, while 
levels of Lyso-Gb3 (+16 Da) were somewhat lower (20.6-246.2 pmol/mmol creatinine) for 
males and (0.0-148.3 pmol/mmol creatinine) for females. The levels of Lyso-Gb3 (-28 Da) 
were very low and ranged between (0.0-38.0 pmol/mmol creatinine). However, the analogues 
Lyso-Gb3 (+50 Da), Lyso-Gb3 (+14 Da) and Lyso-Gb3 (-12 Da) were virtually undetectable. 
In all cases, the levels of each analogue were undetectable in control male and female 
subjects. Unlike classical Fabry patients, there was less of a distinction between male and 
female Fabry patients carrying the cardiac variant on the levels of all Lyso-Gb3 analogues. 
Collectively, the observed levels of urinary Lyso-Gb3 and its analogues in both genders of 
cardiac variant Fabry patients were very low.  
The relative distribution of urinary Lyso-Gb3 and its various analogues was examined in our 
cohort of Fabry patients diagnosed with the cardiac variants. This data is presented in the 
form of a pie chart (Figure 5.11).  In keeping with findings from classical Fabry patients, the 
levels of urinary Lyso-Gb3 constituted small percentage from the total observed metabolites 
in both male and female patients (males 6% vs. females 7%). However, the large percentage 
of Lyso-Gb3 was converted to its analogues. These analogues were detected in both male and 
female cases at broadly similar levels, comprising 31% and 19% for Lyso-Gb3 (+34 Da); 
40% and 19% for Lyso-Gb3 (+16 Da), 7% and 43% for Lyso-Gb3 (+50 Da), 11% and 6% for 
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Lyso-Gb3 (-2 Da), 4% for Lyso-Gb3 (+14 Da), 1% for Lyso-Gb3 (-28 Da), 0% and 1% for 
Lyso-Gb3 (-12 Da) in males and females respectively. 
Figure 5.12 shows ROC analysis of urinary Lyso-Gb3 and its analogues in cardiac variant 
Fabry patients. The results show that urinary Lyso-Gb3 analogues (-2 Da, +16 Da, +34 Da 
and the total pool of Lyso-Gb3 analogues) showed high sensitivity and specificity as a 
diagnostic predictor for cardiac variant Fabry males. However, in the case of Fabry females, 
only the total pool of urinary Lyso-Gb3 analogues showed high sensitivity and specificity, 
suggesting its utility as a diagnostic predictor for cardiac variant Fabry females. While 
control subjects did not show detectable levels of urinary Lyso-Gb3 analogues, caution 
should be taken with regards to their use individually for diagnostic purposes due to their low 
















Figure 5.10: Urinary Lyso-Gb3 analogues levels in cardiac variant Fabry patients: Data 
were pooled from the patients and control subjects and presented as box plots. The 
concentrations were measured using Lyso-Gb3 calibration curve. Data were analysed using 
SPSS. The subjects were divided to 4 groups as follows: Fabry male (FM), Fabry female 
(FF), control male (CM) and control female (CF). For each group: n = number of subject; M 
= Mean; m = median; the range of minimum and maximum values in brackets; box= 
maximum and minimum quartiles; line inside the box = median; whiskers = maximum and 
minimum non-outlier values; ο = outlier values. Various groups were compared against each 
other using Mann-Whitney U tests. The differences were considered statistically significant if 






Figure 5.11: The relative distribution of urinary Lyso-Gb3 and its analogues in cardiac 
variant Fabry patients. (a) Cardiac variant Fabry males (n=11). (b) Cardiac variant Fabry 
females (n=11). Both cardiac variant Fabry males and females showed a low percentage of 
Lyso-Gb3 in their plasma compared to the total measured metabolites. Nevertheless, larger 






Figure 5.12: ROC analysis for diagnostic accuracy of urinary Lyso-Gb3 analogues to 
predict Fabry disease in cardiac variant Fabry patients: untreated hemizygous cardiac 
Fabry males vs. control males (left panel); untreated heterozygous cardiac Fabry females vs. 
control females (right panel). Graphs were generated using SPSS software. 
 
 
In order to test the utility of using total urinary Lyso-Gb3 and its analogue as a biomarker for 
the diagnosis and monitoring FD, the total metabolites has been used and the statistical 





Figure 5.13 The levels of total urinary Lyso-Gb3 and its analogues in cardiac variant 
Fabry patients. Data were pooled from the patients and control subjects and presented as 
box plots. The concentrations were measured using Lyso-Gb3 calibration curve. Data were 
analysed using SPSS. The subjects were divided to 4 groups as follows: Fabry male (FM), 
Fabry female (FF), control male (CM) and control female (CF). For each group: n = number 
of subject; M = Mean; m = median; the range of minimum and maximum values in brackets; 
box= maximum and minimum quartiles; line inside the box = median; whiskers = maximum 
and minimum non-outlier values; ο = outlier values. Various groups were compared against 
each other using Mann-Whitney U tests. The differences were considered statistically 








5.3.6 Correlation between the levels of urinary Lyso-Gb3 and its various analogues in 
Fabry patients 
We next set out to explore whether the urinary levels of Lyso-Gb3 analogues correlated with 
Lyso-Gb3 levels in Fabry patients. There is no correlation observed between most of the 
levels of urinary Lyso-Gb3 analogues and the levels of Lyso-Gb3. This is due to the low 
abundance of these metabolites in urine samples. In all cases, the correlations didn’t reach the 
statistical significance except with two analogues: Lyso-Gb3 (-28 Da) and Lyso-Gb3 (-2 Da) 




Figure 5.14: The correlations between 





5.3.7 Correlation between the levels of urinary Lyso-Gb3 and plasma Lyso-Gb3 in 
Fabry patients 
We next set out to explore whether the concentrations of urinary Lyso-Gb3 correlated with 
the levels of Lyso-Gb3 in plasma samples from the same individuals Fabry patients and at the 
same collection time point. There were 38 Fabry patients have dual biological samples 
(plasma and urine) at the same date and time point. Due to a large amount of the urinary 
Lyso-Gb3 being converted to various analogues, we applied two ways of comparison. Firstly, 
we compared the levels of Lyso-Gb3 in plasma and urine samples (Figure 5.15). Secondly, 
we compared the sum of the measured metabolites (Lyso-Gb3 plus its analogues) in both 
biological samples (Figure 5.16). Both analyses showed a significant correlation between the 
levels in plasma and urine. As expected the correlation between the total metabolites in 
plasma and urine was stronger (Pearson correlation p values <0.0001) than the correlation 














Figure 5.16 Correlation between the levels of total Lyso-Gb3 and its analogues in 






Lyso-Gb3 has been detected in both the plasma [46] and urine [202] of Fabry patients. It had 
shown that the analysis of Lyso-Gb3 in urine samples from Fabry patients is possible despite 
the low abundance of Lyso-Gb3 and its various analogues in urine compared to their 
abundance in plasma [46, 202]. 
Using metabolomics approaches, a Canadian group has developed assays to measure the 
levels of Lyso-Gb3 and its various analogues in urine samples from Fabry patients [85, 202, 
225]. In a study performed by Auray-Blais and colleagues [85] LC-MS/MS was employed to 
measure the levels of urinary Lyso-Gb3 and analogues in Fabry patients. This analysis 
constituted a major technical advancement in the field as it proved to be highly specific, very 
sensitive and produced highly reproducible results. This study identified seven novel Lyso-
Gb3 analogues (Lyso-Gb3 (-28 Da); Lyso-Gb3 (-12 Da); Lyso-Gb3 (-2 Da); Lyso-Gb3 (+14 
Da); Lyso-Gb3 (+16 Da); Lyso-Gb3 (+34 Da), and Lyso-Gb3 (+50 Da). Fragmentation 
studies using MS/MS confirmed that these analogues were structurally similar to Lyso-Gb3 
but had modifications to the sphingosine moiety. 
Using the LC-MS/MS protocol developed as a part of the current study, we attempted to 
quantify the levels of Lyso-Gb3 and its related analogues in urine samples taken from our 
cohort of classical and cardiac variant Fabry patients, comparing these to control individuals. 
Using this technique, we proved that it was possible to quantify the amounts of Lyso-Gb3 in 
urine samples from classical Fabry patients. Moreover, this protocol was sufficiently accurate 
and sensitive to differentiate between classical Fabry patients, cardiac variant Fabry patients 
and control subjects. Findings generated as part of this study are in broad agreement with 
those reported by Auray-Blais and colleagues [85, 202, 225] who have used similar 
approaches to quantify Lyso-Gb3 and its analogues as a disease-specific biomarkers in FD. 
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Significant differences in the levels of urinary Lyso-Gb3 were observed between classical 
and cardiac variant Fabry patients. Despite the later showed levels approximately six fold 
lower than the levels in classical Fabry patients, the amounts of Lyso-Gb3 in urine samples 
from cardiac variant Fabry patients were sufficiently high to differentiate this cohort of Fabry 
patients from control individuals.  
Our results showed a significant correlation between the levels of urinary Lyso-Gb3 in Fabry 
patients and factors like sex and different phenotypes of Fabry patients. This is in agreement 
with Auray-Blais and colleagues [85, 201]. 
Unlike the situation in plasma, where Lyso-Gb3 constituted the major component of the total 
Lyso-Gb3 pool (Lsyo-Gb3 and all analogues), the situation was reversed in urine samples. In 
plasma, where the concentrations of Lyso-Gb3 constituted about 80% of the total Lyso-Gb3 
pool in both classical Fabry male and female patients, this was approximately less than 20% 
in urine samples. In urine samples, the average concentration of the various Lyso-Gb3 
analogues constituted about 80% of the total Lyso-Gb3 pool compared to an average of 
approximately 20% in plasma samples. In some Fabry patients, urinary Lyso-Gb3 analogues 
showed a relative distribution reach to 98% from the total Lyso-Gb3 pool. This finding 
suggests that unlike plasma where measuring Lyso-Gb3 is sufficient, measurements of the 
total pool of Lyso-Gb3 and its analogues in urine samples, constitutes a better analytical tool 
for diagnosis. 
The results of Lyso-Gb3 and its analogues revealed the presence of distinct species in the 
urine of both male and female classical Fabry patients, to varying extents, with Lyso-Gb3 
(+16 Da), Lyso-Gb3 (+34 Da), Lyso-Gb3 (-2 Da) and Lyso-Gb3 (+50 Da), constituting the 
most abundant analogues. Again, in all cases, the amounts of various analogues were always 
higher in male Fabry patients compared to females. In all instances, these comparisons were 
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found to be highly statistically significant. Our findings are also in broad agreement with a 
recent study by Lavoie and colleagues [225] who identified the existence of seven novel 
urinary Lyso-Gb3 analogues Lyso-Gb3 (-28 Da), Lyso-Gb3 (-12 Da), Lyso-Gb3 (-2 Da), 
Lyso-Gb3 (+14 Da), Lyso-Gb3 (+16 Da), Lyso-Gb3 (+34 Da) and Lyso-Gb3 (+50 Da) in 
samples collected from classical Fabry patients. 
Similar trends were observed in cardiac variant Fabry patients, where distinct analogues were 
detected in both male and female patients, with Lyso-Gb3 (+16 Da), Lyso-Gb3 (+34 Da), 
Lyso-Gb3 (-2 Da), Lyso-Gb3 (+14 Da) and Lyso-Gb3 (+50 Da), being the most abundant 
analogues. In all cases, the levels of specific analogues were higher in samples from male 
patients compared to females with the exception of Lyso-Gb3 (+50 Da), where broadly 
similar concentrations were detected. In all cases, these comparisons were found to be highly 
statistically significant. 
All 6 analogues of Lyso-Gb3 which have been detected in plasma from Fabry patients 
(Chapter 4) were detected in the urine samples of Fabry patients except the analogue Lyso-
Gb3 (+18 Da) which was detected in plasma only. Furthermore, the two analogues Lyso-Gb3 
(-12 Da) and Lyso-Gb3 (+14 Da) were detected only in urine but not in plasma. 
Given the low abundance of Lyso-Gb3 and its associated analogues in urine compared to 
plasma, coupled with variability in specific analogue detection between patients, we decided 
to repeat this analysis by quantifying the total pool of Lyso-Gb3 and its analogues in both 
classical Fabry patients and cardiac variant Fabry patients. In both cases, the combined total 
of LysGb3 plus analogues was significantly higher in Fabry patients compared to control 
subjects. Collectively, these analyses reveal that measurement of the total pool of Lyso-Gb3 
and analogues in urine samples is sufficiently specific and sensitive to make an initial 
174 
 
diagnosis of FD in most patients given the complete absence of Lyso-Gb3 in the urine of 
control subjects. 
The levels of total Lyso-Gb3 and it analogues in classical males were higher than levels in 
controls with no overlap suggesting that this can be used a promising biomarker alongside 
plasma Lyso-Gb3 in diagnosis of FD. In classical females, most patients had Lyso-Gb3 well 
above the control subject but some classical females had undetectable levels like controls. In 
this case a positive result will add to diagnostic confidence of FD but a negative result does 
not rule out FD. 
In cardiac variant male and female patients, most showed total Lyso-Gb3 levels above control 
subjects but similar to classical females some cardiac variant patients showed undetectable 
levels. Hence the use of urinary Lyso-Gb3 has limitations as a diagnostic biomarker in this 
subgroups. 
In conclusion, findings presented in this chapter support the use of urinary Lyso-Gb3 and its 
analogues as promising biomarkers for the diagnosis of both classical and cardiac variant 
Fabry patients. The important issue with using urinary Lyso-Gb3 is the need to quantify all 
the analogues and not just Lyso-Gb3 alone due to the predominance of analogues in urine 
sample. We did not attempt to establish the clinical significance of any particular analogue 
due to limited urinary sample size. A further study powered to explore the clinical 
significance and variability of these analogues across sex and phenotypes of FD may cast a 

















CHAPTER - 6 
DEVELOPMENT OF A NOVEL METHOD TO ASSAY 




Notice: Part of the work presented in this chapter has been published in the Journal of The 














Fabry disease (FD) is a rare multi-systemic X-linked lysosomal storage disorder. This inborn 
error of glycosphingolipid metabolism results from the absence or deficiency of α-gal-A, 
(OMIM 301500) which is responsible for hydrolytic cleavage between the galactose residues 
in Gb3. The un-metabolised GSLs accumulate in various organs, resulting in a range of 
pathologies in the kidneys, heart, brain, eye, peripheral nervous system and skin. Male 
patients show symptoms at an early age while females display symptoms when older. The 
precise incidence of FD is not known: the reported figures vary widely. 
The rarity of the disease and wide spectrum of symptoms displayed by Fabry patients make 
diagnosis based on clinical manifestation problematic. FD is currently diagnosed by 
measuring the activity of α-gal-A and/or by mutation analysis of the α-gal-A gene where 
enzyme analysis may not be informative in females [27, 28, 30, 35, 41, 47, 48]. Enzyme 
replacement therapy (ERT), using recombinant α-gal-A has become the standard treatment 
for symptomatic Fabry patients since 2001 [44, 45, 210]. However, the clinical benefit of this 
expensive treatment is limited, depending on the clinical stage at which therapy is initiated. 
Gb3 levels in plasma or urine can be used to monitor the efficacy of ERT and as a diagnostic 
biomarker although with limited sensitivity [26, 89, 160, 201, 207, 269, 270]. Gb3 levels in 
biological samples decrease considerably within two weeks of starting ERT but later increase 
in some patients probably due to development of α-gal-A antibodies and do not show a good 
correlation with effects on clinical symptoms or organ function [89, 160]. 
Gb3 and its isoforms/analogues have been detected at elevated levels in plasma and urine of 
Fabry patients using mass spectrometric approaches [26, 201, 207, 212, 213, 271]. Several 
analytical methods have been reported for urinary Gb3 extraction and analysis. Auray-Blais 
and co-workers originally used filter paper discs saturated with urine which were dried and 
Gb3 extracted with methanol and analysed by LC-MS/MS [201]. Later, Kruger and 
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colleagues [207] combined liquid extraction/protein precipitation and solid phase extraction 
for urinary Gb3 extraction before LC-MS/MS analysis. Despite being fairly complex and 
time consuming, these methods both generated invaluable data on urinary Gb3 levels in FD. 
Recently, an advanced multiplex method has been established by Auray-Blais team where 
they were successful in measuring the levels of different Gb3 isoforms and analogues using 
liquid-liquid extraction and LC-MS/MS [26, 212]. 
In this study we report the development of a rapid, robust assay for Gb3 based on a novel 
liquid-liquid extraction followed by MALDI-TOF MS and validate it using urine from 
patients with classical FD and healthy control subjects. 
 
6.2 MATERIALS AND METHODS 
6.2.1 Patient samples: 
 Fabry patients with diagnoses confirmed by mutation analysis and enzyme activity test were 
enrolled in the study after giving written informed consent (ethical approval reference: 
09/H1010/75). Urine samples were collected from 19 classical Fabry patients, 21 cardiac 
variant Fabry patients and 47 age and gender matched control subjects (patient details are 
shown in Table 6-1. Urine samples were stored at -80˚C until further processing without any 
centrifugation or filtration. Classical Fabry patients are defined as having typical Fabry 
disease manifestations and known classical mutations with the deficiency of α-gal-A enzyme 
activity (<1%). Nonetheless, cardiac variant Fabry patients were identified by having known 






HPLC grade water and acetonitrile (ACN) were purchased from (VWR international- UK). 
Acetone was purchased from (Fisher Scientific-UK). HPLC grade methanol (MeOH, 
≥99.9%), HPLC grade chloroform (CHCl3, ≥99.9%), 5-chloro-2-mercaptobenzothiazole 
(5C2M), 2- mercaptobenzothiazole, 6-aza-2-thiothymine, 2-(4-hydroxyphenylazo) benzoic 
acid, 2,5-dihydroxy benzoic acid (DHB), super-DHB, sinapic acid, 2,4,6-trihydroxy 
acetophenone monohydrate, 2,5- dihydroxy acetophenone, α-cyano-4-hydroxycinnamic acid 
acid, picolinic acid and 9-aminoacridine hemihydrate were purchased from (Sigma Aldrich, 
UK). Porcine Gb3 standard and N-Heptadecanoyl ceramide trihexoside (C17:0) internal 
standard were purchased from Matreya (Pleasant Gap, PA).  
6.2.3 Total Gb3 standard 
Total Gb3 (source: porcine RBC) was used for method development and standard curve 
purposes. Total Gb3 stock solution (200ng/μl) was prepared by dissolving 10mg of Gb3 
standard in 50ml of MeOH then stored at -20°C. 
6.2.4 Gb3 internal standard 
N-Heptadecanoyl ceramide trihexoside internal standard (0.5 mg) was dissolved in 1ml of 
MeOH: CHCl3 (2:1) and then 49ml of MeOH added to generate 50 ml of internal standard at 
50ng/μL. This solution was stored at -20°C in glass until used as 2ng/μL.  
6.2.5 Extraction of urinary Gb3 
100μL each of urine, MeOH containing 200ng of Gb3 internal standard and CHCl3 were 
mixed and incubated in a sonicating water bath for 5 min at room temperature. The mixture 
was then centrifuged at 13000rpm for 5min and 1μL of the lower (CHCl3) layer spotted 
directly onto a stainless steel 384-position MALDI target in triplicate. MALDI-TOF-MS: 
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Once dry, the samples were overlaid with 1μL of 5C2M matrix (saturated solution in 
50%MeOH). MS and MS/MS (using laser induced dissociation in LIFT mode) were acquired 
on a Bruker Ultraflextreme TOF instrument equipped with a 1 kHz laser in positive ion 
mode. The MS spectra used for quantitation were the sum of 20,000 laser shots acquired in a 
random walk pattern. The peak areas used for Gb3 quantitation were extracted from the 
spectra using ClinproTools software (Bruker). 
 
6.2.6 Gb3 internal standard and assay calibration 
N-Heptadecanoyl ceramide trihexoside was used as the internal standard throughout this 
study. A standard curve was produced by extracting a series of Gb3 dilutions ranging from (0 
to 40) ng/μL made in depleted urine from a healthy individual containing 2 ng/μL internal 
standard. The depleted urine was prepared by passing through a C18 cartridge and effective 
removal of Gb3 confirmed by parallel depletion of urine from a classical Fabry patient 
analyzed by MALDI-MS (Figure 6-1). The 4 most abundant Gb3 species have been used to 
calculate urinary total Gb3 level. The sodiated molecular ions of Gb3 species are at mass-to-
charge ratios (m/z) of: 1130.7 (C22:0), 1146.7 (C22:0-OH), (1158.7 (C24:0) and 
1174.7(C24:0-OH). The main peak of the Gb3 internal standard is at m/z 1060.7 (C17:0) with 
a secondary peak at m/z 1076.7 (C17:0-OH). The total area of both internal standard peaks 
and all 4 Gb3 species were used to determine the response ratio (Equation 1) and this used in 
conjunction with a calibration curve to determine urinary Gb3 concentrations. 
 
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑟𝑎𝑡𝑖𝑜 =𝑡𝑜𝑡𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 4 𝑚𝑜𝑠𝑡 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑡 𝐺𝑏3 𝑠𝑝𝑒𝑐𝑖𝑒𝑠 /𝑎𝑟𝑒𝑎 𝑜𝑓 𝐺𝑏3 




Limit of detection (LOD) and limit of quantitation of total Gb3 in urine were determined 
using (Equation 2) and (Equation 3) respectively, where F = 3.3 and 10 for LOD and LOQ 
respectively, stdev = standard deviation and b: Slope of the regression line (Figure 6-2). 
𝐿𝑂𝐷 = 𝐹 × 𝑠𝑡𝑑𝑒𝑣/𝑏 ……………………………………………………………… (Equation-2) 
𝐿𝑂𝑄 =𝐹 × 𝑠𝑡𝑑𝑒𝑣/𝑏……………………………………………………………….. (Equation-3) 
 









Number 12 11 7 10 22 25 
Mean age (y) 39.8±15.1 49.6±12.9 58.7±16.1 51.2±21.2 50.1±20.3 67.8±13. 9 
Range age (y) 18-55 19-65 32-80 29-85 20-82 51-85 
 
Table 6-1 Anthropometric data of Fabry patients and healthy controls: The table shows 
some details of all subjects participating in this part of the study including number and age of 







Figure 6.1 Validation of Gb3 depletion: MS spectra of urine samples pre- and 
post-depletion were studied. (a) Urine from classical Fabry patient pre -depletion. 
(b) Depleted urine from classical Fabry patient post -depletion. (c) Urine from a 
healthy control post-depletion. (d) Urine from healthy control pre-depletion. Gb3 





Figure 6.2 Calculation of LOD and LOQ of urinary total Gb3: the figure 
shows MS spectra were acquired from MALDI-TOF-MS (a) MS spectra of 
urinary Gb3 at the LOD, (b) MS spectra of urinary Gb3 at the LOQ, (c) MS 
spectra of depleted urine. LOD & LOQ were determined as follows: 𝐿𝑂𝐷 =
𝐹 × 𝑠𝑡𝑑𝑒𝑣
𝑏
 & 𝐿𝑂𝑄 =
𝐹 × 𝑠𝑡𝑑𝑒𝑣
𝑏
. Where F = 3.3 and 10 for LOD and LOQ respectively, 




6.3.1 Optimisation of Gb3 extraction from urine 
Depleted urine was spiked with 2.5μL of porcine total Gb3 standard [200ng/μL] generating a 
final concentration of 5ng/μL and the performance of various extraction procedures involving 
different volumes of MeOH, acetone and CHCl3 were assessed by MALDI-TOF-MS. We 
found using 1:1:1 (v:v:v) of urine, MeOH and CHCl3 to be the optimal condition for Gb3 
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extraction into the hydrophobic layer (CHCl3 layer) based on peak intensity and signal-to-




Figure 6.3 Validation of liquid-liquid extraction using different solvents: we 
have compared 3 different chemical solvents in order to select the optimal 
solvent for Gb3 extraction from urine samples. The extraction has been achieved 
using these 3 solvents then analysed using MALDI-TOF-MS. The peak 
intensities were compared and the solvent which gives higher intensities was 
selected for Urinary Gb3 extraction. These solvents were:  (a) acetone: 
MeOH:H2O, (45:45:10) (b) MeOH:CHCl3, (2:1) (c) MeOH:CHCl3 (1:1), the 






Figure 6.4 Validation of liquid-liquid extraction: MALDI-TOF-MS spectra of 
Gb3 species and Gb3 internal standard in: (a) the aqueous layer (upper layer) 
and (b) Chloroform layer (lower layer). Gb3 species and Gb3 internal standard 
were spiked in normal urine from a healthy control subject , the figure adapted 
from [1]. 
 
6.3.2 Optimization of MALDI-TOF-MS 
We acquired and compared the MALDI spectra for depleted urine spiked with 5ng/μL Gb3 
using 12 different matrix compounds (spectra shown in Figure 6-5). The matrices were used 
as saturated solutions both in 50%MeOH and 50%ACN. Spectra obtained with 5C2M in 
50%MeOH provided the best signal intensity and signal-to-noise ratio. Example MS spectra 
showing Gb3 peaks in the urine of a Fabry patient, porcine Gb3 standard and a healthy 





Figure 6.5 Evaluation of different matrix compounds: MALDI-TOF spectra of 
porcine Gb3 generated using 12 different matrix compounds  prepared as 
saturated solutions in 50%MeOH are shown.  The m/z range covers the mass 
range of the most intense 3 peaks of Gb3 (m/z 1158.7, 1174.7 & 1130.7).  These 
matrix compounds used were: (A) 2-(4-hydroxyphenylazo) benzoic acid, (B) 2-
mercaptobenzothiazole, (C) 5-chloro-2-meracptobenzothiazole, (D) 2,5-
dihydroxy acetophenone, (E) 6aza-2-thiothymine, (F) 9-aminoacridine 
hemihydrate, (G) α-cyano-4-hydroxycinnamic acid, (H) 2.5-Dihysroxybenzoic 
acid (DHB), (I) picolinic acid, (J) super-DHB, (K) sinapic acid, (L) 2,4,6-




Figure 6.6 Mass spectra of Gb3 and internal standard: MS spectra of Gb3 
species and Gb3 internal standard were acquired from MALDI-TOF-MS. (a) 
Purchased porcine Gb3 standard (b) Urine from untreated classical Fabry male 
and (c) Healthy control urine, the figure adapted from [1]. 
 
 
6.3.3 MS/MS Confirmation of Gb3 peaks in Fabry patient urine 
MS spectra of Fabry patient urine contain peaks with exactly the same m/z values as those in 
purchased porcine Gb3:m/z 1046.7 (predicted structure C16:0), 1074.7(C18:0), 
1102.7(C20:0), 1128.7(C22:1), 1130.7(C22:0), 1146(C22:0-OH), 1156.7(C24:1), 
1158.7(C24:0), 1172.7(C24:1-OH:) and 1174.7(C24:0-OH). To confirm that the peaks in 
Fabry patient urine spectra correspond to Gb3 they were subjected to MALDI-TOF/TOF 
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MS/MS. The MS/MS spectra of the urine peaks show the loss of sugar moieties (Figure 6-7) 
and confirm that these ions correspond to Gb3 species by the presence of the fragment m/z 
264.2 which represents sphingosine (sphingosine-2[H2O]). The purchased porcine Gb3 




Figure 6.7 MS/MS Confirmation of Gb3 peaks in Fabry patient urine: MALDI-
TOF/TOF MS/MS of: a) Gb3-Internal standard  m/z 1060.7 (C17:0); and the 3 most 
abundant Gb3 species in Fabry patient urine:  m/z 1130.7 (C22:0), 1158.7 (C24:0) and 
1174.7 (C24:0-OH). The peaks corresponding to ions generated by the loss of 1 or 
2 sugars (-162 and -324 Da respectively) have different m/z values for each 
species whereas the fragments corresponding to sphingosine -2H20, (m/z 264.1) 
and di- and tri-saccharide ions (m/z 347 and 509) are invariant, the figure 





6.3.4 Quantitative measurement of urinary Gb3 by MALDI-TOF-MS 
To correct for variations in extraction and ionisation efficiencies an internal standard was 
added to all urine samples prior to extraction. The internal standard appears as a peak at m/z 
1060.7 (C17:0) (plus a secondary peak at m/z 1076.7(C17:0-OH)). No peaks were seen at 
these m/z values in the MALDI spectra of any of the extracted urines used in this study in the 
absence of internal standard (Figure 6.8) (also, no contaminants with the same masses as the 
Gb3 peaks were detected). Gb3 concentrations were calculated from the (total Gb3/internal 
standard) area ratio as described in Methods and using the calibration curve shown in Figure 
6.9. Inter-assay and intra-assay variability were measured to assess the reliability of the 
method. Ten healthy controls urine samples were used. Each sample was spiked with 2.5μL 
of total Gb3 standard [200ng/μL] generating a final concentration of 5ng/μL. Each sample 
was processed as 3 independent technical replicates. Each extract was spotted onto the 
MALDI target in triplicate giving 9 readings for each sample. The same procedure was 
repeated on 3 different days resulting in each sample been analysed 27 times. The results 
showed high reproducibility and reliability of the method with an intra-assay coefficient of 
variation of 9.9% and inter-assay of 13.7%. The lower limit of detection was 0.15 ng/μL and 
limit of quantitation was 0.30 ng/μL. The assay was linear up to the highest Gb3 
concentration investigated (40 ng/μL). Gb3 generates multiple peaks in mass spectra. The 
total area of the 4 most intense peaks (m/z 1130.7 (C22:0), 1146.7 (C22:0-OH), 1158.7 
(C24:0) and 1174.7(C24:0-OH)) was used to measure the ratio of Gb3 to the internal 
standard. These 4 peaks were selected because they have the highest intensities and they were 
detected in all patients while the other peaks (other Gb3 species) were not always detected. 
We found that the ratio of these 4 peaks to one another is constant across individuals i.e. 
classical Fabry disease results in accumulation of all 4 Gb3 species (Figure 6.10). Although 
we have used the sum of the 4 main peaks for quantitation (considering that this might be the 
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Figure 6.8 Gb3 internal standard in human urine:  The presence of Gb3 
internal standard peaks in human urine has been tested: (a) Fabry urine without 
adding internal standard. (b) Fabry urine spiked with Gb3 internal standard , the 











Figure 6.9 Urinary Gb3 standard curve: Increasing amounts of porcine Gb3 standard 
covering the reported clinical range and a constant amount of Gb3 internal standard were 
spiked into depleted urine from a healthy control subject. Thereafter, the lipids 
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Figure 6.10 Correlation between urinary Gb3 species: The figure shows that there is a 
correlation between the main urinary Gb3 species (m/z 1130.7, 1158.7 and 1174.7). Using 









6.3.5 Urinary total Gb3 levels in classical Fabry patients 
The levels of urinary total Gb3 in classical Fabry patients (n=19) and healthy controls (n=47) 
were measured. Prior to statistical comparison the urinary Gb3 concentrations were 
normalised to urinary creatinine as shown in Figure 6.11. The mean normalised concentration 
in the classical Fabry males (n=12, mean = 280.9 μg/mmole creatinine) was significantly 
higher than in control males (n=22, mean = 8.0 μg/mmole creatinine), (p<0.0001). The 
normalised mean concentration of classical Fabry females (n=7, mean = 48.3 μg/mmole 
creatinine) was significantly higher than in control females (n=25, mean = 16.4 μg/mmole 
creatinine), (p<0.05). However, the normalised mean concentration in the classical Fabry 
males was higher than in Fabry females, although this did not reach statistical significance 
(p>0.05).  
Using the urinary Gb3 concentrations measured in the 56 individuals (including 5 untreated 
classical Fabry males, 4 untreated classical Fabry females, 22 control males and 25 control 
females) in this study to detect FD generated a receiver operator characteristic (ROC) curve 






Figure 6.11 Urinary total Gb3 levels in classical Fabry patients: box-and-whiskers plot 
chart showing urinary Gb3 levels in both genders of classical Fabry patients and control 
subjects. The concentrations were measured using Gb3 calibration curve. Data were analysed 
using SPSS. The subjects were divided to 6 groups as follows: Fabry male (FM), Fabry 
female (FF), control male (CM) and control female (CF). For each group: n = number of 
subject; M = Mean; m = median; the range of minimum and maximum values in brackets; 
box= maximum and minimum quartiles; line inside the box = median; whiskers = maximum 
and minimum non-outlier values; ο = outlier values. Various groups were compared against 
each other using Mann-Whitney U tests. The differences were considered statistically 








Figure 6.12 ROC analysis for urinary total Gb3 in classical Fabry patients: Receiver 
operator characteristic (ROC) curve of Urinary total Gb3 in classical Fabry males vs. control males 
(left panel) and in classical Fabry females vs. control females (right panel).    
  
  
6.3.6 Urinary total Gb3 levels in cardiac variant Fabry patients: 
The levels of urinary total Gb3 in cardiac variant Fabry patients (n=21) and healthy controls 
(n=47) were measured. Prior to statistical comparison the urinary Gb3 concentrations were 
normalised to urinary creatinine (Figure 6.13). The mean normalised concentration in the 
cardiac variant Fabry males (n=11, mean = 15.1 μg/mmole creatinine) was higher than in 
control males (n=22, mean = 8.0 μg/mmole creatinine) but did not reach the statistical 
significance (p>0.05). Nevertheless, the normalised mean concentration of cardiac variant 
Fabry females (n=10, mean = 21.3 μg/mmole creatinine) was significantly higher than in 
control females (n=25, mean = 16.4 μg/mmole creatinine), (p<0.05). However, variation in 
the normalised mean concentration of total urinary Gb3 between the two genders of cardiac 
variant Fabry patients was statistically not significant (p>0.05).  
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Using the urinary Gb3 concentrations measured in the 59 individuals (including 6 untreated 
cardiac variant Fabry males, 6 untreated cardiac variant Fabry females, 22 control males and 
25 control females) in this study to detect FD generated a receiver operator characteristic 
(ROC) curve as shown in (Figure 6.14).  
 
Figure 6.13 Urinary total Gb3 levels in cardiac variant Fabry patients: box-and-whiskers 
plot chart showing urinary Gb3 levels in both genders of cardiac variant Fabry patients and 
control subjects. The concentrations were measured using Gb3 calibration curve. Data were 
analysed using SPSS. The subjects were divided to 6 groups as follows: Fabry male (FM), 
Fabry female (FF), control male (CM) and control female (CF). For each group: n = number 
of subject; M = Mean; m = median; the range of minimum and maximum values in brackets; 
box= maximum and minimum quartiles; line inside the box = median; whiskers = maximum 
and minimum non-outlier values; ο = outlier values. Various groups were compared against 
each other using Mann-Whitney U tests. The differences were considered statistically 





Figure 6.14 ROC analysis for Urinary Gb3 in cardiac variant Fabry patients: Receiver 
operator characteristic (ROC) curve of Urinary total Gb3 in cardiac variant Fabry males vs. 
control males (left panel) and in cardiac variant Fabry females vs. control females (right 
panel).    
 
 
6.3.7 Correlation between urinary Gb3 levels and Lyso-Gb3 levels in Fabry patients: 
The correlation between the levels of urinary total Gb3 in Fabry patients and the levels of 
urinary Lyso-Gb3 has been tested in this work. Figure 6.15  shows that urinary total Gb3 is 
correlated with urinary Lyso-Gb3 in Fabry patients with Pearson Chi-Square p value 
<0.0001. Moreover, urinary total Gb3 is correlated with the total levels of urinary Lyso-Gb3 
and its analogues in Fabry patients with Pearson Chi-Square p value of <0.01  (Figure 6.15). 
Based on outcomes of this study supported with similar findings in previous studies, we can 
say that urinary total Gb3 could be a useful biomarker for classical hemizygous Fabry males 
but it is not the best choice for symptomatic heterozygous Fabry females and both gendres 
with atypical cardiac variant FD. As it has been postulated in Chapter 4 and 5, Lyso-Gb3 in 
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plasma and urine showed better utility in diagnose and management FD more than uruinary 




Figure 6.15 Correlation between urinary total Gb3 and urinay-Lyso-Gb3 in Fabry 
patients: the figure shows the correlation between urinary Gb3 and urinary Lyso-Gb3 (left 




By coupling a novel liquid-liquid extraction and MALDI-TOF-MS with an internal standard 
we have been able to develop a rapid (<15 minutes from start to finish) method for measuring 
Gb3 in urine. Considerable optimisation of the Gb3 extraction and MS analysis has been 
performed to produce an assay with good reproducibility, sensitivity and specificity sufficient 




N- Heptadecanoyl ceramide trihexoside has been used as an internal standard in this study 
because it has very similar chemical properties to human Gb3 but cannot be synthesised by 
humans (due to the odd number of carbon atoms). The internal standard generates a main 
peak at m/z 1060.7 (C17:0) and a minor peak at m/z 1076.7 (C17:0-OH) (most likely due to 
oxidation, both peaks were combined in calculations). Following liquid-liquid extraction 
human urine is devoid of peaks at these m/z values unless the internal standard is added. 
Including the internal standard in our assay has enabled a high degree of reducibility and 
reliability to be reached with correspondingly low intra-assay and inter-assay coefficients of 
variation. The assay is based on MS, however, MS/MS was used to verify the identity of the 
Gb3 peaks: the most abundant peaks at m/z 1130.7 (C22:0), 1146.7 (C22:0-OH), 1158.7 
(C24:0) and 1174.7 (C24:0-OH) all show identical fragmentation pattern by losing sugar 
groups (-162Da) and generating the di-dehydrated sphingosine moiety (m/z 264.2) as 
previously reported for Gb3 [201, 269-272]. 
In one study, Branton and colleagues [273] have shown that individual presenting with a 
conservative amino acid change display a significantly delayed onset of symptoms when 
compared to those with non-conservative amino acid substitutions. However, a study by 
Vedder and colleagues [89] did not find any correlation between the levels of plasma or 
urinary Gb3 and clinical symptoms supporting that the better utility of Lyso-Gb3 as a 
potential biomarker for FD, over its acylated precursor molecule Gb3. A similar study also 
failed to identify any correlation between urinary Gb3 levels in Fabry patients and the disease 
severity or treatment response, suggesting that the measurement of plasma or urinary Gb3 
could be an unreliable biomarker specially in hemizygous Fabry females [160]. 
In conclusion, our method significantly reduces the number of steps and time required to 
complete the test compared with the current standard methods. The method could be easily 
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implemented in any laboratory with access to a MALDI mass spectrometer and used for non-













































Fabry disease (FD, OMIM 301500) is an X-linked LSD caused by a deficiency of α-gal-A 
resulting in accumulation of GSLs, mainly Gb3 and its derivatives, in the walls of small 
blood vessels, cardiomyocytes, renal glomerular and tubular epithelial cells, neurons of the 
autonomic nervous system, small unmyelinated nerve fibers and to some extent in all other 
tissues with lysosomes [17, 25, 27-30, 80]. Affected males typically present in childhood 
with episodes of severe neuropathic pain in the hands and feet. This is followed by the 
development of angiokeratoma, proteinuria, progressive renal impairment, cardiomyopathy, 
and cerebrovascular events, culminating in major disability and death, generally before age 
60 years [80]. According to the Human Gene Mutation Database (www.hgmd.cf.ac.uk) (last 
accessed at www.hgmd.cf.ac.uk, May, 23, 2016), more than 800 mutations in the GLA gene 
have been described and most are private mutation. Estimated birth prevalence range between 
1:40,000 and 110,000 [47-50]. However, recent new-born screening data and targeted 
screening suggest a higher prevalence up to 1:3000 [48]. Most individuals identified through 
screening lack characteristic classical Fabry signs or symptoms such as neuropathic pain, 
angiokeratoma or cornea verticillata, and the disease pursue a different clinical course limited 
to a single organ system and called Fabry variant to distinguish them from classical Fabry 
with typical signs and symptoms. One subgroup of these subjects, are the “cardiac variants”, 
who are typically free of the usual clinical manifestations of the disease for most of their 
lives, then present with progressive LVH and conduction abnormalities, which often require 
cardiac intervention and leads to premature death. 
Because of founder effect, in England, there is large cohort of cardiac variant with the N215S 
mutation. The pathogenicity of N215S mutations is well described as a disease causing 
mutation. However, like other atypical Fabry patients, most male have significant residual α-
gal-A enzyme activity, in contrast to the very low or absent enzyme activity in classical Fabry 
males. The atypical late presentation, presence of residual enzyme in a variant Fabry and the 
202 
 
increasing number of GLA mutation of unknown significance led to diagnostic challenge in 
Fabry expert centres. In a day to day practice this phenotypic and genotypic heterogeneity 
resulted in over diagnosis of Fabry with the consequence of stigmatising patient and 
subjecting them to cumbersome and high cost ERT. 
 
A reliable diagnosis in affected classical males can be made by the measurement of α-gal-A 
activity in plasma or peripheral blood leukocytes. The diagnosis of the affected cardiac 
variant male and both classical and variant female will require GLA mutation analysis. In 
some cases, mutation analysis may not be sufficient. Accumulating evidence suggest that 
Lyso-Gb3 is significantly elevated in the plasma of all male patients with classical FD and to 
a lesser extent in symptomatic female patients with excellent sensitivity and specificity. 
Recent consensus guidelines acknowledged the use of Lyso-Gb3 as an important diagnostic 
marker for FD [224, 258, 259] but there is limited data about its usefulness to assess disease 
severity and response to ERT and chaperon [165, 274-281].  
 
FD is not only heterogenic in terms of the spectrum of gene variations or mutations that can 
occur, but is also heterophenotypic in terms of its clinical manifestations and the array of 
symptoms that affected individual present with. However, in most instances patients typically 
present with the involvement of three organs: heart, kidney and nervous system. Disease 
progression ultimately leads to heart failure, renal failure or stroke. 
Although patients diagnosed with classical FD present with multiple tissue and organ 
involvement, some patients develop complications in only a single organ. These are referred 
to as cardiac or renal variants, often presenting as clinically relevant late onset variants FD 
[224, 282, 283]. Additional variants of the GLA gene have been identified; termed genetic 
variants of unknown significance [259], where patients present with nonspecific features (e.g. 
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LVH) or are asymptomatic and detected during screening. These patients pose a particular 
diagnostic challenge as a misdiagnosis can impose significant lifetime burden of 
investigation, monitoring and treatment. Further, atypical variants and classical Fabry 
females may exhibit the same symptoms and severe organ involvement as classical Fabry 
males, even though α-gal-A enzyme activity in these patients is often only slightly reduced.  
While the levels of plasma or urinary Gb3 have utility in diagnosing classical Fabry 
hemizygotes, its measurement is not helpful to identify clinical manifestation or disease 
severity in either hemizygous males or heterozygous females [46, 152].  
 
In our study, the deacylated form (a degradation product) of the accumulating Gb3, Lyso-
Gb3 appeared to be a better predictor of GLA mutation, than measurement of α-gal-A 
enzymatic activity in classical Fabry heterozygotes and atypical variants Fabry patients. 
Moreover, the study hypothesized that assessing Lyso-Gb3 can play an important role in the 
diagnosis and monitoring of classical and clinically relevant cardiac variant FD. The study 
evaluated the sensitivity and specificity of plasma and urinary Lyso-Gb3 levels in subjects 
with classical and cardiac variant mutation. Furthermore, the study analysed plasma Lyso-
Gb3 levels in Fabry patients’ pre- and post-ERT and evaluated plasma and urinary Lyso-Gb3 
change with time. 
 
In Chapter 3 we were able to develop reliable and robust SPE extraction and HPLC-MS/MS 
based methods to extract and analyse Lyso-Gb3 and its associated analogues from plasma 
and urine. All methodologies were subject to further improvement of the various techniques. 
For example, we found that SPE was superior to liquid-liquid extraction due to the latter 
requiring the use of halogenated solvents (chloroform); however, the standard guidelines of 
clinical laboratories avoid the use of this type of solvent for environmental reasons. 
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Moreover, SPE is a fairly simple and rapid protocol that does not require many steps of 
sonication and centrifugation as is required in liquid-liquid extraction. 
 
Internal standards are fundamental in the quantitative mass spectrometry methodologies.  
Generally, an internal standard is a chemical substance characterized by being similar to the 
measured analyte in terms of chemical structure, processing and analysis behaviour. No 
isotopic version of Lyso-Gb3 is commercially available. Moreover, the preparation of 
isotopic labelled Lyso-Gb3 in-house is a complex, laborious process and requires specialist 
knowledge. So we focused on the use of the plant-derived GSG as an internal standard for the 
whole study of Lyso-Gb3 analyses in plasma and urine. GSG behaves exactly like Lyso-Gb3 
in terms of MCX extraction, HPLC separation and MS/MS fragmentation. Bovine GSG, 
which was employed initially, and Lyso-Gb3 give rise to exactly the same fragment m/z 
282.2 which could cause carry over and/or confusion. Therefore, I have tested the suitability 
of using plant-derived GSG which contains an extra double-bond in the sphingosine moiety 
giving a fragment of m/z 280.3. The use of plant-derived GSG removes any potential carry 
over, and was used in the whole study of Lyso-Gb3 analyses in plasma and urine. 
 
Likewise, to optimise the analytical part of the process, we tested the newly developed nano-
Viper fittings - HPLC connection tubing and found it to be superior to the standard fittings 
regarding quantitation of Lyso-Gb3 and related metabolites. 
As this project deals with clinical samples, it was critical to ensure that the instrument 
performance is stable between runs. We prepared our own in-house Lyso-Gb3 QCs to 
monitor the performance of the instrument. Overall, the MS performance was highly stable 
giving acceptable Intra- and inter-assay variability. Moreover, the MS calibration and tuning 
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were performed before each run of clinical samples and the results recorded in order to 
follow up the instrument performance over the duration of the project. 
As outlined in Chapter 4, using a reliable and robust LC-MS/MS methodology, coupled with 
the use of an inexpensive and commercially available internal standard, GSG, we were able 
to confirm that the levels of Lyso-Gb3 in plasma samples can be used as a reliable diagnostic 
biomarker for FD. Plasma Lyso-Gb3 can easily discern classical hemizygous Fabry males 
and classical heterozygous Fabry females from control subjects. These findings are consistent 
with previous studies using HPLC assays [46] or LC-MS/MS methodologies [204, 215, 224, 
258, 284]. 
In our cohort of Fabry patients, the levels of plasma Lyso-Gb3 in classical Fabry males (the 
lowest value = 45.3 nM) were much higher than the levels observed in control male subjects 
(the highest value = 2.1 nM). This 20 fold difference confirms that plasma Lyso-Gb3 is a 
strong and a reliable diagnostic tool for diagnosing classical Fabry males. In this respect, our 
findings are in keeping with those of Smid and co-workers [258] who, using an LC-MS/MS-
based approach, also found that the classical Fabry males enrolled in their study had levels of 
plasma Lyso-Gb3 that exceeded a threshold of 45 nM (range = 45-150 nM) and far exceeded 
those of normal healthy male control subjects (range = 0.3-0.6 nM). On the other hand, 
despite the lower levels of plasma Lyso-Gb3 in classical Fabry females (values ranging from 
3-43.9 nM) compared to classical Fabry males (range = 45.3-210.8 nM), the low levels of 
plasma Lyso-Gb3 found in healthy female control subjects (range 0.3-2.3nM), makes a 
diagnosis of classical FD females also possible using this biomarker. Essentially similar 
findings were observed by Smid and co-workers [258], who also found that the levels of 
plasma Lyso-Gb3 in classical Fabry females were considerably lower than those observed in 
classical Fabry male subjects (range 1.5-41.5nM vs 45-150nM), yet were sufficiently high to 
make a diagnosis of FD. 
206 
 
In the current study, we also examined the utility of measuring levels of plasma Lyso-Gb3 for 
the diagnosis of non-classical FD patients, in this case, 38 patients who had been diagnosed 
as cardiac variant FD. The majority of this group carried the N215S mutation (≈ 90%). 
Although the total amounts of plasma Lyso-Gb3 were considerably lower in both male and 
female cardiac variant Fabry patients (5.7-19.5 nM vs 1.2-12.6 nM), compared to classical 
Fabry males and females (range = 45.3-210.8 nM and 3.0-43.9 nM, respectively) the levels 
were sufficiently high to differentiate these patients from healthy male and female control 
subjects (0.3-2.1 nM and 0.3-2.3 nM, respectively). While a certain degree of caution should 
be taken with cardiac variant Fabry female, only a patient in this subgroup showed an overlap 
with controls. Despite the significant variation in levels of plasma Lyso-Gb3 between 
classical and cardiac variant Fabry patients, the findings of our study confirm that plasma 
Lyso-Gb3 can be used as a potentially reliable biomarker for the diagnosis of cardiac variant 
Fabry males. In their study, Smid and co-workers [258] also found that non classical Fabry 
males and females displayed elevated levels of plasma Lyso-Gb3 compared to healthy male 
and female control subjects. Thus, despite certain instances where cardiac variant Fabry 
females displayed a degree of overlap in their plasma Lyso-Gb3 levels when compared to 
control females, plasma Lyso-Gb3 still appears to have utility as a diagnostic biomarker for 
cardiac variant Fabry females. 
In their study, Smid and co-workers could not ascribe a “cut-off” to classical Fabry females, 
due to a slight overlap in the levels of plasma Lyso-Gb3 in non-classical Fabry females [258]; 
however, they also concluded that Lyso-Gb3 was a reliable diagnostic tool for identifying FD 
in classical females. 
Niemann and colleagues [224] have suggested that classical Fabry patients and non-classical 
Fabry patients (such as those with carrying the cardiac variant), could be differentiated on the 
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basis of their plasma Lyso-Gb3 levels. Niemann et al [224] recommended that the plasma 
Lyso-Gb3 can be used to differentiate between classical Fabry patients and non-classical (e.g. 
cardiac variant) Fabry patients. The findings from our study identified significant variation 
between plasma Lyso-Gb3 levels in the two aforementioned FD phenotypes. Moreover, it 
proved relatively straightforward to distinguish classical Fabry patients from cardiac variant 
Fabry patients based on their levels of plasma Lyso-Gb3 where the lowest observed level in 
classical Fabry males was more than 2 fold higher than the highest observed level in cardiac 
variant males (45.3nM vs 19.5 nM) respectively. Hence, plasma Lyso-Gb3 is a potentially 
useful diagnostic biomarker for FD, as it can be used to categorise and distinguish different 
phenotypes of FD patients. 
In the current study, we observed that the levels of plasma Lyso-Gb3 in three cardiac variant 
Fabry males showed a slight increase over time and this increase may represent disease 
progression. However, Smid and colleagues [258] found that the levels of plasma Lyso-Gb3 
did not increase appreciably over time in adult patients. Thus, due to lack of long term follow 
up, it is very difficult to determine whether this slight increase in plasma Lyso-Gb3 levels in 
our untreated Fabry patients, was simply related to age or it had any prognostic implication. 
Interestingly, a total of eight cardiac variant patients on ERT showed a trend towards falling 
Lyso-Gb3 levels. Moreover, in a group of twelve classical Fabry patients on ERT, trend 
toward falling Lyso-Gb3 levels was noted. The falling Lyso-Gb3 levels of patients on ERT 
suggest that Lyso-Gb3 has a role in monitoring FD. 
Numerous recent publications advocate the use of Lyso-Gb3 rather than Gb3 as a diagnostic 
biomarker for FD [46, 204, 215, 222]. The concentrations of plasma Lyso-Gb3 have shown 
useful in diagnosing FD, and at least in one study, shown to correlate with disease severity 
[215]. Findings presented in Chapter 4 of this thesis further substantiate these claims and 
support the utility of measuring plasma Lyso-Gb3 levels in the diagnosis of classical and 
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cardiac variant forms of the disease. Moreover, in agreement with a study by van Breemen 
and colleagues [165], I have shown that the levels of plasma Lyso-Gb3 are reduced in 
classical male Fabry patients receiving ERT and may, therefore, have a potential utility in 
monitoring patients’ response to ERT. 
In the current study, outlined in Chapter 6, we were able to establish a novel MALDI-TOF-
MS based method to measure total urinary Gb3 in Fabry patients. The method is simple, 
rapid and straightforward. It could easily be implemented in any clinical laboratory which has 
access to a MALDI-MS and, furthermore it is noninvasive and cost-effective procedure for 
the detection of classical FD. 
The total amounts of urinary Gb3 were sufficiently high in classical FD males (range = 2.7-
1931.3 µg/mmol creatinine) to differentiate them from control males (range = 3.7-23 
µg/mmol creatinine) despite an overlap in small number of subjects in the two groups. 
Urinary Gb3 levels in classical Fabry females (range = 11.1-126.7 µg/mmol creatinine) 
overlapped with that of control females (range 2.2-37.1 µg/mmol creatinine). Similar results 
were found for male and female cardiac variant Fabry patients (5.7-31.8 µg/mmol creatinine 
vs 5.8-109 µg/mmol creatinine), compared to classical FD males. The levels in cardiac 
variant Fabry males and females overlapped with control males and females (3.7-23 
pM/mmol creatinine and 2.2-37.1 pM/mmol creatinine, respectively). We found that urinary 
Gb3 can be a potential diagnostic tool for the diagnosis of classical Fabry hemizygotes only 
but cannot identify classical Fabry heterozygotes or non-classical FD patients carrying 
cardiac variants. These findings are in keeping with a study by Smid et al [258], where 
specific emphasis was given to measuring the levels of plasma Lyso-Gb3 in patients with 
non-classical FD and with GLA mutations of unknown significance, who were classified as 
variants FD, uncertain or as not having FD. Using Gb3 as a biomarker, they failed to 
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differentiate between these groups, with Gb3 measurements taken from plasma samples only 
identifying classical male Fabry patients. 
As a minimally-invasive procedure, the use of biological fluids circumvents the need for 
taking biopsies from various tissues and organs. Recently, a number of groups have 
developed metabolomics-based technologies to measure Lyso-Gb3 and its various analogues 
in urine samples from Fabry patients [85, 201, 225]. 
 
Using the sensitive HPLC-MS/MS protocol developed during the course of this study, we 
proceeded to quantify the levels of Lyso-Gb3 and its associated analogues in urine samples 
taken from classical and cardiac variant Fabry patients. Again, urine samples from healthy 
control subjects were included as a reference. Using this technique, we had proven that it was 
possible to quantify the amounts of Lyso-Gb3 in urine samples from both classical and a less 
extent in cardiac variant Fabry patients. Compared to plasma, the concentration of Lyso-Gb3 
in urine samples from classical Fabry hemizygotes and heterozygotes were an order of 
magnitude lower. Also, in contrast to plasma, the presence of various Lyso-Gb3 analogues in 
urine constituted the bulk of the total pool of Lyso-Gb3, with specific Lyso-Gb3 analogues 
constituting the major component. The protocol was sufficiently specific and sensitive 
enough to differentiate both classical and asymptomatic cardiac variant Fabry patients from 
control subjects. Findings generated as part of my study are in general agreement with those 
of Auray-Blais and colleagues [85, 225] who used similar approaches to quantify Lyso-Gb3 
and associated analogues as a disease-specific biomarker in FD. 
   
Although the levels of urinary Lyso-Gb3 were substantially different between classical and 
cardiac variant Fabry patients, the levels in cardiac variant Fabry patients were sufficiently 
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high enough to differentiate these patients from healthy controls. The lack of detectable 
urinary Lyso-Gb3 in healthy male and female control subjects revealed that urinary Lyso-
Gb3 could be used to diagnose both male and female patients with either classical or cardiac 
variants forms of the disease. 
In previous studies, Auray-Blais and colleagues [85] measured the levels of urinary Lyso-
Gb3, which, when normalized to the levels of creatinine, were found to correlate significantly 
with sex, treatment, age and the types of mutations observed in Fabry patients. The 
relationship between genotype and phenotype has been studied in Fabry patients. In one 
study, Branton and colleagues have shown that individual presenting with a conservative 
amino acid change display a significantly delayed onset of symptoms when compared to 
those with non-conservative amino acid substitutions [273]. However, another study [89], 
showed that there is no correlation between the levels of plasma or urinary Gb3 and disease 
severity, clinical presentations in Fabry patients and ERT response [160]. The 
aforementioned evidence enhances the theory that the measurement of plasma or urinary Gb3 
could be an unreliable biomarker for Fabry patients especially in classical Fabry 
heterozygotes and patients with atypical FD forms. 
Lyso-Gb3 constitutes the major component of the total Lyso-Gb3 pool (Lsyo-Gb3 and its 
related analogues) in plasma samples from both classical Fabry hemizygotes and 
heterozygotes (>80%). Nevertheless, the situation was reversed in urine samples compared to 
plasma, where urinary Lyso-Gb3 level was reduced to represent approximately (<10%) of the 
total urinary Lyso-Gb3 pool in urine samples. In urine samples, the sum concentration of the 
various Lyso-Gb3 analogues constituted approximately 90% of the total Lyso-Gb3 pool 
compared to approximately 20% in plasma samples. This finding suggests that unlike plasma, 
measurement of the total pool of Lyso-Gb3 and associated analogues in urine samples 
constitutes a better analytical tool for diagnosis. 
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Using a time-of-flight metabolomics approach, Canadian researchers [206, 226] analysed the 
presence of various Lyso-Gb3 analogues from the plasma of Fabry patients in an attempt to 
identify “more specific” biomarkers for this disease. Their studies identified six Lyso-Gb3 
analogues at m/z values of 758 (-28 Da), 784 (-2 Da), 802 (+16 Da), 804 (+18 Da), 820 (+34 
Da), and 836 (+50 Da) whose expression was increased in classical Fabry hemizygotes 
compared to classical Fabry heterozygotes, but was absent from age-matched controls. My 
analysis of Lyso-Gb3 and associated analogues revealed the presence of distinct species in 
the urine from both genders of classical Fabry patients, to varying extents, with Lyso-Gb3 (-
28 Da), Lyso-Gb3 (+14 Da), Lyso-Gb3 (+34 Da) and Lyso-Gb3 (+50 Da), constituting the 
most abundant analogues. Again, in all cases, the amounts of various analogues were always 
higher in Fabry males compared to Fabry females. In all instances, these comparisons were 
found to be statistically highly significant. My findings are also in broad agreement with a 
recent study by Lavoie and colleagues [225], who identified the existence of seven novel 
urinary Lyso-Gb3 analogues with m/z values of 758 (-28 Da), 774 (-12 Da), 784 (-2 Da), 800 
(+14 Da), 802 (+16 Da), 820 (+34 Da), and 836 (+50 Da) in classical Fabry patients. 
Similar trends were observed in cardiac variant Fabry patients, where distinct analogues were 
detected in both male and female patients, with Lyso-Gb3 (-28 Da), Lyso-Gb3 (-2 Da), Lyso-
Gb3 (+16 Da), Lyso-Gb3 (+34 Da) and Lyso-Gb3 (+50 Da), being the most abundant 
analogues. In all cases, the levels of specific analogues were higher in samples from male 
patients compared to females with the exception of Lyso-Gb3 (+50 Da), where broadly 
similar concentrations were detected. In all cases, these comparisons were found to be highly 
statistically significant. 
Given the low abundance of Lsyo-Gb3 and associated analogues in urine compared to 
plasma, we quantified the total pool of Lyso-Gb3 and associated analogues in both classical 
Fabry and cardiac variant Fabry patients. In both cases, the combined total of Lyso-Gb3 plus 
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analogues was significantly higher in Fabry patients compared to control subjects. To my 
knowledge, these analyses reveal for the first time, that measurement of the total pool of 
Lyso-Gb3 and analogues in urine samples is not only sufficiently specific, but also sensitive 
enough to make an initial diagnosis of classical and cardiac variant forms of FD given the 
complete absence of Lyso-Gb3 in the urine of control subjects. Measurement of the total pool 
of urinary Lyso-Gb3 overcomes problems associated with the identification and 
quantification the expected small amounts of urinary Lyso-Gb3 and its related analogues. 
It is important to underscore the importance of measuring the total levels of Lyso-Gb3 and its 
associated analogues in urine samples from FD patients, as it proved to be a highly sensitive 
and highly specific analytical tool in aiding FD diagnosis. This sensitivity was due to the 
complete absence of Lyso-Gb3 and its various related analogues in urine samples taken from 
heathy control subjects. Similar levels in control subjects were shown in urine samples by 
Auray-Blais and co-workers [202] and in plasma samples by Aerts and collaborators [46]. 
Moreover, these findings demonstrate that the measurement of urinary Lyso-Gb3 is superior 
to the measurement of urinary Gb3, as the latter has been shown to be found in control 
subjects which expected to be due to the presence of the normally accruing Gb3 isoform 
(C18:0) [201]. 
Smid et al [259] reported that in some cases of non-classical FD phenotype, the diagnosis 
cannot be confirmed definitely by using genetic or enzymatic tests. In their consensus 
recommendation they suggested that using the histological tests of the heart can be used as a 
useful diagnostic tool for FD in non-classical Fabry patients (such as cardiac variant 
phenotype). The study [259] recommended two exit criteria (tests which can be used to 
exclude FD). The first criterion is the abnormal low ECG voltage and the second criterion is 
the severe LVH (>15 mm) at young age (<20 years). Nevertheless, the characteristic storage 
in the endomyocardial biopsy on electron microscopy can be used as a gold criterion for 
213 
 
definite diagnosis of FD [259]. In my study we have demonstrated that a positive Lyso-Gb3 
level can support the diagnosis of FD in such situations and a negative Lyso-Gb3 along with 
criteria above can be of help in excluding FD. 
Limitations of the study 
 A major limitation of this study was the general lack of availability of clinical specimens 
(blood and urine) from both classical and non-classical FD patients. This was inevitable due 
to the rarity of the disease. Approximately 100 samples were collected from clinics run at the 
Northern Hospital in Sheffield, the Royal Free hospital in London, and the Queen Elizabeth 
hospital in Birmingham - UK. While 100 cases is a respectable number, given the rarity of 
the disease, multicenter collaborations would generate a larger number of samples and 
provide better statistical evaluation of the newly derived methodologies and its clinical utility 
for assessing disease severity and treatment monitoring. 
Despite the positive findings of our study, the lack of long term-follow up samples is a 
limitation of this study. It is likely that if patients were followed up over a longer duration of 
time, then any change in Lyso-Gb3 in ERT naïve and patients on ERT would be more 
evident. 
While urinary Lyso-Gb3 appears to be a fairly stable compound, the various analogues are 
quite labile. While the urine samples were snap frozen on collection immediately in liquid 
nitrogen, any such testing of urinary samples in the future should take this fact into account 






Contributions to the field 
Our study subsequently led to development of regional laboratory service for testing Lyso-
Gb3 in Queen Elizabeth Hospital, Birmingham, UK. This service is now open to Fabry 
patients across England. Although it is a regional service, it is open to all Fabry patients 
across UK. We feel this will translate to improved care for Fabry patients.  Having a service 
now in place puts us in a situation to monitor Lyso-Gb3 levels long term. 
During the course of this study, a novel rapid MALDI-TOF-MS based method has been 
developed for measuring urinary total Gb3 in Fabry patients. This work has been published in 
the American Journal of Mass Spectrometry [1] [Appendix-6]. 
An important discovery from this research project was to identify the utility of measuring the 
total levels of Lyso-Gb3 and associated analogues in the urine of Fabry patients. The highly 
specific and sensitive nature of the LC-MS/MS protocol was able to differentiate clearly 
between classical Fabry and non-classical Fabry patients. This will not only aid diagnosis but 
may also have utility in the therapeutic monitoring of patients receiving ERT. 
A major strength of this study is the inclusion of a large number of Fabry patients diagnosed 
as having the cardiac variant forms of FD mainly the mutation N215S. To my knowledge, 
this is the only study that has examined these patients Lyso-Gb3 profile in detail. 
 
Future work  
- Future work will focus on recruiting large number of Fabry patients to see if Lys-Gb3 
can be used as disease severity assessment tool and treatment monitoring. 
- Measurement and study of the cofactor saposin and its isoforms and study if there is a 
role in pathogenicity and diagnosis and monitoring of FD. 
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- To extend the study to include larger numbers of Fabry patients who present with an 
uncertain genetic diagnosis (as defined by the “Hamlet study: Fabry or not Fabry, 
Valorization of clinical and laboratory assessments for improved diagnosis of Fabry 
disease”), to evaluate the utility of urinary Lyso-Gb3 and metabolite measurements in 
unclear cases of FD mainly patients with cardiac variant and renal variant mutations.  
- The identification of other novel related analogues and/or isoforms of Gb3 and Lyso-
Gb3 as potential biomarkers for the diagnosis and monitoring of Fabry patients. 
In conclusion, the use of biological fluids circumvents the need for taking biopsies from 
various tissues and organs. Lyso-Gb3, a deacylated form of Gb3 has been identified as a 
storage product in FD. Interestingly, in addition to Lyso-Gb3, at least six other Lyso-Gb3 
related analogues in plasma and seven related analogues in urine with varying base 
composition have been identified. While the relative distribution of Lyso-Gb3 analogues in 
urine is often higher than Lyso-Gb3 itself, the relative distribution of these metabolites in 
plasma has shown that Lyso-Gb3 is the major metabolite present. Plasma Lyso-Gb3 is a 
sensitive marker for FD and its concentration in plasma is much higher than in Urine. Despite 
its high water solubility, Lyso-Gb3 is not readily cleared by the kidney. Although male 
Patients with FD presenting with a classical phenotype can be identified by their very high 
levels of plasma Lyso-Gb3, the diagnostic value of smaller increases of plasma Lyso-Gb3 
levels in atypical late onset cardiac variant patients seems to be attainable. 
Lyso-Gb3 is a reliable diagnostic tool to discern classical Fabry males and females from 
control subjects. The current study suggests that the same applies to patients with cardiac 
variant phenotype. Lyso-Gb3 values of Fabry females overlap with controls. Consequently, in 
uncertain cases, increased Lyso-Gb3 values are suggestive of FD, but normal values cannot 
exclude FD. Confirmation in larger cohorts and data on the specificity of small Lyso-Gb3 
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Fabry disease patients’ data form  
 
Patient sample information 
Patient identifier: …… Initials: ……. DOB: ………. Sex: …………. Weight: …………………… 
Hospital: ……………………………………………………………………………………………… 
Date of collection: ……………………………………………………………………………………… 
Sample  preparation 
 Material required: 
 1 plastic serum blood collection tube (5-10 ml) 
 1 Universal bottle (10-50 ml) 
 6 plastic freezer storage tube, sterile (10 ml) 
 
 Procedure 
 Collect blood into the serum blood collection tube using your institution’s recommended 
procedure. 
 Allow blood to clot at room temperature for 30-60 minutes (no longer). 
 Centrifuge the tube at 2-8°C for 15 minutes at 1300 x g. Note: Tubes must be centrifuged at 
the appropriate speed to ensure proper serum separation. 
 Carefully transfer the serum into the labeled freezer storage tube. 
 Immediately freeze the storage tube upright at –60oC or colder. 
 Urine should be collected into a cup or bottle midstream and as sterile as possible. Transfer 10 
ml of urine into each storage tube. Note: Urine samples should not be filtered or 
centrifuged.Immediately freeze all storage tubes upright at -60°C or colder. 
Diagnosis (complete at 1
st
 patient visit) 
Leukocyte α-gal-Activity: ………………………………………………………  nmol/hr/mg protein     
                                            .. …………………………………………………… nmol/min/mg protein 
Name of test lab & normal range: …………………………………………………………………… 
 
Plasma α-gal-Activity: .…………………………………………………………………. nmol/hr/mL    
                                           . ..……… …………………………………………………… nmol/min/mL 
Name of test lab & normal range: …………………………………………………………………… 
 
Mutation: ……………………………………………………………………………………………… 
Name of test lab: ……………………………………………………………………………………….. 
Clinical symptoms:                                   Yes      No                            
If yes, age at onset of first symptoms: ……………………………………………………………….. 
Laboratory results 
Date of Sample Test: ……………………………………………………………………………..…… 
Serum Creatinine: ……………………………………………………………………………   µmol/L   
eGFR: …………………. (mL/min/1.73m
2
) or measured GFR: ………………………………..…… 
Urine Albumin: ....…………………………………………………………………………....… mg/dL        
Urine Protien Extraction Rate: ……………………………………………………...….. mg/24hours 




Clinical end points 
Blood Pressure:  Systolic: …………………………  (mm Hg), Diastolic: ……………………mm Hg 
 
1) Neurological Involvement: 
  Anhidrosis/hypohidrosis    Yes No 
Pain attacks                       Yes No 
Heat intolerance               Yes No 
White Matter Lesions Yes No 
Stroke                   Yes No 
Transient Ischemic Attack (TIA):    Yes No 
(2) Cardiac Involvement: 
  LVM index   (g/m
2
)              
……………. 
Arrhythmia    Yes No 
Myocardial Infarction       Yes No 
Abnormal ECG  Yes No 
Any cardiac intervention Yes No 
(3) Renal Involvement: 
  Hypertension                  Yes No 
Dialysis                 Yes No 
kidney Transplant Yes No 
(4) Ear: 
  Tinnitus                     Yes No 
Hearing impairment           Yes No 
(pure tone average >25 dB) Yes No 
Vertigo Yes No 
(5) Eye: 
  Tortuous vessels                      Yes No 
Cornea verticillata Yes No 
(6) Skin and GI: 
  Angiokeratomas or telangiectasia Yes No 
GI symptoms Yes No 
Additional comment: …………………………………………………………………………………  
Treatment (complete at 1
st
 patient visit) 
Enzyme Replacement Therapy:                 Yes      No 
If Yes, Drug:                   agalsidase alfa            agalsidase beta 
Dose (mg/kg): ……………………………           Frequency: …………………… 
Date of ERT initiation: …………………     Date of last infusion: ……………   
Medications: 
Angiotensin-converting enzyme (ACE) Inhibitors and/or Angiotensin receptor blockers (ARBs):                                                       
                                                   Yes            No 
Asprin:                                             Yes             No 













The Scientific Contribution and Participation 
 I have been trained in mass spectrometry in the Waters‐CHUS Expertise Centre 
(Sherbrooke - Canada) in Clinical Mass Spectrometry 19–23 November 2012. 
 Cancer and Genomic Sciences postgraduate researchers Festival, Birmingham-UK, 5–
7 June 2013 (Oral presentation). 
 Cancer and Genomic Sciences postgraduate researchers Festival, Birmingham-UK, 5–
7 June 2014 (Oral presentation). 
 Medical and Dental Sciences College Postgraduate Festival 30 March 2015 (poster 
presentation). 
 Analytical tools for cutting-edge metabolomics a joint meeting of the analytical 
division of the royal society of chemistry and the international metabolomics society - 
London, UK on 30
th
 April 2014 (Poster presentation).  
 Society for the Study of Inborn Errors of Metabolism (SSIEM) 2014 Annual 
Symposium, Innsbruck, Austria, 2–5 September 2014 (Poster presentation). 
 Society for the Study of Inborn Errors of Metabolism (SSIEM) 2015 Annual 
Symposium, Lyon, France, 1–4 September 2014 (Poster presentation). 
 4th Update on Fabry Nephropathy: Biomarkers, Progression and Treatment 
Opportunities, Manchester, UK, 1–2 June 2015 (Poster Presentation). 
 Fabry disease & the institute of translational medicine (metabolic, renal & cardiac 
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HPLC-MS instruments utilised in the study 
 
 
